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  ABSTRACT 
TWEAK (TNF-like weak inducer of apoptosis) and Fn14 (FGF-inducible protein 14) are TNF 
(tumour necrosis factor) superfamily members which have multifunctional capabilities. They 
have been shown to regulate inflammation, angiogenesis, cell fate, and tumourigenesis. 
They have recently been shown to contribute to hepatic inflammatory responses and 
regeneration during liver insult and chronic inflammatory liver disease (CILD). We propose 
that TWEAK and Fn14 may regulate CILD via human intra-hepatic endothelial cells (HIEC) and 
subsequently be developed in future as novel therapeutic agents towards CILD. Our 
investigation showed that TWEAK was predominantly expressed in leukocyte infiltrates in 
CILD tissue, it was highly regulated by interferon-γ in leukocytes, and contributed directly 
towards leukocyte recruitment via HIEC. Fn14 expression in CILD tissue was expressed in 
endothelium and portal vessels, and Fn14 expression was highly regulated by TNF-α and 
interleukin-1β in HIEC. We showed that TWEAK can directly contribute to angiogenesis in the 
inflamed liver via HIEC, by orchestrating a specific angiogenic cytokine response, and that 
TWEAK and Fn14 may contribute to portal-associated lymphoid tissue formation. We further 
found that TWEAK mediated functions via HIEC were highly regulated via NF-kB and Erk 
signalling, and that TWEAK can directly mediate HIEC reactive oxygen specie production and 
responses to necrosis. We can conclude from our findings that TWEAK and Fn14 may 
regulate CILD by complex signal transduction, and specifically mediate the inflammatory 
angiogenic responses by adopting paracrine mechanisms; whereby Fn14 is endogenously 
expressed in HIEC, and TWEAK and Fn14 interactions during CILD are facilitated by TWEAK 
positive leukocyte infiltration. 
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1.1 Introduction 
Liver disease is the 5th largest cause of death in England and Wales, contributing to 16’000 
deaths in 2008 alone, and at present contributing to 2% of all deaths in the UK (British liver 
trust. 2015. Facts about liver disease). Each year there is an increase in the number of people 
suffering from a form of liver disease, and it is the only disease which has shown a year on 
year rise in incidence (Figure 1.1). Liver disease is presenting in people averaging at 33-55 
years of age, and patients dying from liver disease average at 59 years of age in comparison 
to patients with heart and lung disease, who average at 82-84 years of age. What sets liver 
disease apart from other diseases is that the main causes of liver disease such as obesity, 
alcohol abuse, and viral diseases are all preventable. The majority of liver diseases 
documented have been caused by alcohol abuse, contributing to 37% of all registered liver 
diseases (British liver trust. 2015. Facts about liver disease). Chronic liver diseases can 
subsequently lead to financial implications and strain on the health care system, as liver 
disease management can only be carried out in hospitals and currently occupies 8-10% of all 
UK hospital admissions. The need for liver transplants is increasing, and the available donor 
livers are insufficient. Therefore, there is a need to raise awareness of liver disease and 
preventative measures amongst people, and most importantly there is a significantly urgent 
need to develop novel therapies directed towards promoting liver regeneration, which can 
ultimately reduce the incidence of developing chronic liver disease requiring transplantation 
(British liver trust. 2015. Facts about liver disease).  
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1.2 The Immune System 
The immune system has developed to protect the host from damage caused by harmful 
pathogenic organisms. It functions to successfully remove pathogens whilst protecting the 
host from damage, and retaining the ability to distinguish self from non-self. There are two 
branches of immunity which work independently, as well as dependently interacting with 
one another forming efficient protection for the host. The innate immune system consists of 
the host defence mechanisms biologically in place in the body, leading to rapid responses to 
foreign organisms. These include physical, chemical, and biological barriers. The innate 
system consists of neutrophils, monocytes and macrophages for pathogenic removal, whilst 
 
Figure 1.1 Liver disease mortality statistics: mortality rates from 1971 to 2008 caused by 
liver disease have shown a consistent rise. In contrast, deaths caused by other diseases 
and road accidents have shown a decline over the same time frame.  
 
Adapted from; www.britishlivertrust.org.uk 
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making use of chemokine and cytokine secretion, soluble effector molecules, and the 
complement system for targeting pathogens. The adaptive immune response targets specific 
antigens. This response has a delayed, pro-longed onset in comparison to the innate immune 
system, but retains memory of the invasion thus preventing future attack. B and T 
lymphocytes are key cells of the adaptive immune response and express specific receptors 
for antigens present on invading pathogens, which can then be targeted for removal by the 
innate response (Parkin e Cohen, 2001; Chaplin, 2010).   
 
1.3 The Liver 
The liver is the largest internal organ in the developed human body, totalling 2.5% of the 
total body weight (Juza e Pauli, 2014). It is highly efficient and often described as being the 
first line of defence to protect the host from external insult, as the liver plays an important 
role facilitating the host immune response. The liver filters blood from circulation and the 
gastrointestinal tracts where it comes into direct contact with pathogens. The highly 
complex structure of the liver facilitates its many functions including metabolism of 
nutrients for absorption, bile secretion, the clearance of toxins, and immune surveillance (Si-
Tayeb, Lemaigre e Duncan, 2010; Jenne e Kubes, 2013).  
 
1.3.1 Liver Anatomy: Anatomically the liver is situated to the right upper quadrant of the 
abdomen, to the right of the stomach, below the diaphragm, where it is protected by the 
ribcage. The liver is secured within the abdomen in a connective tissue capsule and the 
peritoneum. It consists of the left and right lobes (which are separated by the Falciform 
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ligament), and the caudate and quadrate lobes which extend from the posterior side of the 
right lobe. The liver is made up of several functional units which consist of hexagonal lobules 
of hepatocytes. At the periphery of each lobule a portal triad is formed consisting of a portal 
vein, hepatic artery, and a bile duct (Si-Tayeb, Lemaigre e Duncan, 2010). The portal triad 
drains into a central vein leading to the inferior vena cava to transport blood back to the 
heart via sinusoidal capillaries. These capillaries are lined by fenestrated endothelial cells, 
which facilitate contact of portal blood with hepatocytes (Figure 1.2) (Malarkey et al., 2005).  
 
1.3.2 Liver Blood Supply and Biliary System: The liver has a dual blood supply and can filter 
30% of the total volume of circulating blood every minute (Sheth e Bankey, 2001). It receives 
portal and arterial blood from two main vessels; the hepatic artery which carries oxygenated 
blood from the aorta, and the portal vein which carries blood from the digestive tract, 
spleen, and pancreas to the liver (Sheth e Bankey, 2001; Jenne e Kubes, 2013). The blood is 
carefully filtered through the liver sinusoidal network where blood pressure significantly 
reduces and the flow of blood is slowed down, this maximises contact between the flowing 
blood and the endothelium for efficient clearance of pathogens (Oda, Yokomori e Han, 
2003). Pathogen removal is achieved by endocytosis by liver endothelial cells, liver resident 
macrophages called Kupffer cells (KC), NK (Natural Killer) cells and NKT cells (Jenne e Kubes, 
2013). An important function of the liver is bile production and transportation. Bile is 
transported within the liver by bile canaliculi and bile ducts which form a biliary tree in the 
liver. Bile canaliculi are situated adjacent to hepatocytes and run parallel to hepatic 
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sinusoids. These ensure that bile is efficiently drained away from the liver to the gall bladder 
via hepatic ducts where it remains until required for fat digestion (Roskams et al., 2004).  
 
1.3.3 Liver Metabolic Functions: Hepatocytes within the liver have a central role of 
metabolising complex carbohydrates, proteins, and lipids. Carbohydrate metabolism leads to 
increased levels of glucose entering the liver via the portal vein. Hepatocytes function to 
store this excess glucose as glycogen for release when required to maintain blood glucose 
levels (Klover e Mooney, 2004). Hepatocytes produce energy in the form of ATP by the 
metabolism of fatty acids and proteins entering the liver. Protein metabolism by hepatocytes 
requires processing of amino acids into urea which can be excreted in urine. Hepatocytes 
thus facilitate gluconeogenesis and produce lipids such as cholesterol. Targeted release of 
enzymes allows hepatocytes to remove harmful toxins from the liver such as drugs and 
alcohol. The liver can store essential nutrients, vitamins, and minerals obtained from 
circulation including vitamin A and D, B12, and essential minerals such as iron which can be 
released and used when required by the body. The liver also functions to produce blood 
plasma components such as albumin, prothrombin and fibrinogen (Klover e Mooney, 2004; 
Martini, Ober e Welch, 2006; Lodish, 2008).  
 
1.4 Cells of the liver  
1.4.1 Hepatocytes: Hepatocytes are the most abundant cell type in the liver constituting 70-
80% of liver mass. They are situated around sinusoidal capillaries organised into bi-
hepatocyte cords usually two hepatocytes thick. Hepatocytes are critical for liver function; 
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including liver regeneration, filtering portal venous blood, liver metabolic processes, bile 
production, protein synthesis, and toxin neutralisation. Hepatocytes contain a large number 
of cellular organelles mainly smooth and rough endoplasmic reticulum and mitochondria 
which facilitate these functions. They also have important roles in pathogen detection and 
aiding the immune response of the host. Hepatocytes facilitate the innate immune response 
by secretion of cytokines. Hepatocytes can also initiate the adaptive immune response by 
antigen presentation to naïve T cells and expression of MHC I and II (major 
histocompatibility complex) for lymphocyte interactions (Warren et al., 2006; Jenne e Kubes, 
2013).  
 
1.4.2 Biliary Epithelial Cells: Biliary epithelial cells (BEC) line bile ducts. BEC comprise 3-5% of 
total liver cells and function in bile modification and transportation, liver homeostasis, 
facilitating growth of other resident liver cells, and toxin neutralisation in the biliary system. 
They also function as inflammatory response mediators to injury and disease by the 
expression of adhesion molecules, cytokines, chemokines, and pattern recognition receptors 
to facilitate leukocyte infiltration to the site via portal vessels (Németh et al., 2009; Priester, 
Wise e Glaser, 2010; Juza e Pauli, 2014). The biliary system is continuous from the GI tract 
and prone to microbial infection, thus the flow of bile is essential as a preventative measure 
from infection. In biliary diseases, bile flow is obstructed and as a consequence higher rates 
of infection within the liver are observed (Björnsson, Kilander e Olsson, 2000). Subsequently 
biliary cirrhosis is a consequence of persistent inflammatory responses targeting the biliary 
epithelium which compromises the bile transportation system, and perpetuates 
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inflammation lead tissue damage via apoptosis and necrosis. This can lead to pathogenesis 
such as the bile duct vanishing syndrome which is a common feature of diseases of the 
biliary epithelia (Priester, Wise e Glaser, 2010).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 The liver architecture: The gross anatomy of the liver consists of the left and 
right liver lobe separated by the Falciform ligament. The liver functional units consist of 
hexagonal lobules of hepatocytes. At the periphery of each lobule, a portal triad is formed 
consisting of a portal vein, hepatic artery, and a bile duct. The portal triad drains in to a 
central vein leading to the inferior vena cava. Sinusoidal capillaries are lined by fenestrated 
endothelial cells, which facilitate contact of portal blood with hepatocytes. The biliary tree 
is formed by bile canaliculi which transport the bile produced by liver cells. Bile canaliculi 
run parallel to hepatic sinusoids (Si-Tayeb, Lemaigre e Duncan, 2010).  
Image: (http://medcell.med.yale.edu/systems_cell_biology_old/liver_and_pancreas.php) 
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1.4.3 Hepatic Stellate Cells: Hepatic stellate cells (HSC) are located in the space of Disse; the 
perisinusoidal space between hepatocytes and Intra-hepatic endothelial cells. HSC have a 
star like conformation which allows them to attach to the IHEC (Intra-hepatic endothelial 
cells). Normal HSC contain lipid droplets within the cytoplasm which are important for 
vitamin A storage. They also are regulators of the basement membrane like matrix in hepatic 
sinusoids and thus regulate blood flow and portal pressure within the liver. Their critical 
function is the regulation of fibrosis during liver injury and insult, which they facilitate by 
excessive production of ECM (extra cellular matrix) and collagen deposition (Winau et al., 
2008). HSC become activated, adopting a myofibroblastic phenotype during liver insult, 
subsequently leading to scar formation and loss of liver function, and ultimately chronic 
cirrhosis (Bartley et al., 2006). During chronic insult to the liver, HSC trans-differentiate, 
proliferate and facilitate matrix re-modelling. An enhanced inflammatory response is 
initiated, mediated by the chronically inflamed tissue and myofibroblasts are recruited to 
the site of injury. Once the liver insult is removed and the liver is repaired, the activated HSC 
are either returned back to their quiescent state or undergo apoptosis. Subsequently when 
this reversion process is impaired, chronic fibrosis is observed (Ramm, 2009). HSC also 
contribute to the liver immune response leading to liver damage by the expression of and 
responding to several cytokines, chemokines, growth factors, and inflammatory mediators. 
PDGF (platelet derived growth factor) and TGF-β (transforming growth factor beta) have 
been shown to promote the proliferative and fibrogenic response of HSC, and subsequently 
several molecules including MCP-1 (monocyte chemoattractant protein 1) and TNF-α 
(tumour necrosis factor alpha) contribute to the fibrogenic response by inhibiting HSC 
apoptosis (Pinzani e Marra, 2001). 
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1.4.4 Liver Immune Cells: Kupffer cells (KC) are liver resident macrophages making up 20% of 
non-parenchymal liver cells, with a primary role for the clearance of pathogens, red blood 
cells, and antigen presentation. It has been suggested that KC originate from bone marrow, 
and other work has also suggested that they are derived from local liver haematopoietic 
stem cells. They are stationary cells, situated adjacent to IHEC, where they have contact with 
flowing blood in the sinusoidal endothelium, and thus can have direct access to pathogens, 
where they can bind and endocytose them. This distinguishes KC from other monocyte and 
macrophage populations which crawl in search for potential pathogens (Sheth e Bankey, 
2001; Bilzer, Roggel e Gerbes, 2006). KC also have direct contact with hepatocytes and can 
phagocytose apoptotic hepatocytes. Subsequently, the absence of KC and their receptors 
has been shown to lead to chronic bacteraemia and even host death (Bilzer, Roggel e 
Gerbes, 2006; Helmy et al., 2006). KC endocytosis is further facilitated by the presence of 
various immune receptors on the surface of KC. Under basal conditions, KC poorly activate 
the adaptive immune response. Inflammatory conditions and pathogens can enhance KC 
activity promoting T cell activation. Activated KC are further known to express chemokines 
and cytokines, which can activate other KC (Jenne e Kubes, 2013).  
 
Liver resident lymphocytes consist of approximately 1010 cells in the liver; these include 
innate lymphocytes such as NK cells, and adaptive T and B lymphocytes. NK cells form up to 
50% of lymphocytes in the liver (Racanelli e Rehermann, 2006) and have important immuno 
regulatory roles whereby they respond to ligands present on damaged, infected, and tumour 
cells. They also express a large number of cytokines when activated which facilitate immune 
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response functions, and are regulated by MHC expression by hepatocytes and HSC. NK cells 
control the proliferation and migration of NKT cells (Jenne e Kubes, 2013). NKT cells are 
highly abundant in the liver in comparison to other organs, 50% of NKT cells express the T 
cell receptor (TCR) with the majority of CD8+ T cells to CD4+ T cells (classical NKT cells), and 
the non-classical NKT cells which can co-express TCR-αβ and TCR-δβ. They also have central 
immuno-regulatory roles, expressing a large number of cytokines, and have anti and pro-
inflammation properties. NKT cells actively contribute to immune surveillance in the liver by 
patrolling the liver vasculature for potential pathogens, and they recognise antigens 
possessing MHC class 1 CD1d (cluster of differentiation 1d) (Exley e Koziel, 2004; Racanelli e 
Rehermann, 2006). 
 
Intrahepatic dendritic cells (DC) are derived from the bone marrow and are typically 
observed in the liver vasculature such as the central veins and portal tracts. Resting dendritic 
cells have antigen presentation functions and are described as having tolerogenic functions. 
When DC are activated they carry their antigen products and they migrate to extra-hepatic 
lymph nodes via the lymphatics in the portal tracts and Space of Disse, and initiate an 
immune response by activating lymphocytes (Racanelli e Rehermann, 2006; Jenne e Kubes, 
2013). 
 
1.4.5 Intra-Hepatic Endothelial Cells: IHEC form 50% of the reticulo-endothelial system which 
is comprised of IHEC and KC (Juza e Pauli, 2014). The primary function of this system is the 
removal of waste products, clearance of viruses and lipo-polysacharides (LPS) from blood. 
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This is achieved by efficient pathogen detection, capture and antigen presentation 
(Smedsrød, 2004; Racanelli e Rehermann, 2006). They have no organised basement 
membrane and form the Space of Disse, creating a gap which avoids direct interaction 
between themselves and hepatocytes (Figure 1.3). IHEC separate hepatocytes from blood 
flow in the sinusoidal lumen. They cluster into sieve plate structures which form 
fenestrations of approximately 100nm diameter, this allows passage and exchange of fluids, 
solutes, and molecules between the sinusoidal lumen and parenchyma, and thus allowing 
interactions of these with hepatocytes (Wisse et al., 1996; Lalor et al., 2006). This facilitates 
contact between residing hepatocytes and flowing lymphocytes (Jenne e Kubes, 2013).  
 
IHEC tightly regulate the immune response and inflammation in the liver. This is achieved by 
an abundance of receptors present on the surface of these cells, including scavenger, 
mannose, and immunoglobulin receptors. IHEC can express MHC I and II, adhesion 
molecules, and various immune receptors to initiate receptor mediated endocytosis; 
internalising antigens, cellular waste products, and immune complexes, and presentation of 
blood and gut derived pathogens to T cells in circulation (Jenne e Kubes, 2013). During 
critical disease processes IHEC lose their fenestrations and can form a basement membrane 
leading to subsequent hepatic dysfunction, as IHEC have a more vascular capillarised 
morphology with increased expression of CD31 and VCAM (Xu et al., 2003). Loss of 
fenestrations is linked to disease (Mak e Lieber, 1984), liver infection (Steffan et al., 1995) 
and ageing (LeCouter et al., 2003). IHEC also have the ability to prevent the activation of 
HSC, however capillarised IHEC which form in diseased livers, lose this functional 
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characteristic which can thus contribute to chronic fibrosis (DeLeve, 2013). IHEC are also 
critical to the angiogenic response (the formation of new blood vessels from pre-existing 
vessels) of the liver. This is critical to resolve liver injury during tissue damage, wound 
healing, and remodelling processes (See chapter 4), as IHEC can undergo proliferation and 
migration, and form vascular structures; tightly regulated by VEGF (vascular endothelial 
growth factor) (DeLeve, 2013). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 Organisation of hepatic cells within the lobule: The sinusoid is comprised of 
IHEC and hepatocytes. IHEC separate hepatocytes from blood flow in the sinusoidal lumen. 
IHEC have no organised basement membrane and so form the Space of Disse. They cluster 
into sieve plate structures which form fenestrations, this allows tightly regulated passage 
and exchange of fluids, solutes and molecules and thus allowing interactions of these with 
hepatocytes. Kupffer cells are found situated next to IHEC where they have direct contact 
with flowing blood and can phagocytose pathogens from flow. HSC are found present in 
the Space of Disse, they regulate hepatic blood flow and pressure and have critical 
functions in perpetuating liver fibrosis when activated. Bile ducts are found parallel to 
hepatic sinusoids, they facilitate transport of bile. Image: (Kang et al., 2013). 
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1.5 Leukocyte – endothelium interactions 
Leukocyte – endothelial interactions are vital for the regulation of inflammatory processes in 
response to immune activation, infection, and injury. The general leukocyte recruitment 
cascade involves the movement of leukocytes to the vascular endothelial wall as they leave 
circulation (Figure 1.4). This process requires leukocyte tethering to the endothelium, 
initiated by selectin mediated capture. Rolling is the process between firm and lack of 
adhesion, which is initiated by the activation of receptors expressed on endothelial cells such 
as selectins, integrins, adhesion molecules, and immunoglobulins (Ley et al., 2007). 
Enhanced shear stress allows firm bonds between selectins and their ligands, and the rolling 
velocity determines the level of leukocyte exposure to stimuli on the vessel wall. Specifically, 
rolling requires interactions of L-selectin, P-selectin and E-selectin; which are expressed on 
leukocytes and endothelial cells, with glycosylated ligands specifically PSGL-1 (p-selectin 
glycosylated ligand 1) (McEver e Cummings, 1997). Selectin interactions thus allow the 
binding of leukocytes to endothelium under conditions of blood flow, and are further 
enhanced by cytokine and chemokine activation of leukocytes via G protein coupled 
receptors present on endothelial cells in response to selectin mediated rolling, this initiates 
an intracellular signalling cascade. Subsequent signalling from integrins and chemokines 
allow firm arrest of leukocytes whilst α4, β2 integrins support rolling and mediate adhesion 
via adhesion molecules (Shamri et al., 2005). The leukocytes adhere to the endothelium and 
migrate between and through endothelial cells which requires leukocytes to change shape, 
this process is mediated via activated integrins, cytoskeletal reorganisation, and cell motility. 
The leukocytes are then directed to the site of inflammation in the tissue as they 
transmigrate across the endothelium (Ley et al., 2007; Granger, 2010).  
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Figure 1.4 leukocyte recruitment cascade: Leukocytes leave circulation and migrate 
towards the endothelial cell wall. The endothelium then captures the leukocytes, rolling is 
initiated followed by arrest and firm adhesion. This process is strengthened by G protein 
coupled receptor interactions between leukocytes and endothelial cells via cytokine and 
chemokine activation. This initiates intracellular signalling cascades. The leukocytes 
transmigrate through the endothelium and are directed towards the site of inflammation 
where they contribute towards resolution of inflammation and tissue repair. All of these 
processes are tightly regulated by specific molecules such as selectins, integrins and 
immunoglobulins which mediate each specific process.  
http://www1.imperial.ac.uk/resources/A0F93F15-C796-4B19-9631-06877300AE3B/pic3.jpg 
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1.6 Leukocyte-endothelium interactions in the liver 
The liver under normal physiological conditions has large granular lymphocytes called pit 
cells, present in the sinusoidal endothelium, which are thought to have entered the liver via 
circulation (Doherty e O'Farrelly, 2000). Lymphocytes are also present in portal tracts and in 
the parenchyma via circulation, and perform local surveillance activities (Faint et al., 2001). 
The local distribution of lymphocytes in normal liver and diseased liver varies and is highly 
dependent on the stimuli leading to subsequent leukocyte recruitment. KC are also present 
within the liver, and may largely be replenished by monocytes in circulation (Gale, Sparkes e 
Golde, 1978). Infiltration of monocytes contributes to liver inflammatory and fibrotic 
responses during liver injury (Imamura et al., 2005; Heymann, Trautwein e Tacke, 2009). 
These can aid the progression of fibrosis by the subsequent release of enhanced cytokine 
expression, augmenting the inflammatory response and the subsequent activation of HSC 
(Imamura et al., 2005). Migration of monocytes into the tissues and differentiation into 
macrophages and DC is determined by adhesion proteins, chemokines, and pattern 
recognition receptors (Geissmann et al., 2010). Lymphocyte infiltration within the liver is 
also a tightly regulated process which is first determined by the port of entry of 
lymphocytes; either from the gut or circulation, and also contributes to distinctive infiltrate 
patterns (Figure 1.5). For example in normal liver, ICAM-1 (Intracellular adhesion molecule – 
1), VAP-1 (vascular adhesion protein – 1) and low chemokine expression has been observed. 
In inflammatory diseased liver increased ICAM-1 and chemokine expression has been 
observed with the addition of VCAM-1 (Vascular cell adhesion molecule), and P and E-
selectin expression, whilst VAP-1 expression has been shown to be maintained throughout 
(Lalor et al., 2002; Jenne e Kubes, 2013).  
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Subsequently, leukocyte recruitment in the liver has also been shown to be co-ordinated by 
liver sinusoids via adhesion molecule interactions with the sinusoidal endothelium (Jaeschke 
e Smith, 1997). Blood flow while passing through the liver sinusoids significantly decreases 
 
Figure 1.5 Leukocyte endothelium interactions during liver inflammatory disease: this 
figure illustrates the different molecules which promote leukocyte interactions with 
endothelial cells. These molecules include adhesion molecules, cytokines, chemokines, and 
retention molecules. Portal vessels, bile ducts and hepatic sinusoids within the liver under 
normal and inflammatory conditions can promote differing responses of leukocyte 
interactions. They achieve this by the expression of specific molecules to initiate specific 
leukocyte cascade responses (Lalor et al., 2002). 
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allowing endothelium and leukocyte maximal interactions. The endothelium has adhesion 
protein expression including ICAM and VAP-1 which promote lymphocyte adhesion and 
trans-endothelial migration (McNab et al., 1996; Yoong et al., 1998). In diseased liver, 
adhesion protein expression has been found up-regulated, and VCAM expression has also 
been found in the sinusoidal endothelium, followed by neovascularisation processes. During 
inflammatory conditions these adhesion proteins play important roles during leukocyte 
recruitment; leukocyte capture in the sinusoidal endothelium has been shown to be 
modulated by VAP-1, VCAM and α4 integrins, and firm adhesion achieved by β2 integrins 
and ICAM (Lalor et al., 2002). 
 
It has been reported that in chronic Inflammatory liver disease (CILD) such as PBC, PSC and 
hepatitis C, leukocyte infiltrates can organise into portal associated lymphoid tissue (PALT) 
(Adams e Afford, 2002; Grant et al., 2002). PALT are formed to facilitate leukocyte 
recruitment and retention during CLD. These follicles are formed by B and T lymphocyte 
accumulation, dendritic cell recruitment, CD34+ vessel formation, and increased number of 
high endothelial venules. During chronic liver disease, new blood vessels show enhanced 
expression of adhesion proteins and chemokines, and new vessel formation has been shown 
to trigger the formation of secondary high endothelial venules, which facilitate the 
recruitment of lymphocytes (Wanless, Nakashima e Sherman, 2000; Hjelmström, 2001; 
Grant et al., 2002). Dendritic cells have also been detected in portal tracts which are 
recruited in response to liver infection and contribute towards PALT (Kudo et al., 1997).  
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1.7 Chronic inflammatory liver disease 
CILD is a leading cause of morbidity and mortality in the world. CILD can be caused by 
genetic factors, viral infections, toxicity, metabolic disorders, and autoimmunity. The onset, 
progression and pathogenesis of various CILD is a highly complex process, therefore for the 
purpose of this thesis some CILD will be discussed briefly. 
 
1.7.1 Alcoholic liver disease: Alcoholic liver disease (ALD) is caused by the excessive 
consumption of alcohol, leading to several chronic conditions in the liver including; steatosis, 
steatohepatitis, fibrosis, cirrhosis, and ultimately in some cases leading to hepatocellular 
carcinoma. The progression of ALD is still speculation lead and thought to be linked to 
processes such as insulin resistance and metabolic syndromes (Purohit, Gao e Song, 2009). 
The consequences of ALD are loss of liver function; including hepatocyte death, HSC 
activation leading to fibrosis, and damage caused by the inflammatory responses of the 
innate immune system (Byun e Jeong, 2010). It has been found that ALD progresses from a 
large range of molecular and cellular events. Briefly; steatosis in ALD livers is thought to be 
derived by HSC derived endocannabinoid and interactions with the CB1 receptor 
(cannabinoid receptor type 1) (Jeong et al., 2008). Subsequent inhibition of anti-fibrotic 
measures after exposure to excessive alcohol is thought to be mediated by NK cells and IFN-
γ (interferon gamma) against HSC, and further perpetuated by TGF-β expression (Jeong, Park 
e Gao, 2008). Fat accumulation observed in hepatocytes is thought to be due to imbalanced 
fat metabolism caused by excessive alcohol intake, such as enhanced triglyceride synthesis 
and inhibited mitochondrial lipid oxidation (Purohit, Gao e Song, 2009). KC have been shown 
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to contribute to ALD progression by responding to excessive LPS infiltration from the gut 
caused by alcohol, subsequent enhanced inflammatory responses are initiated by KC, 
followed by enhanced reactive oxygen species, collagen, and TGF-β expression (Mandrekar e 
Szabo, 2009). 
 
1.7.2 Non-alcoholic steatohepatitis: Non-alcoholic steatohepatitis (NASH) resembles ALD but 
is diagnosed after excluding that the patient has not consumed excessive alcohol. NASH is 
developed from the progressive pathogenesis of NAFLD (Non-alcoholic fatty liver disease), 
by subsequent enhanced inflammation, steatohepatitis, fibrosis, and cirrhosis. The onset of 
NAFLD is usually associated with metabolic disorders such as diabetes, obesity, 
dyslipidaemia, and nutritional causes. The progression of NASH is thought to be due to 
several causes such as excessive inflammatory cytokine presence, mitochondrial 
dysfunction, oxidative stress, insulin resistance lead adipose tissue lipolysis leading to 
enhanced free fatty acid accumulation (Dowman, Tomlinson e Newsome, 2011). 
 
1.7.3 Cholangiopathies: Cholangiopathies are diseases caused by the destruction of 
cholangiocytes (BEC). These are characterised by the destruction or loss of BEC by apoptosis 
and necrosis, and subsequent ductal branches formed in order to try and regain bile duct 
function by BEC proliferation, and persistent inflammation. This leads to hepatic cirrhosis 
and portal hypertension (O'Hara et al., 2013). Primary biliary cirrhosis (PBC) is autoimmune 
mediated liver damage caused to the intrahepatic biliary tree, which is characterised by the 
presence of automitochondrial antibodies present in serum. This can cause chronic 
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cholestasis which is the build-up of excess bile, inflammation of the portal tract, and fibrosis, 
ultimately leading to cirrhosis and liver failure. PBC is also characterised by granuloma 
formation, and in later stages nodule formation and fibrous tissue. PBC is primarily limited to 
smaller interlobular and septal bile ducts, and PBC is highly prevalent in women in 
comparison to men at a ratio of 9 to 1, suggesting possible genetic causative factors (Selmi 
et al., 2010; Selmi et al., 2011). 
 
Primary sclerosing cholangitis (PSC) is best described as an immune mediated disease rather 
than an autoimmune mediated liver disease. It is caused by inflamed bile ducts, leading to 
scar tissue formation, which can narrow the bile ducts preventing bile transport to the gut, 
and causing a build-up of bile in the liver. PSC is mostly found to effect intra and extra-
hepatic bile ducts. PSC is most commonly found in men, and genetic causative factors have 
been proposed for the onset of PSC. PSC is also often associated with irritable bowel 
syndrome (IBS), with 70% of PSC patients developing IBS. This is thought to be due to ‘the 
leaky gut’ syndrome which allows the influx of microbes and metabolites from the gut to the 
biliary tree, and there are also links of enhanced lymphocyte infiltrate to the liver from the 
gut leading to PSC progression via inflammation. PSC is also linked to cholangiocarcinoma 
formation which is not often seen in PBC patients (Silveira e Lindor, 2008; O'Hara et al., 
2013). 
 
1.7.4 Hepatocellular Carcinoma: Hepatocellular carcinoma (HCC) is often the final 
consequence of pathogenesis from chronic cirrhosis of many inflammatory liver diseases 
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including; autoimmune disease, hepatitis B and C, alcohol, chronic inflammation, and 
haemachromatosis. Hepatitis virus infection is a major risk factor for HCC. 70% of patients 
with HCC have HCV (Hepatitis C virus) in their serum (Nishioka, 1991). It is hypothesised that 
the cirrhosis associated with disease and viral infection caused by the consistent damage 
and repair cycle induced by the immune system, enhances the risk of mutations as cells 
follow the cell cycle. This is also seen in cases of chronic cirrhosis which go on to develop 
HCC (Gomaa et al., 2008). This has also been seen in patients with HBV (Hepatitis B virus). 
The HBx (Hepatitis B viral protein) has been associated with encoding oncogenic viral 
proteins which lead to HCC development, this has been demonstrated in transgenic mice 
overexpression of HBx protein. It has also been shown that HCC progression may be 
mediated by p53 suppression (Michielsen, Francque e van Dongen, 2005; Liu e Kao, 2007). 
Similarly cirrhosis induced by toxic damage by Aflatoxin B1, enhances progression of HBV 
induced HCC (Bruix et al., 2001), and cirrhosis induced by diabetes related NAFLD and NASH 
has been shown to enhance the risk of developing HCC by 3 fold (Davila et al., 2005).  
 
1.8 Liver Regeneration 
In between the constant exposure to pathogens, toxins, injury, viruses, and disease, the liver 
has the ability to efficiently regenerate itself. Liver mass regeneration has been studied 
extensively using models of partial hepatectomy (PHx) of up to 70% (Figure 1.6), often 
accompanied by other liver injury models such as CCL4 (carbon tetra chloride) to study 
inflammatory and necrotic responses during regeneration. Hepatocytes are the main driving 
cells of liver regeneration, whereby their ability to undergo indefinite DNA synthesis allows 
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the liver to compensate for damage and loss of tissue via hepatocyte proliferation (Fausto e 
Campbell, 2003). In the normal liver, hepatocytes and IHEC remain in a quiescent state. After 
PHx, hepatocytes remain uninjured however the hepatic vascular structure significantly 
changes leading to enhanced sinusoidal blood flow, subsequent portal capillary pressure, 
and influx of growth factors and hormones. In response to these changes, hepatocyte 
proliferation is the first to be initiated regulated by cytokine activation, transcription factors, 
growth factors, cell cycle regulation, matrix remodelling, and various regeneration regulating 
genes, specifically; urokinase plasminogen activator (uPA) and HGF (hepatocyte growth 
factor) (Kang, Mars e Michalopoulos, 2012). Hepatocytes undergo DNA synthesis for two 
cycles within 24-36 hours post PHx followed by a wave of apoptosis to compensate for the 
excessive proliferation (Sakamoto et al., 1999). Hepatocyte proliferation is followed BEC 
proliferation by 48-72 hours this is then followed by KC and HSC proliferation, and finally 
IHEC are activated in response to hypoxia and hepatocyte signalling to proliferate and 
migrate to formed hepatocyte clusters, leading to separation of hepatocytes, recanalization, 
and the initiation of vascular sinusoidal structure formation (Wack et al., 2001; Kang, Mars e 
Michalopoulos, 2012).  
 
Hepatocytes produce mitogenic signals for other non-parenchymal cells in the liver by the 
expression of growth factors specific to proliferation such as PDGF, VEGF, FGF (fibroblast 
growth factor), and angiopoietins (Block et al., 1996; Michalopoulos, 2007). Non 
parenchymal cells in response provide hepatocytes with growth factors such as HGF, EGF 
(epidermal growth factor) and HB-EGF (heparin binding epidermal growth factor), as well as 
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KC provide TNF-α and IL-6 (Interleukin-6). HGF is initially activated from inactive stored HGF 
in the liver ECM, and then subsequently HGF is synthesised by IHEC and HSC. HGF binds and 
activates its tyrosine kinase receptor MET to activate signalling to promote hepatocyte 
proliferation and aid hepatocyte survival, to maintain their correct morphology, and 
promote hepatocyte mitogenesis (LeCouter et al., 2003). HGF has been shown to 
significantly contribute to in vivo and in vitro liver regeneration and proliferation, and 
without the presence of HGF, liver regeneration has been shown to be a redundant process 
(Liu et al., 1994; Block et al., 1996). TNF-α and IL-6 produced by KC contribute to liver 
regeneration indirectly by activating other processes which contribute to liver regeneration. 
TNF has shown to contribute to regeneration via activation of NF-kB (nuclear kappa light 
chain activator of B cells) and growth factors. IL-6 has been shown to activate STAT3 (signal 
transducer and activator of transcription 3) and act as a direct mitogen for BEC. KC depletion 
has subsequently shown inhibitory effects on liver regeneration (Liu et al., 1998; Webber et 
al., 1998; Michalopoulos, 2007), and antibodies and genetic deletions abrogating the TNF 
response have also shown inhibited liver regeneration responses (Kirillova, Chaisson e 
Fausto, 1999; Michalopoulos, 2007). 
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Remodelling of vascular structures via angiogenesis is crucial to the regeneration process of 
the liver via endothelial cells. Sato T et al showed after PHx in rodent liver models, IHEC 
proliferation was coupled to VEGF related proteins and Angiopoietin/Tie family proteins 
expressed simultaneously, suggesting an IHEC response closely related to angiogenesis (Sato 
et al., 2001). bFGF has been shown to enhance IHEC proliferation, and subsequently bFGF 
and VEGF are known factors for regulating liver regeneration as well as angiogenesis 
(LeCouter et al., 2003). VEGF have been shown to promote proliferation of endothelial cells 
during regeneration and enhancing vascular permeability by maintaining endothelial cell 
  
Figure 1.6 Liver regeneration after partial hepatectomy: The liver has the ability to 
regenerate liver mass after up to 70% PHx. Liver regeneration is a highly regulated 
process supported by indefinite proliferation of hepatocytes which is facilitated by 
growth factors, cytokines, chemokines, hormones, and signalling promoted by other 
resident liver cells including KC, HSC and IHEC. (Kang, Mars e Michalopoulos, 2012) 
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fenestrations. VEGF also supports the breakdown of the endothelial extracellular matrix by 
enhanced expression of proteases, specifically uPA, MMP’s (Matrix metalloproteinases) and 
collagenase. Hepatocytes normally express low amounts of VEGF but enhanced VEGF 
expression has been observed during liver regeneration leading to enhanced cytokine 
induction and hypoxia. Several studies have shown VEGF induction post PHx which may 
induce IHEC and hepatocyte proliferation leading to gain of liver mass and hepatic recovery 
(Fernández et al., 2009). VEGF may induce HGF expression from IHEC to enhance hepatocyte 
proliferation, contributing to a liver regeneration process driven by IHEC and hepatocyte co-
regulation. It has been found in a recent study that the endothelial progenitor cell 
populations may be adopting paracrine mechanisms with IHEC to facilitate regeneration, 
where they showed that IHEC progenitor cells enhanced the ability of IHEC to undergo 
proliferation via an angiogenesis tube formation assay. They found that this was mediated 
by the up-regulation of angiogenesis inducing factors; VEGF and PDGF (Kaur et al., 2012). 
The role of IHEC during liver regeneration has become a controversial issue, as more recent 
publications have made suggestions that bone marrow derived liver progenitor cells of IHEC, 
may be the main contributors of liver regeneration. They have suggested that these cells are 
recruited in response to injury, and are expressing far higher amounts of HGF in comparison 
to IHEC, hence driving hepatocyte proliferation. However, as these cells share cell surface 
markers it has been challenging to distinguish between cell populations of IHEC and IHEC 
progenitors (Wang et al., 2012). 
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1.9 TNF Superfamily 
TNF was first chemically isolated in 1984 from macrophage conditioned media and found to 
have the ability to necrotise tumour cells (Old, 1985), it has since been found to be 
expressed by many different cells including monocytes, macrophages, and lymphocytes. 
Since this discovery; the TNF Superfamily (TNFSF) of ligands and receptors has developed 
and grown to approximately 19 ligands and 32 receptors which can form several ligand 
receptor pairs (Table 1). TNFSF ligands possess the TNF homology domain, which is a folded 
anti parallel β sandwich, which assembles to form a trimer and forms a binding site capable 
of binding multiple receptors (Ware, 2003; Aggarwal, Gupta e Kim, 2012). TNF ligands are 
typically type II transmembrane proteins with an extracellular domain which can be cleaved 
to form a functional soluble cytokine (Ware, 2003). Membrane bound and soluble proteins 
can activate various signalling pathways. TNF receptors are mostly expressed as type I 
transmembrane proteins and contain one to six cysteine rich domains (CRD) in their 
extracellular region. TNF receptors can possess a death domain in their carboxyl terminal, 
this can form death inducing signalling complexes (DISC) with death inducing ligands such as 
TNF, Fas-L (Fas Ligand), and TRAIL (TNF related apoptosis inducing ligand), and mediate 
apoptotic cell death. Some receptors do not have the death domain and function via TRAF 
(TNF receptor activating factor) binding in response to TNF receptor ligand interactions to 
activate various signalling pathways including NF-kB (Aggarwal, 2003).  
 
TNFSF members are important mediators of the adaptive immune response and can regulate 
a range of functions from necrosis, apoptosis, proliferation, differentiation, inflammatory 
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responses, tumourigenesis and viral replication. The range of functions observed from TNF 
ligand and receptor interactions may be in large due to the ability of each ligand to bind 
several receptors (Table 1). TNF ligands are predominantly expressed by immune effector 
cells, whereas TNF receptors (TNFR) have a wider expression pattern. For example, TNF is 
expressed by several immune cells whereas TNFR1 has shown expression in all types of cells, 
signifying the diverse functional capabilities of TNF via its receptor interactions (Aggarwal, 
2003; Aggarwal, Gupta e Kim, 2012; Bremer, 2013). TNF ligands and receptors have been 
found to be key regulators during pathological disease progression. In developing a deeper 
understanding of their interactions, functions, and signalling mechanisms in various diseases, 
we can improve and develop potential targeted therapies via the immune system towards 
inflammatory disease and cancer in future. 
 
1.10 TNFSF during inflammatory liver disease 
Many TNFSF members are known to contribute to the inflammatory response mediated by 
the immune system which is often seen during the progression of inflammatory liver 
disease. For the purpose of this thesis, some TNF ligands which have been highly 
characterised and studied extensively for their receptor interactions will be discussed briefly: 
 
1.10.1 TNF-α: TNF-α was the first identified member of TNFSF of ligands and found to be 
expressed mostly by cells of the immune system including macrophages and lymphoid cells, 
as well as a variety other cells including endothelial cells and fibroblasts. It has a membrane 
bound 26 kDa (kilo dalton) form which can be cleaved by TNF-α converting enzyme (TACE) to 
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release a soluble functional 17kDa form. TNF functions via interactions with two receptors, 
TNFR1 and TNFR2, and can subsequently regulate a whole host of biological functions. 
Notably it has been known to be a key ligand mediating the host pro-inflammatory response 
specifically via NF-kB signalling (Bradley, 2008) TNF has been reported in several studies to 
contribute to liver disease. Briefly; TNF-α has been found up-regulated in hepatic tissue and 
serum from ALD samples obtained from humans and mice, suggesting TNF induced 
cytotoxicity may have a role in metabolic dysfunction. It was further speculated that TNF 
induced cytotoxity was mediated by NF-kB which promotes hepatic protection, as down-
regulation of NF-kB up-regulated TNF expression, leading to TNF induced hepatocyte death 
(McClain et al., 1998). Similarly serum TNF-α has been described as a potential marker for 
liver disease, as serum levels of TNF-α have been found to correspond to the severity of liver 
damage induced in patients with a history of acute pancreatitis (Liang et al., 2010). TNFR1 
mediated fibrosis in hepatic damage has also been observed (Tarrats et al., 2011). HSC 
isolated from TNFR1 knockout mice showed decreased pro-collagen expression, HSC 
proliferation, and PDGF dependent mitotic signalling. It was further found that TNFR1 
mediated MMP-9 expression. Subsequent in vivo studies in TNFR knockout mice showed 
attenuated fibrosis during liver injury. These results indicated a critical role of TNF in 
mediating liver fibrosis during liver injury via HSC, and demonstrated that TNFR1 may be a 
potential target for therapeutic development in future (Tarrats et al., 2011). Furthermore, 
TNF-α has been found to regulate LPS induced cholestatic sepsis in the liver via aquaporin-8; 
a hepatocyte canalicular protein. A TNF fusion protein TNF75:Fc was shown to inhibit LPS 
induced aquaporin-8 expression and bile flow impairment, and subsequent TNF-α 
recombinant protein down-regulated aquaporin-8 expression (Lehmann et al., 2008). TNF 
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has been shown to also mediate hepatic growth hormone resistance during sepsis in rat 
cultured hepatocytes via interfering with the Jnk (c-jun N terminal kinase) 2/STAT 5 signalling 
pathway, and growth hormone has been shown to contribute to muscle protein catabolism 
during sepsis (Yumet et al., 2002).  
 
1.10.2 CD40-Ligand: CD40-Ligand (CD40-L) has been found expressed on activated T cells, B 
cells, monocytes, and several other cell types (Kawabe et al., 2011). Its receptor CD40 was 
initially characterised to be expressed on B cells, but has also since been found expressed on 
a wide variety of cell types including DC, monocytes and non-haematopoietic cells. CD40 
ligand-receptor interactions have known functions in regulating cellular adaptive immune 
and inflammatory responses including specific antigen presentation functions (Elgueta et al., 
2009; Kawabe et al., 2011). CD40 receptor ligand interactions have been shown to modulate 
cell fate and inflammation during CLD in several studies. Afford et al 1999 showed CD40 
induction can promote apoptosis in cultured human hepatocytes in CLD, they showed that 
this process was induced via Fas activation as enhanced Fas-L was observed after CD40 
ligation. They subsequently showed that CD40 mediated hepatocyte apoptosis was down-
regulated in response to anti Fas-L mAb (monoclonal antibody) (Afford et al., 1999). CD40 
expression has been observed in liver disease tissue as a marker of apoptosis, with enhanced 
expression observed in viral hepatitis tissue (Schmilovitz-Weiss et al., 2004). CD40 has been 
described as a functional receptor during HCV associated liver disease. It has been shown to 
be an indicator of hepatocyte cell fate; as CD40 positive hepatocytes have been found in 
HCV liver tissue, localised to periportal and lobular areas, and in areas of increased 
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inflammatory infiltrates (Shiraki et al., 2006). CD40 expression was found to correlate to 
disease severity indicated by histology grading. Enhanced CD40 mediated apoptosis has 
been observed in hepatocytes in combination with Actinomycin D, and anti-CD40 was shown 
to activate the pro-inflammatory NF-kB signalling pathway in HepG2 cells (Shiraki et al., 
2006). Anti CD40 therapy in inbred mice has shown B cell and macrophage mediated 
inflammatory liver disease progression which was suppressed by B cell deficient mice, and by 
macrophage depletion. Disease progression by anti-CD40 was mediated by inflammatory 
cytokines IFN-γ and TNF-α via inflammatory cell recruitment (Kimura et al., 2006). 
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 TNF Ligands Cell Expression TNF Receptors Cell Expression 
TNFSF1 TNF-β NK, T and B cells TNFR1, TNFR2 Most normal and transformed cells, immune and 
endothelial cells 
TNFSF2 TNF-α Macrophages, NK, T and B cells TNFR1, TNFR2, HVEM Immune and endothelial cells 
TNFSF3 LT-α/β DC's. T and B cells LT-βR T cells and NK cells 
TNFSF4 OX40L T and B cells, DC's, endothelial cells and smooth 
muscle cells 
OX-40 T cells and neutrophils 
TNFSF5 CD40L T cells, NK cells, mast cells, basophils and 
eosinophils 
CD40 B cells, monocytes, DC's, thymic epithelium, Reed-
Sternberg cells 
TNFSF6 FasL/ CD95L splenocytes, thymocytes, non-lymphoid tissues and 
NK cells 
Fas, DcR3 Epithelial, hepatocytes, lymphocytes and transformed 
cells, lung and colon cells 
TNFSF7 CD27L T and B cells, NK cells, mast cells, smooth muscles 
and thymic epithelial cells 
CD27 haematopoietic progenitor and T cells 
TNFSF8 CD30L T and C cells, monocytes, granulocytes, thymic 
epithelial cells 
CD30 Reed-Sternberg cells 
TNFSF9 4-1BBL B cells, macrophages, DC's and mast cells 4-1BB T, NK, mast and neutrophils 
TNFSF10 TRAIL NK, T cells and DC's TRAILR1, TRAILR2, TRAILR3, 
TRAILR4, OPG 
normal, transformed cells 
TNFSF11 RANKL T cells, thymus and lymph nodes RANK, OPG osteoclast, osteoblasts, T cells, endothelial cells  
TNFSF12 TWEAK monocytes, macrophages, transformed cells, 
tumour cells, mesenchymal stem cells 
Fn14 endothelial cells, tumour cells, epithelial cells, 
fibroblasts 
TNFSF13 APRIL macrophages, lymphoid cells and tumour cells BCMA, TACI B cells, lymphocytes, spleen, thymus, lymph nodes, 
liver and adrenal tissue. 
TNFSF13B BAFF T cells, monocytes, macrophages and DC's TACI, BAFFR, BCMA T and B cells, lymphocytes, spleen, thymus, small 
intestine, lymph tissue 
TNFSF14 LIGHT T cells, granulocytes, monocytes and DC's LIGHTR, LT-βR, HVEM, DR3 T and B cells, monocytes and lymphoid cells, 
haematopoietic and stromal cells 
TNFSF15 VEGI Endothelial cells, B cells, macrophages and DC's DR3 DcR3 NK cells and T cells 
TNFSF18 GITRL/ EDA-A1/ EDA-
A2 
HUVECs, skin GITR, EDAR2, XEDAR T cells, ectodermal, embryonic hair follicles 
NI   TROY embryonic skin, epithelium, hair follicles and brain 
NI   RELT lymphoid tissue and haematopoietic tissue 
NI APP Expressed in most tissues Dr6 T cells, most tissues 
NI NGF Immune cells NGFR neuronal axons, Schwann cells and perineural cells 
Table 1 The TNF superfamily: The TNF superfamily of ligands and receptors and their expression (MacEwan, 2002; Aggarwal, 2003; Ware, 2003; 
Aggarwal, Gupta e Kim, 2012) 
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1.10.3 Fas-Ligand: Fas-L also known as CD95-L is found expressed on immune cells. Fas is an 
apoptosis signalling receptor to Fas-L which has an intrinsic death domain. Fas expression 
has been found on lymphocytes, hepatocytes, and transformed cells. As well as regulating 
apoptosis by DISC formation via interactions with its ligand, Fas has been shown to mediate 
cellular differentiation, proliferation and activation, as well as co-ordinating the immune 
response, and pro-inflammatory signalling via NF-kB (Strasser, Jost e Nagata, 2009; Bremer, 
2013). Initially Fas was described as having a specific role in clonal deletion of mature T cells 
in Fas knock out mice (Adachi et al., 1996). However Fas mediated apoptosis has also been 
implicated in the progression of liver disease and pathogenesis in several studies. Fas and its 
ligand have been associated with liver cirrhosis derived HCC by the regulation of apoptosis. 
Fas was detected in inflammatory infiltrate in chronic hepatitis C patients using an 
immunohistochemistry (IHC) approach, and as this progressed in patients displaying 
advanced cirrhosis, this directly correlated with enhanced Fas expression showing enhanced 
expression in fibrotic and necro-inflammatory areas of tissue. Enhanced soluble Fas was 
subsequently detected in patients with cirrhosis and HCC in comparison to normal healthy 
patients (Hammam et al., 2012).  T cells overexpressing Fas-L function in inducing liver 
damage in an autoimmune Fas mutation mouse model causing lymphocyte infiltration, 
apoptosis of hepatocytes, and endothelialitis. The mouse model displayed defective 
activation induced death of T cells via a Fas mediated pathway, and subsequently lead to 
over expression of the Fas-L which induced cytotoxicity when spleen cells were engrafted 
into the host liver. This study showed that Fas-L can directly influence liver damage via 
lymphocyte activation (Bobé et al., 1997). 
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1.10.4 TRAIL: TRAIL is a TNFSF ligand which can bind 5 different receptors of the TNFSF 
(Aggarwal, Gupta e Kim, 2012). It is expressed on NK and T cells and DC. TRAIL has been 
shown to mediate liver injury via the innate immune response. In a bile duct ligation model, 
enhanced TRAIL hepatic mRNA expression in NK and NKT cells was observed in comparison 
to wild type controls. TRAIL knock out bile duct ligation models showed overall reduced liver 
injury by a decrease in fibrosis and enhanced survival (Kahraman et al., 2008). TRAIL is 
particularly intriguing in liver disease as normal hepatocytes do not express this ligand (Hao 
et al., 2004), TRAIL receptors however have been shown expressed in sensitized hepatocytes 
(Malhi et al., 2007), indicating possible paracrine mechanisms of TRAIL ligand-receptor 
interactions. TRAIL has been shown to contribute to tumourigenesis. It has been shown to 
induce receptor mediated apoptosis in tumour cells while healthy cells show no apoptotic 
cell death induced by TRAIL (Shin et al., 2002), making TRAIL an attractive target for tumour 
therapy. Subsequently HCC resistance to TRAIL has been seen and studied extensively and 
the search for novel factors which may overcome this resistance has been the main focus of 
this research. TRAIL receptors have been found expressed on HCC cells and therefore 
attempts to induce apoptosis in HCC cells have been employed via TRAIL activation. It has 
been shown that TRAIL in combination with kinase inhibitors and chemotherapy drugs can 
induce apoptosis in HCC cells by overcoming BCL-2 induced apoptosis resistance (Koehler et 
al., 2009). Similarly TRAIL resistance by HCC cells has been shown to be inhibited by EGFR 
(epidermal growth factor receptor) targeted TRAIL in combination with proteasome 
inhibitors, where EGFR has been shown to promote HCC proliferation (Wahl et al., 2013).  
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 1.11 TWEAK  
1.11.1 TWEAK discovery: TWEAK is a member of the TNF superfamily of ligands found by 
Chicheportiche et al in 1997 (Chicheportiche et al., 1997), and was described as a TNF like 
weak inducer of apoptosis (TWEAK). It was found to weakly induce apoptosis in a 
transformed adenocarcinoma cell line HT29; when these cells were activated with IFN-γ. 
TWEAK was identified from a mouse macrophage cDNA library which was screened for TNF 
sequence motifs, and found to have β-sandwich structures which is a common feature of 
TNF ligands, and found to be highly conserved between mice and humans (Chicheportiche et 
al., 1997). Soon after, it was reported by Marsters et al that a cDNA related to TNF encoding 
an Apo3 receptor binding site was cloned and subsequently named Apo3 ligand (Marsters et 
al., 1998); this cloned cDNA was identical to TWEAK. TWEAK is a type II transmembrane 
protein like most TNFSF ligands. The TWEAK gene is located at chromosomal position 
17p13.1. Full length TWEAK protein is synthesised as a 249 amino acid (aa) protein, with a 
206 aa C terminal extracellular region which contains the TNFSF homology domain, a 25 aa 
transmembrane region, and an 18 aa N terminal intracellular region. TWEAK can be cleaved 
at the C terminal domain to form a functionally active soluble protein. Soluble TWEAK forms 
a homotrimer, and has a highly conserved C terminal receptor binding sequence (Figure 1.7) 
(Chicheportiche et al., 1997; Marsters et al., 1998). 
 
1.11.2 TWEAK expression: The expression of TWEAK was found in a wide range of tissues 
including the brain, pancreas, heart, skeletal muscle, and cell lines (Chicheportiche et al., 
1997). Liver TWEAK expression was generally found to be low in comparison to tissue from 
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the heart and kidney. It was also found that TWEAK had the ability to induce excretion of 
chemokines, notably IL-8 (Chicheportiche et al., 1997). TWEAK expression has also been 
reported in a wide range of cells including macrophages (Kim et al., 2004), monocytes 
(Chicheportiche et al., 1997; Desplat-Jégo et al., 2009), DC, NK cells (Maecker et al., 2005), 
fibroblasts (Semov et al., 2002), and B and T lymphocytes (Burkly, Michaelson e Zheng, 2011; 
Dharmapatni et al., 2011; Michaelson et al., 2011). TWEAK expression has also been 
observed in non-lymphoid type cells such as endothelial cell lines (Stephan et al., 2013), 
tumour cells (Kawakita et al., 2005) and astrocytes (Desplat-Jégo et al., 2002). This is not 
consistent with other TNFSF ligands which usually have more specific and well defined cell 
type expression which is mostly limited to cells of immune, lymphoid and haematopoietic 
lineage (Aggarwal, Gupta e Kim, 2012). The expression of TWEAK has been reported to be 
mediated by IFN-γ and PMA (phorbol myristate acetate), where increased TWEAK expression 
was observed in response to these cytokines (Maecker et al., 2005). LPS activation on the 
other hand, has shown differential regulation of TWEAK mRNA expression depending on the 
cell type; where up-regulated mRNA expression was observed in monocytes (Chacón et al., 
2006) and down-regulated expression was observed in macrophages (Chicheportiche et al., 
2000). 
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1.12 Fn14 
1.12.1 Fn14 discovery: The discovery of the correct functional TWEAK receptor was a 
complex process which took a few years after discovering TWEAK. The following year after 
TWEAK was originally characterised, Marsters et al 1998 suggested that the receptor for 
TWEAK was DR3 (death receptor 3), proposing that DR3 was the death receptor which 
regulated TWEAK apoptotic activity (Marsters et al., 1998). This finding was quickly 
 
Figure 1.7 TWEAK and Fn14 human crystal structure: A) Shows a side view cartoon 
crystal structure of the human TWEAK trimer and indicated receptor binding site within 
the dashed elipse. B) Shows superimposed CRD (cysteine rich domain) co-localisation of 
other TNF receptors (coloured ribbons) to map the potential binding site of Fn14. The 
TWEAK surface is set as transparent cartoon. C) Shows an NMR model of receptor 
binding site (dashed elipse) of TWEAK with Fn14 CRD (blue). Only one receptor is shown. 
D) Shows a stereo view of TWEAK-Fn14 CRD binding site interphase with hydrogen bond 
regions (Lammens et al., 2013). 
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disproved, as subsequent studies showed that TWEAK can bind to cells which do not have 
the DR3 receptor (Kaptein et al., 2000; Nakayama et al., 2002). In 2001 Wiley et al 
successfully identified Fn14 (FGF inducible protein 14) as the functional receptor to TWEAK. 
They used an expression cloning strategy to identify the receptor from human umbilical vein 
endothelial cells (HUVEC) (Wiley et al., 2001). The TWEAK receptor was identical to a 
receptor identified previously, which had induced expression from NIH 3T3 fibroblasts in 
response to FGF 1 and 2. The receptor had a predicted molecular mass of 14 kDa; and so was 
named Fn14 (Meighan-Mantha et al., 1999; Wiley e Winkles, 2003). Competitive inhibitor 
and binding studies were employed to determine the interaction affinity constant of TWEAK 
and Fn14, which was found to be similar to other TNFSF receptor ligand pairs (Wiley et al., 
2001).  
 
The Fn14 gene is located on chromosome 16p13.3. Fn14 is expressed as a type 1 
transmembrane 129 aa protein and has one cysteine rich domain (CRD). This is atypical of 
other TNFSF receptors which usually possess multiple CRD’s, however BCMA (B cell 
maturation antigen) and BAFF-R (B cell activating factor receptor) have also been 
documented as possessing one CRD. Fn14 has a 27 aa N terminal signalling peptide 
sequence, and so Fn14 is proteolytically cleaved into a 102 aa mature protein. Fn14 like 
CD40 does not have an 80 aa intrinsic death domain which is typical of many TNF receptors 
(Wiley e Winkles, 2003; Brown et al., 2006). However, it has a 28 amino acid TRAF binding 
sequence which can bind TRAF 1, 2, 3, and 5 leading to specific signalling transduction 
cascades (Figure 1.8) (Brown et al., 2003).  
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1.12.2 Fn14 expression: Fn14 is expressed in a variety of cells and tissues including, 
endothelial (Harada et al., 2002) and epithelial cells (Ebihara et al., 2009), embryonic stem 
cells, immature erythrocytes (Felli et al., 2005) progenitor cells (Jakubowski, Ambrose, Parr, 
Lincecum, Wang, Zheng, Browning, Michaelson, Baetscher, Baestcher, et al., 2005), and 
tumour cells (Tran et al., 2003). Fn14 expression has not been found in B and T cells so far 
 
Figure 1.8: TWEAK and Fn14 mediated functions: Soluble TWEAK forms a homotrimer which 
has a receptor binding domain where it can bind Fn14. Fn14 can present on the cell surface, it 
has a 28 amino acid TRAF binding domain and can bind TRAF 1, 2, 3 and 5, these can activate 
signal transduction via specific pathways, notably NF-kB, and mediate several functions 
including inflammation, cell fate and angiogenesis dependent upon the cell type, context and 
environment.  
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(Maecker et al., 2005), there has however been expression detected in monocytes (Maecker 
et al., 2005) and macrophages (Schapira et al., 2009). Fn14 tissue expression has been 
observed in regenerating liver tissue post PHx (Feng et al., 2000) and inflammatory brain 
tissue (Serafini et al., 2008). Expression of Fn14 has been found to be regulated by growth 
factors such as FGF (Meighan-Mantha et al., 1999), VEGF (Donohue et al., 2003), EGF and 
PDGF (Wiley et al., 2001), and its expression has been found to be regulated by various 
cytokines, such as TNF-α (Justo et al., 2006), IFN-γ (Maecker et al., 2005), TGF-β, and IL-1β 
(Interleukin -1 beta) (Hosokawa et al., 2006). Fn14 expression has generally found to be low 
in normal tissue, however in diseased tissue this expression has been found induced; most 
often in response to growth factors and cytokines released in these pathological 
environments, for instance in normal brain tissue low Fn14 expression was found, but 
enhanced in brain tumour samples (Brown et al., 2003; Wiley e Winkles, 2003; Burkly e Dohi, 
2011). 
 
1.13 TWEAK-Fn14 expression inducible factors 
Several TWEAK and Fn14 activating factors have been found in studies investigating the 
expression patterns and functions of this ligand-receptor system in normal and 
pathophysiological environments. These will be discussed briefly: 
 
1.13.1 IFN-γ: IFN-γ is a key regulator of the immune system and it has known expression 
from a range of cells such as macrophages, T cells, and NK cells. IFN-γ was initially described 
as a macrophage activating factor as it was shown to tightly regulate the macrophage 
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response in the innate immune system, mediating anti-pathogen, anti-tumour, and antigen 
presentation and processing functions (Schroder et al., 2004; Schoenborn e Wilson, 2007). 
Enhanced TWEAK activation has been described in cells stimulated with IFN-γ. 
Chicheportiche reported TWEAK activated apoptosis in HT29 cells in response to IFN-γ 
stimulation (Chicheportiche et al., 1997). It was also reported that TWEAK potentiated anti-
tumour activity exerted by IFN-γ activated monocytes (Nakayama et al., 2000). IFN-γ was 
also found to regulate Fn14 expression in cells of the immune system including monocytes, 
NK cells and dendritic cells (Maecker et al., 2005). 
 
1.13.2 TNF-α: TNF-α has been shown to be a significant regulator of TWEAK and Fn14 
activity, as TWEAK and TNF-α in combination have been shown to regulate various functions. 
Soluble TWEAK has been shown to protect human adipocytes from insulin resistance 
activated by TNF-α (Vázquez-Carballo et al., 2013). TWEAK and TNF-α have also been shown 
to regulate osteoblast functions via the MAPK (mitogen activated protein kinases) pathway 
(Vincent et al., 2009). Fn14 expression has been found to be regulated by TNF-α and IFN-γ, 
and potentiating TWEAK induced apoptosis in murine cortical tubular cell lines (Justo et al., 
2006). 
 
1.13.3 FGF: Fibroblast growth factors 1 and 2 were first described as mitogenic regulators in 
fibroblasts. Now they are also described to be key cell fate mediators; regulating cell 
survival, proliferation, differentiation, and in vivo development (Dorey e Amaya, 2010). 
Meighan-Mantha et al first showed that FGF activated fibroblasts release Fn14 (Meighan-
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Mantha et al., 1999). Subsequently, FGF induced fibroblasts and aortic smooth muscle cells, 
have been found to show enhanced Fn14 expression in other studies, and Fn14 has been 
shown to inhibit angiogenesis induced by FGF suggesting that Fn14 and TWEAK are key 
regulators of FGF induced angiogenesis (Feng et al., 2000; Wiley et al., 2001). 
 
1.13.4 IL-1β: interleukin was first discovered in 1977 and found to facilitate leukocyte 
interactions. Interleukins are expressed by cells of the immune system including 
lymphocytes, macrophages, monocytes, dendritic cells, and NK cells. They regulate immune 
system and inflammatory functions. IL-1β is a member of the interleukin family and has been 
implicated in various inflammatory and immune mediated diseases such as RA, Psoriasis and 
irritable bowel syndrome (Akdis et al., 2011). IL-1β activated aortic smooth muscle cells have 
shown enhanced Fn14 expression (Muñoz-García et al., 2006). IL-1β in combination with 
TWEAK and TGF-β have been shown to induce a pro-inflammatory response in human 
gingival fibroblasts (Hosokawa et al., 2006). 
 
1.13.5 TGF-β: transforming growth factor-β is a regulator of cell fate, in vivo development, 
and tumour biology. It is expressed by a wide variety of cells and is thus implicated in a wide 
variety of functions (Kubiczkova et al., 2012). TGF-β has been described as mediating 
inflammatory responses of TWEAK and Fn14. In combination with TWEAK, TGF-β has been 
shown to induce RANTES production by human keratinocytes inducing an inflammatory 
response (Jin et al., 2004). TGF-β in combination with Fn14 has been shown to reverse 
intervertebral disc degeneration caused by TWEAK (Huh et al., 2010). Meighan-Mantha et al 
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showed enhanced Fn14 mRNA expression in response to TGF-β activation in murine 
fibroblasts (Meighan-Mantha et al., 1999). 
 
1.14 TWEAK and Fn14 functional interactions 
1.14.1 TWEAK and Fn14 signalling: TWEAK with its receptor Fn14 has been described as a 
multifunctional ligand and receptor, with functions from cell fate, proliferation, 
angiogenesis, inflammatory mediation and tumour cell biology (Figure 1.8) (Winkles, 2008). 
This multifunctional ability is most likely due to TWEAK and Fn14 interactions which activate 
various signalling pathways, such as NF-kB (Roos et al., 2010) and MAPK (Donohue et al., 
2003). This activation of various signalling pathways via TWEAK and Fn14, over time and 
subsequent investigations, has proven to be a cell specific and context dependent 
mechanism (Burkly, Michaelson e Zheng, 2011). The complex signalling regulation via TWEAK 
and Fn14 interactions will be discussed in detail in Chapter 5. However briefly; TWEAK and 
Fn14 signalling is mediated via interactions of this ligand and receptor and the subsequent 
binding of TRAFs which lead to the activation of various transcription factors. TNFSF ligand 
and receptor mediated signalling is often seen to be via the activation of the classical NF-kB 
signalling pathway. TWEAK activated functions have also been extensively studied to signal 
via NF-kB as well as several other signalling pathways including p38 MAPK, Erk 1/2, Jnk and 
NF-kB Rel B (Winkles, 2008).  
 
TWEAK and Fn14 expression in normal tissue is generally found to be low. Enhanced TWEAK 
and Fn14 expression can lead to tissue damage or can limit damage depending on the 
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environment and tissue type; for example in the normal liver, TWEAK overexpression has 
been shown during liver regeneration (Karaca et al., 2014). However in induced fibrosis 
models, liver regeneration fibrosis was reduced by blocking TWEAK activation using anti 
TWEAK mAb, indicating a damaging effect with the presence of this ligand (Kuramitsu et al., 
2013). There have been no abnormalities discovered in normal development or growth in 
TWEAK and/or Fn14 knock out mouse models, however enhanced innate and adaptive 
immune responses have been observed. TWEAK -/- mice showed significant accumulation of 
NK cells in secondary haematopoietic tissues compared to WT mice. The TWEAK -/- mice 
further showed hypersensitivity to bacterial endotoxin increasing IFN-γ and IL-12 expression 
from innate cells, oversized spleens, and enhanced memory and helper T cell response to 
ageing and tumour formation (Maecker et al., 2005); suggesting a crucial role of TWEAK and 
Fn14 in mediating innate and adaptive immune responses during disease and injury.   
 
1.14.2 TWEAK and Fn14 interactions with other TNFSF members: TWEAK and Fn14 
interactions with other members of the TNFSF have been characterised extensively 
highlighting the complexity of signal transduction via this ligand and receptor. TWEAK and 
Fn14 have been found to down-regulate CD40 ligand and receptor signalling complex 
formation, which has been found to compromise TRAF-2 mediated signalling which regulates 
CD40 functions. TWEAK activation has been found to inhibit signalling via NF-kB and MAPK’s 
induced by CD40 activation, which was found to be impaired by defective signalling complex 
formation of CD40 ligand and receptor via TWEAK (Salzmann, Lang, et al., 2013). TWEAK 
mediated apoptosis induced in Kym-1 cells has been found to be dependent on TNF-TNFR1 
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activation, as subsequent inhibition of apoptosis was observed when antibodies to TNF and 
TNFR1, and TNFR1 Fab fragments were used (Schneider et al., 1999). The use of TRAIL and 
Fn14 fusion proteins have been shown to down-regulate disease severity in induced 
autoimmune encephalomyelitis mouse models. This was indicated by a reduced clinical 
score, inflammation, cytokine response and incidence. This fusion protein was developed on 
the basis of TWEAK and Fn14 association with pathological inflammation and the ability of 
Fn14 to block TWEAK activity, and the ability of TRAIL to inhibit the pathogenic response of 
activated T cells (Razmara et al., 2009). Fn14:TRAIL fusion proteins have also been shown to 
inhibit HCC growth. It is thought that TWEAK signalling potentiates TRAIL resistance in HCC, 
therefore blocking TWEAK signalling with Fn14 will reverse TRAIL resistance and induce 
apoptosis in HCC. In vitro it was shown that this fusion protein induced apoptosis in HCC cell 
lines, and normal hepatocytes were unaffected by this induced apoptosis. In in vivo mouse 
models, subcutaneously injected Fn14:TRAIL stunted tumour growth, and it was shown that 
Fn14, TRAIL, and both in combination in their soluble forms did not show the same apoptosis 
induction in HCC cell lines (Aronin et al., 2013). 
 
1.14.3 TWEAK and CD163 receptor: There have been reports of TWEAK activity present in 
Fn14 negative cell populations. The ability of TWEAK to induce apoptosis without the 
presence of a death domain in Fn14, is an intriguing aspect to the functional capabilities of 
TWEAK. Therefore it has been speculated that there may be other functional unidentified 
receptors present for TWEAK. CD163 is from the scavenger receptor cysteine rich 
superfamily, and has been predominantly found expressed on monocytes and macrophages 
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(Pulford et al., 1992). Bover et al 2007 adopted a peptide screening strategy to identify new 
TWEAK binding proteins. They found CD163 as a potential binding receptor for TWEAK, and 
found that CD163 was present on Fn14 negative monocyte populations which bound TWEAK 
in a dose dependent manner. They also found that TWEAK and IFN-γ mediated HT29 
apoptosis can be blocked by this receptor . Since then Moreno et al have found that TWEAK 
and CD163 ratios correlate to disease severity in atherosclerotic plaques and athero-
thrombosis (Moreno et al., 2009; Moreno et al., 2010). LLaurado et al showed TWEAK and 
CD163 ratios in serum may indicate cardiovascular disease severity (Llauradó et al., 2012). 
 
1.15 TWEAK mediated leukocyte recruitment 
Over the years, TWEAK activated inflammatory responses have been a focus of TWEAK/Fn14 
functional activities. TWEAK mediated inflammatory responses have been extensively 
characterised by leukocyte infiltration and recruitment via cellular interactions, cell surface 
adhesion proteins, and chemokine expression. TWEAK activated human gingival fibroblasts 
showed enhanced ICAM and VCAM expression which could subsequently be regulated by 
TGF-β, which enhanced ICAM expression but had suppressive influences on VCAM, leading 
to an enhanced inflammatory response, contributing to periodontal gingival disease 
(Hosokawa et al., 2006). Subsequently TGF-β activating kinase -1 knock out mouse models 
showed diminished MMP-9, CCL-2 and VCAM expression in response to TWEAK activation in 
cultured myoblasts and fibroblasts (Kumar et al., 2009). In human dermal microvascular 
endothelial cells and in vivo cutaneous vasculitis mouse models, E-selectin and ICAM 
expression were enhanced in response to TWEAK activation, which directly contributed to 
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cutaneous vasculitis progression. TWEAK activated endothelial cells also enhanced leukocyte 
recruitment which was shown using adhesion assays (Chen et al., 2013). In other 
investigations, ICAM and VCAM expression regulation by TWEAK were closely modulated by 
other cytokines in inflammatory disease progression. Such as ICAM and VCAM enhanced 
expression in response to TWEAK and IFN-γ activation in fibroblast like synoviocytes, 
contributing to rheumatoid arthritis inflammatory progression (Mo Kang 2008). TWEAK 
activated endothelial cells also showed enhanced ICAM expression accompanied by 
inflammation mediating cytokines CCL2, IL-8 and IL-6 (Stephan et al., 2013).  
 
TWEAK activation mediated leukocyte recruitment has been characterised in a number of 
inflammatory diseases and in pathological settings. TWEAK has been found to be a 
tumourigenic cytokine contributing to enhanced tumour growth and decreasing the anti-
tumour immune response. Detection of leukocytes in the blood, spleen and tumours showed 
that TWEAK blockade by RG7212 (TWEAK mAb) lead to monocyte and macrophage number 
decrease in circulation, but enhanced expression was observed in tumours. CD3+ T cells 
were subsequently found enhanced in blood and tumours. It was also found that TWEAK 
activation lead to enhancement of leukocyte recruitment protein expression such as CD274, 
CCL2, CXCL10 and CXCL11. TWEAK was also found to mediate T cell activation and 
macrophage differentiation. Depleting CD8+ T cells and NK cells showed a loss of tumour 
inhibition by RG7212, but CD4+ T cell depletion lead to enhanced tumourigenic properties, 
indicating specific leukocyte tumourigenic responses co-ordinated by TWEAK (Yin et al., 
2013). TWEAK activation has also been shown to lead to T cell infiltration in the kidney (Gao 
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et al., 2009). TWEAK activated renal tubular cells showed the non-canonical pathway 
activation accompanied by CCL21A expression. In vivo acute kidney injury models showed 
TWEAK knockout depleted CD3+ lymphocytes which are usually found highly expressed 
(Sanz et al., 2010). TWEAK administration in a peritoneal inflammatory mouse model 
showed enhanced expression of MCP-1, Fn14 expression and GR1+ macrophage 
recruitment. TWEAK activation also lead to enhanced CD8+ T cells and neutrophils 
contributing to peritonitis (Sanz, Aroeira, et al., 2014). In periodontal gingival disease, 
TWEAK and Fn14 expression was observed in monocytes and fibroblasts. TWEAK expression 
was associated with increased renal and vascular damage, and enhancing the pro-
inflammatory responses seen in atherosclerotic lesions and kidney disease (Muñoz-García et 
al., 2009). These studies all indicate a significant role of TWEAK and Fn14 in contributing to 
local inflammatory responses in disease settings via regulating leukocyte recruitment and 
direct leukocyte interference, facilitated by expression of selectins, adhesion molecules and 
cytokines.  
 
1.16 TWEAK and Fn14 regulation of inflammatory disease 
Inflammation is often in response to infection, trauma, toxicity, and autoimmunity. 
Inflammation is a highly regulated process, however when this is de-regulated leading to 
excessive or prolonged inflammatory responses, pathogenesis of disease is often observed 
(Medzhitov, 2008). During inflammatory disease, leukocytes can facilitate actions of resident 
non haematopoietic cells. TWEAK is highly expressed on cells of heamatopoietic origin and 
activated during acute disease processes which can have beneficial and detrimental effects 
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(Burkly, Michaelson e Zheng, 2011). It has been hypothesised based on several experimental 
models and findings that during acute tissue injury and disease, TWEAK can facilitate tissue 
repair by initiating an inflammatory response, inducing cellular proliferation, angiogenesis, 
and progenitor differentiation, which can lead to tissue repair. During chronic inflammatory 
disease however TWEAK and Fn14 may facilitate pathological tissue destruction, whereby 
TWEAK and Fn14 up-regulated expression may sustain the inflammatory response, 
progenitor expansion may be reduced, and chronic angiogenesis and proliferation eventually 
may lead to detrimental effects of pathological remodelling and tissue degeneration (Figure 
1.9) (Burkly et al., 2007). This hypothesis has been proven by a number of studies 
investigating the functional roles of TWEAK and Fn14 in chronic inflammatory diseases. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9 TWEAK mediated chronic inflammatory disease regulation: In normal tissue 
TWEAK and Fn14 expression is low. During acute injury, TWEAK and Fn14 expression is up-
regulated promoting inflammation, cellular proliferation, angiogenesis, and progenitor 
expansion leading to tissue repair. During chronic inflammatory disease, it is hypothesised 
that TWEAK and Fn14 sustained up-regulation deregulates these processes leading to 
tissue degeneration and pathological remodelling (Burkly et al., 2007) 
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1.16.1 Rheumatoid Arthritis: Rheumatoid arthritis (RA) is a debilitating chronic inflammatory 
disease, characterised by joint swelling, and progressive cartilage and bone destruction 
(Pincus e Callahan, 1993). This involves severe inflammation caused by the induction of 
inflammatory cytokines, chronic angiogenesis, synovial cell proliferation, and changes in 
vascular permeability which leads to fibrosis of the synovium (Fava et al., 1994; Paleolog, 
2002; McInnes e Schett, 2007). TWEAK is a known mediator of RA. There is growing in vitro 
and in vivo evidence of TWEAK and Fn14 expression present in synovial fluid, and anti-
TWEAK mAb has been shown to alleviate joint swelling caused by RA (Kamata et al., 2006). 
Subsequently, TWEAK and Fn14 expression has been found up-regulated on synovial cells, 
and recombinant TWEAK protein has been shown to enhance cytokine induction and ICAM 
expression on these cells. This process was reversed with TWEAK mAb treatment (Kamijo et 
al., 2008). In vivo collagen induced arthritis (CIA) mouse models have been used to 
determine the functional regulation of TWEAK and Fn14 in RA disease progression. In CIA 
mouse models, anti-TWEAK mAb treatment has shown a significant decrease in disease 
severity, indicated by decreased paw swelling, synovial cell hyperplasia, inflammatory cell 
infiltration, and inhibited angiogenic responses in synovial tissue indicated by fewer vessel 
formation (Kamata et al., 2006). Subsequently Fn14 expression has been found up-regulated 
in synovial tissue from CIA models (Park et al., 2012). Phase I clinical trials using TWEAK mAb 
BIIB023 in RA patients has shown reduced serum levels of TWEAK 6 hours post dosage (0.03-
20mg/Kg) which lasted for up to a month, which also showed a decrease in inflammatory 
markers, including MCP-1, macrophage inhibitory protein-1, tissue inhibitor of 
metalloproteinase-1 and inducible protein-10 in comparison to placebo controls. The use of 
BIIB023 was found to be safe and well tolerated by RA patients (Wisniacki et al., 2013). 
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1.16.2 Systemic Lupus Erythematosus: Systemic Lupus Erythematosus is an autoimmune 
disease characterised by autoantibody production. It can lead to immune complex deposits 
forming in organs, and can cause disease such as Lupus Nephritis (LN). TWEAK has been 
described as being directly involved in the inflammatory response in LN progression, and can 
promote renal cell proliferation, apoptosis and fibrosis in tissue (Michaelson et al., 2012). 
TWEAK has been found highly up-regulated in the urine in LN patients, and it has been 
proposed that TWEAK can serve as a clinical biomarker for LN, as no urinary expression of 
TWEAK was subsequently observed in healthy patients and other disease controls (Schwartz 
et al., 2009). In vivo graft vs host induced LN mouse models showed reduced kidney disease 
severity once treated with anti-TWEAK antibodies, which ameliorated the damaging 
inflammatory response to LN. Fn14 knock out models with induced LN also showed 
decreased kidney disease severity coupled to an inhibited inflammatory response, indicating 
that TWEAK and Fn14 contribute to kidney disease induced by LN (Zhao et al., 2007). A 
similar response of TWEAK induced kidney disease was observed in nephrotoxic serum 
nephritis models, however the response was not mediated by the systemic inflammatory 
immune response, rather it was regulated directly in the local kidney immune response 
promoting fibrosis and inflammatory infiltration via TWEAK (Xia, Y. et al., 2012). A phase II 
clinical randomised placebo controlled trial using BIIB023 in patients with LN in underway, to 
observe the efficiency of using this antibody as an add-on therapy in patients who have 
failed to undergo disease remission using standard steroid and mycophenolate mofetil 
therapy (Sanz, Izquierdo, et al., 2014).  
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1.16.3 Neuro-inflammation: TWEAK also has been shown to directly mediate inflammatory 
diseases of the brain. The blood brain barrier (BBB) is made up of microvascular endothelial 
cells, pericytes, astrocytes and tight junctions, and required to separate the circulatory 
system from the central nervous system, whilst facilitating the passage of required 
molecules by active permeabilisation. When this permeabilisation process is disrupted, this 
can lead to inflammatory brain disease including Multiple Sclerosis (MS), ischemic stroke and 
brain edema. TWEAK has been shown to be key in disrupting the BBB leading to an increased 
production of inflammatory cytokines, and increased permeability of the BBB. Anti-TWEAK 
mAb therapy has shown to alleviate symptoms in ischaemic stroke and brain edema models 
(Winkles, 2008; Yepes, 2013). MS models have shown TWEAK expression up-regulated on 
monocytic fractions in comparison to other haematopoietic populations, defining a specific 
inflammatory response via TWEAK during MS (Desplat-Jégo et al., 2009). 
 
1.16.4 Cancer Progression: TWEAK has been described as a key regulator of pro-tumorigenic 
functions which range from promoting angiogenesis, inflammation, cell invasion and 
proliferation; and can thus support and facilitate ideal environments for survival and 
metastasis of tumour cells (Figure 1.10) (Winkles, Tran e Berens, 2006). TWEAK mediated 
angiogenic functions have been extensively investigated since the initial discovery of this 
ligand and receptor system. These will be discussed in detail in Chapter 4. However briefly; 
TWEAK was shown to promote angiogenesis and proliferation in vitro in HUVEC, and in an in 
vivo rat cornea model. TWEAK was shown to directly induce angiogenesis comparable to 
well characterised angiogenesis mediators FGF and VEGF (Lynch et al., 1999). It was 
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subsequently found that Fn14 mediates TWEAK activated angiogenesis (Wiley et al., 2001). 
Further studies have since characterised and confirmed the potential TWEAK and Fn14 have 
in promoting pro-angiogenic functions (Kawakita et al., 2004; Shimada et al., 2012). TWEAK 
has been shown to promote the invasive and migratory capacity of tumourigenic cells, this 
was demonstrated in human glioma cells where Fn14 over expression promoted glial cell 
invasion via the activation of Rac1 (Ras related C3 botulinum substrate 1) and NF-kB, and 
Fn14 expression was found highly up-regulated in glial tumours (Tran et al., 2003; Tran et al., 
2005). Fn14 has been found highly expressed in Her2+ breast tumours (Willis et al., 2008). It 
has subsequently been shown that Her2 over expression in MCF7 (Michigan cancer 
foundation 7) cells induced Fn14 protein expression, which was found to be reduced in 
response to Her2 kinase inhibitors. Fn14 inhibition in Her2+ cells down-regulated migration 
and invasion capacity and MMP-9 expression, indicating the importance of TWEAK and Fn14 
signalling in tumour progression (Asrani et al., 2013). Fn14 expression has subsequently 
been shown to correlate directly with poor prognosis and patient outcome in cancer patients 
(Huang et al., 2011; Kwon et al., 2012). 
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Subsequently, TWEAK and Fn14 expression has been found in a range of tumour types and 
tumour cell lines. TWEAK mRNA and protein expression has been observed to be up-
regulated in HCC tissue and cell lines in comparison to normal liver (Feng et al., 2000). Ho et 
al described TWEAK mRNA expression found in 11 tumour tissue types from 68 tumour 
specimens indicating the range of expression observed, their findings included kidney, 
prostate, cervical cancer and colon cancer. They also described large highly vascularised 
tumours developed when TWEAK over-expressing cells were grafted into nude mice (Ho et 
al., 2004). Fn14 expression was subsequently found up-regulated in HCC tissue and TWEAK 
 
Figure 1.10 TWEAK regulation of tumour progression: TWEAK and Fn14 may regulate 
critical functions such as inflammation, angiogenesis, proliferation and migration, which 
may aid the TWEAK pro-tumourigenic response. This diagram illustrates how TWEAK 
activation by tumour cells may drive endothelial cell proliferation and angiogenesis. 
TWEAK activation by the inflammatory response may subsequently be driven by the 
immune response to the tumour and may lead to the enhanced growth of the tumour cells 
by indirect activation of growth factors, cytokines and chemokines favouring the tumour 
environment. In turn the immune response may favour endothelial cell leukocyte 
recruitment and angiogenic response leading to tumour progression (Winkles et al., 2007). 
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was found to promote cellular proliferation and NF-kB activation in HCC cells (Kawakita et 
al., 2004). Further investigations found up-regulated Fn14 expression in a range of tumours, 
and when tumour cell lines were treated with anti-Fn14 antibodies the proliferation of 
tumour cell lines was down-regulated, indicating tumour progression functions via Fn14 
(Culp et al., 2010). Similarly up-regulated TWEAK and Fn14 expression was found in a range 
of esophageal and pancreatic cancer tissue and cell lines. Blocking TWEAK and Fn14 
signalling using anti TWEAK antibodies showed decreased cell line growth (Yoriki et al., 
2011). 
 
1.17 TWEAK and Fn14 regulation of inflammatory liver disease and regeneration 
There are very limited studies which have investigated the functional roles of TWEAK and 
Fn14 in the liver. Data has indicated that TWEAK and Fn14 regulate proliferative, 
inflammatory and regenerative responses in the liver. Feng et al 2000 initially described low 
Fn14 expression in normal human liver tissue, and subsequent up-regulation of Fn14 mRNA 
in human HCC tissue and transformed cell lines. They also showed in mouse models of liver 
regeneration using PHx and induced hepato-carcinogenesis that Fn14 expression was highly 
up-regulated in early liver regeneration, and sustained up-regulation was observed 
throughout the regeneration process, indicating a critical role for Fn14 during tissue repair 
by controlling hepatocyte proliferation and remodelling (Feng et al., 2000). This was 
followed by a study by Kawakita et al 2004 who showed Fn14 expression found in 4 cell lines 
of HCC; HepG2, Huh7, SkHep1 and HLE.  TWEAK expression was shown to promote cellular 
proliferation of HCC cells in a dose dependent manner; and by activating the NF-kB pathway. 
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They found TWEAK and Fn14 co-expressed on HCC tissue, indicating a possible autocrine 
and/or paracrine influence on cellular proliferation. IHC revealed metastatic HCC showed 
enhanced TWEAK expression in comparison to HCC tissue, and interestingly they found non 
tumour diseased tissue generally negative for TWEAK with exception to areas of lymphocyte 
infiltration. This study confirmed the potential roles of TWEAK and Fn14 signalling during 
HCC progression and metastasis and indicated towards a role for TWEAK mediated 
inflammatory responses during liver disease. They went on to find that TWEAK induced 
proliferation of endothelial cells (HUVEC) and found an enhanced proliferative response and 
expression of IL-8 and MCP-1, further confirming previous studies looking at TWEAK 
regulation of inflammatory mediated angiogenesis, and speculated that TWEAK mediated 
tumourigenesis may be promoted via inflammatory angiogenesis (Kawakita et al., 2004).  
 
The focus then shifted to liver progenitor cell expansion via TWEAK activation. Jakubowski et 
al 2005 showed that TWEAK has the ability to promote the proliferation of hepatic 
progenitor cells and BEC when overexpressed in TWEAK transgenic mice. They showed that 
this was mediated through Fn14 interactions as Fn14 null mice did not show the same 
proliferative effect. They also found Fn14 expression on BEC and in periportal regions of liver 
tissue sections from these transgenic mouse models. They subsequently found no 
proliferative effect on hepatocytes, suggesting a progenitor cell specific response. In a DDC 
(3, 5- diethoxycarbonyl-1, 4-dihydrocollidine) liver injury model they found Fn14 expression 
up-regulated in reactive portal areas, they also found TWEAK expression highly elevated in 
comparison to controls in the parenchyma of the DDC diet mice, and TWEAK mAb inhibited 
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progenitor cell expansion in these models which was found to be regulated by Fn14, as Fn14 
null mice exhibited no progenitor cell hyperplasia. They further found that TWEAK enhanced 
proliferation in vitro in rat BEC, and enhanced Fn14 expression was observed in NASH, ALD, 
HCV and HCC human liver tissue concentrated in areas of bile ducts and fibrotic regions in 
comparison to normal liver, suggesting a direct role of TWEAK and Fn14 signalling during 
liver disease and pathogenesis (Jakubowski, Ambrose, Parr, Lincecum, Wang, Zheng, 
Browning, Michaelson, Baetscher, Baestcher, et al., 2005). Tirnitz-Parker et al 2010 also 
confirmed that TWEAK promoted the expansion of liver progenitor cells, in a CDE (choline 
deficient, ethionine supplemented) induced liver injury model; which was mediated through 
Fn14. They found enhanced Fn14 expression in CDE induced injury models, and showed that 
Fn14 null mice had decreased liver progenitor cell numbers, decreased inflammatory cells 
(CD45+ leukocytes and F4/80+ macrophages), inhibited cytokine production of TNF, IFN-γ, IL-
6 and LT-β (lymphotoxin-beta), and decreased fibrosis indicated by down-regulated collagen 
deposition and TIMP (tissue inhibitor of metalloproteinase) expression, in comparison to 
wild type mice. They also found that TWEAK promoted proliferation of a liver progenitor cell 
line in a dose dependent manner via NF-kB in vitro and in vivo, with enhanced CD45+ 
leukocyte expression. (Tirnitz-Parker et al., 2010; Tirnitz-Parker, Olynyk e Ramm, 2014). 
Subsequently, their findings demonstrated the important functions of TWEAK and Fn14 
during liver injury and regeneration via liver progenitor cells and how TWEAK and Fn14 
regulate the inflammatory and fibrogenic responses during liver injury via possible paracrine 
interactions of inflammatory cells and resident liver cells.  
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Modulation of the TWEAK mediated inflammatory response has been observed in all studies 
investigating the potential of TWEAK and Fn14 regulating liver disease and injury. Tirnitz-
Parker et al found TWEAK expression in macrophages and NK cells in the CDE injury model 
and no Fn14 expression by these inflammatory cells (Tirnitz-Parker et al., 2010). This 
indicated a specific regulation of the inflammatory response via this ligand and receptor in 
liver disease. A follow up study revealed that macrophages in close proximity to ducts in the 
liver produce TWEAK in the CDE liver injury model (Viebahn et al., 2010). The TWEAK 
dependent inflammatory response of liver progenitor cells and BEC was also demonstrated 
in a study where bone marrow derived macrophages were engrafted into normal livers. 
These macrophages were shown to subsequently express elevated TWEAK which initiated 
ductular reactions (Bird et al., 2013). These studies demonstrate how TWEAK is fundamental 
to the autocrine regulation of the inflammatory response during liver mediated injury and 
disease. 
 
Recent studies have further demonstrated that TWEAK and Fn14 are mediators of the liver 
regenerative response by using models of PHx. Fn14 positive cells were shown to drive the 
proliferative response in the regenerating liver. After PHx in wild type mice, Fn14 positive 
cell accumulation was observed, this was demonstrated by Fn14 mRNA and protein 
expression, and IHC analysis. IHC revealed the presence of Fn14 positive cells surrounding 
portal tract regions, it was suggested that these cells resembled hepatocytes. Fn14 was 
shown to drive the proliferative response shortly after PHx which was dependent upon 
TWEAK. Fn14 knockout significantly reduced the ability of the liver to regenerate, as liver 
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progenitor, BEC, and hepatocyte expansion was significantly inhibited (Karaca et al., 2014). It 
has also been shown that post PHx in mouse models of induced fibrosis by CCL4 (carbon 
tetra chloride) injury, the regenerative response was driven by TWEAK and Fn14 signalling. 
They showed that TWEAK neutralising antibodies reduced the pro-fibrotic response, reduced 
progenitor cell proliferation, normalised serum ALT levels, and enhanced liver regeneration. 
Alternatively, TWEAK protein administration enhanced liver progenitor cell proliferation and 
the pro-fibrotic liver response (Kuramitsu et al., 2013). 
 
Studies so far have indicated that TWEAK and Fn14 drive proliferation and regenerative 
responses, and mediate pathogenesis during liver disease via inflammatory regulation. It is 
of high importance to understand this further at a molecular level and to understand the 
interactions, functions, and signalling crosstalk, of TWEAK and Fn14 in the different liver cell 
populations. Studies investigating the role of TWEAK in liver disease regulation have 
observed that progenitor cells drive many of the functional responses observed. Therefore it 
is equally important to further examine the role of differentiated progenitor cells to further 
dissect how TWEAK and Fn14 mediate these responses. The liver angiogenesis mediated 
regenerative response is of prime importance for the development of therapies targeting 
inflammatory liver disease for regeneration. Therefore it is essential to understand TWEAK 
and Fn14 interactions in HIEC (Human Intra-hepatic Endothelial Cells) which are the driving 
feature of liver regeneration via angiogenic responses of the liver.   
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1.18 General Aims 
We believe that TWEAK and Fn14 may regulate hepatic inflammatory and angiogenic 
responses during chronic inflammatory liver disease via human intra-hepatic endothelial 
cells, thus facilitating the regulation of hepatic regeneration. The overall aims of this 
investigation were: 
 To determine the expression of TWEAK and Fn14 in liver tissue sections and isolated 
HIEC. 
 To determine the role of TWEAK and Fn14 during regulation of HIEC functional 
responses, angiogenesis, cell fate, and leukocyte recruitment. 
 To determine intracellular signalling pathways activated via Fn14 in HIEC. 
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CHAPTER 2 
MATERIALS AND METHODS 
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2.1 Human Tissue 
Human liver tissue consented for scientific research, was donated by the Queen Elizabeth 
Hospital, Birmingham UK, to the Centre for Liver Research. Donated livers included explant 
diseased livers, resected marginal tumour liver tissue, and normal donor liver tissue surplus 
to surgical requirement. Ethical approval was obtained from The Local Research Ethics 
Committee (reference: 06/Q702/61). Blood was donated by the Queen Elizabeth Hospital, 
Birmingham, UK, from patients with Haemochromatosis. All tissue was used after obtaining 
written consent from all participants. 
 
2.2 Primary HIEC Isolation 
HIEC were isolated according to a previously described method (Lalor et al., 2006). To 
describe briefly; approximately 30g of liver tissue was finely sliced and digested in 20ml PBS 
(phosphate buffered saline; Oxoid, Basingstoke, UK) with 5ml Collagenase type 1A (Sigma-
Aldrich, UK). This was incubated at 37°C in a humidified incubator with 5% CO2, for 25-45 
minutes, depending on how fibrotic the tissue was. The digest was sieved through a fine 
mesh, and washed with sterile PBS into a sterile beaker. The digest was subsequently 
washed and combined by centrifuging at 2000rpm for 5 minutes with a brake. This was 
continued until the supernatant was clear. The final pellet was re-suspended in PBS. A 
Percoll™ (GE Healthcare, UK) gradient 70%:30% was used to separate the cells. The cell 
mixture was layered on each gradient and centrifuged at 2000rpm for 25 minutes, with no 
brake. The layer of cells at the interphase of the gradient was transferred to universals, 
washed, centrifuged and pelleted as previously described. The final pellet was re-suspended 
in 500µl PBS and 50µl anti HEA-125 Antibody (Ab) (Progen, Biotechnic, Germany), and 
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incubated at 37°C in a humidified 5% CO2 incubator for 30 minutes, with agitation every 10 
minutes. The suspension was washed in PBS and pelleted by centrifuging at 2000rpm for 5 
minutes. The pellet was re-suspended in 500µl ice cold PBS and 10µl goat anti-mouse IgG 
(immunoglobulin G) secondary Ab, conjugated to magnetic Dynabeads™ (Invitrogen, UK) for 
30 minutes on ice with constant agitation. The suspension was diluted in 5ml cold PBS, and 
negative magnetic selection was used to remove BEC, as they conjugated to the HEA-125 
beads. The supernatant was retained and washed in PBS and pelleted by centrifugation, re-
suspended in 500µl ice cold PBS and 10µl CD31 conjugated Dynabeads™ (Invitrogen) for 30 
minutes on ice, with constant agitation. The suspension was made up to 5ml with ice cold 
PBS and positive magnetic selection was used to obtain the HIEC. The cells with beads 
attached were suspended in complete HIEC media, and transferred to a rat tail collagen 
(Sigma-Aldrich, UK) coated 25cm2 (Corning, Costar Incorporated, Bucks, UK) coated flask; 
allowing the cells to adhere for 24 hours before changing the media. 
 
2.3 Complete HIEC Media 
Human endothelial serum free media (Invitrogen) was supplemented with 10% heat 
inactivated human serum (HD Supplies, UK), and 200units/ml Penicillin, 200µg/ml 
Streptomycin, 600µg/ml Glutamine (Invitrogen), 10ng/ml VEGF (Peprotech EC, UK), and 
10ng/ml HGF (Peprotech EC). 
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2.4 Maintenance and Storage of HIEC 
2.4.1 Passaging HIEC: The media was removed and the cells were then washed with 10ml 
PBS before adding 2ml Tryp-LE™ (Invitrogen). The cells were incubated at 37°C for 5 minutes 
to release the cells from the flask. These were then suspended in 10ml PBS before being 
transferred to a universal with 2ml FCS (Foetal calf serum- heat inactivated, Invitrogen) to 
neutralise the Tryp-LE™. The cell suspension was centrifuged at 2000rpm for 5 minutes with 
brake 3 to pellet the cells. The supernatant was discarded, and the cells were re-suspended 
in complete HIEC media at the required density, and then transferred to a T75 flask (Corning 
75cm2). 
 
2.4.2 Counting Cells: After trypsinising and pelleting the cells, the pellet was re-suspended in 
1ml of media. 10µl of this suspension was diluted in 90µl of Trypan Blue (Sigma-Aldrich) and 
viable cells were counted using a haematocytometer chamber. 
 
2.4.3 Freezing and Bringing Cells Up From Frozen: The protocol for passaging cells (Section 
2.4.1) was followed to pellet the cells which were then suspended in FCS with 5% DMSO 
(Dimethyl Sulphoxide, Sigma-Aldrich) at the required density, then transferred to Cryovials, 
and frozen in a Mr Frosty™ isopropanol chamber at -80°C overnight. The Mr Frosty™ 
Chambers allow gradual freezing of cells which prevents ice crystals forming in the cell. The 
vials were then stored in liquid nitrogen until required. To bring up cells from frozen; 1ml of 
warm HIEC media was added to each vial and incubated at 37°C until defrosted. The 
suspension was transferred to a universal and washed with PBS, and centrifuged to pellet 
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the cells. The cell pellet was re-suspended in complete HIEC media and transferred to a rat 
tail collagen coated T75 flask.  
 
2.5 Immunohistochemistry 
2.5.1 Frozen Liver Tissue Sections: Liver tissue blocks 1cm3 were snap frozen in liquid 
nitrogen and 5-7μM thick liver tissue sections were cut using a cryostat. Sections were 
stored at -20°C until required. Frozen liver tissue sections were thawed at room temperature 
for 30 minutes before waxing around the section and fixing in acetone for 5 minutes. The 
sections were then washed in TBS (Tris-Buffered Saline, 25mM Tris (Sigma-Aldrich) and 
50mM NaCl (BDH Supplies, UK) pH 7.6 for 5 minutes. Endogenous peroxidase activity was 
eliminated by incubating the sections for 5 minutes in 0.3% H2O2 in methanol. The sections 
were then washed in TBS pH 7.6 for 5 minutes, before incubating in 2.5% horse serum 
blocking solution (Vector Immpress Kit; MP-7500) for 20 minutes, or the sections were 
blocked using 2% Caesin (Leica Microsystems, Germany) for 10 minutes, to inhibit non-
specific binding. The primary antibodies (Table 2.1) were diluted in the horse serum blocking 
solution or in TBS pH 7.6 and added to the sections for 1 hour on a rocking platform, before 
washing in TBS-Tween pH 7.6 for 5 minutes. Immpress secondary reagent (Vector Immpress 
Kit; MP-7500) was added for 30 minutes and the sections washed again in TBS-Tween pH 
7.6.  
 
2.5.2 Paraffin Liver Tissue Sections: The paraffin sections were de-waxed and hydrated by 
incubating the sections two times in Clearene (Leica Microsystems, Germany) for 5 minutes 
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at room temperature, then incubating the sections in alcohol (Leica) twice for 5 minutes, and 
then re-hydrating the sections in water for 5 minutes. Antigen retrieval was performed by 
incubating the sections for 20 minutes in low pH antigen retrieval solution (Leica) in a 
microwave at full power. The sections were then returned back to room temperature, 
before circling the section with a hydrophobic pen and resuming staining as for frozen liver 
tissue sections. 
 
2.5.3 AEC Substrate: The AEC (3-amino 9-ethylcarbazole) substrate solution (Vector AEC 
peroxidise substrate kit; SK-4200) was added to the sections for approximately 30 minutes, 
or until the desired stain intensity developed. The sections were washed in distilled water to 
stop the reaction, and counter-stained with Mayers Haematoxylin (Signet) for 2 minutes. The 
sections were developed with tap water and mounted using an aqueous mounting solution 
(ThermoScientific, UK) and left to dry overnight.  
 
2.5.4 DAB Substrate: The DAB (3, 3’ diaminobenzidine) substrate solution (Vector) was 
added to the sections for 5 minutes at room temperature, before washing with distilled 
water for 5 minutes. The sections were counterstained with Mayers Haematoxylin for 2 
minutes and developed using tap water. The sections were dehydrated by incubating in 
alcohol twice for 5 minutes, and then Clearene twice for 5 minutes, before mounting with 
DPX mounting media (Leica).  
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2.5.5 Haematoxylin and Eosin stain: All Hematoxylin and Eosin (H and E) staining was carried 
out to a standard protocol (Bancroft e Gamble, 2008). All reagents were obtained from Leica 
Microsystems. 
 
2.5.6 Analysis: Sections were visualised using a light microscope (Nikon) and images were 
processed using Axiovision v 4.4 software. 
 
2.5.7 HIEC Cytospin™ preparations: HIEC were stimulated with and without TWEAK 
(10ng/ml) conditioned media for 24 hours. The HIEC were detached using Tryp-LE, pelleted 
and re-suspended in PBS after counting the cells using a haematocytometer at 1 x 106 
cells/ml. HIEC preparations were subsequently centrifuged on to Poly-L-lysine coated glass 
slides for 5 minutes 550rpm. The slides were allowed to air dry before fixing them in acetone 
for 2 minutes, and wrapping the slides in foil and storing at -20°C until required. 
 
2.5.8 Ki-67 Proliferation Stain: cytospin preparations were thawed until they reached room 
temperature, and subsequently antigen retrieval was carried out for 5 minutes, and staining 
was carried out following protocol from section 2.5.2 and 2.5.3.  
 
2.5.9 Analysis of Nuclear Proliferation Marker: Images were taken from 5 fields of view from 
each section using a light microscope and camera (Nikon), and images were processed using 
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Axiovision v 4.4. Percentage of cells undergoing proliferation was determined by comparing 
ki-67 positive cells to the total number of cells in each image. 
 
2.6 Immuno-fluorescence  
2.6.1 HIEC: HIEC were cultured on glass coverslips until a confluent HIEC monolayer was 
formed, and fixed for 10 minutes using methanol -20°C. After aspirating the excess 
methanol, the coverslips were subsequently frozen at -20°C until required.  
 
2.6.2 Liver Tissue Sections: Liver tissue sections were fixed using acetone, and washed using 
PBS. The Immuno-fluorescence (IF) protocol was identical for fixed cells and sections. The 
cells/ sections were blocked using TBS pH 7.6, 3% BSA (Albumin from bovine serum; Sigma-
Aldrich) and 0.1% Triton X-100 (Sigma-Aldrich) for 1 hour. This was followed by incubating 
them with the primary antibody overnight at 4°C (Table 2.1). The slides were washed 
extensively with PBS for 45 minutes followed by incubation of the fluorescently conjugated 
secondary antibody (Table 2.2) at 37°C for 1-2 hours. The slides were washed again for 30 
minutes using PBS followed by a DAPI (4’, 6 diamidino-2-phenylindole) counterstain, before 
mounting using IF mounting media (DAKO). 
 
2.6.3 Dual Immuno-fluorescence: Liver tissue sections were fixed using acetone and washed 
using TBS pH 7.6 + 0.1% NaN3 + 0.3% Triton X-100 for 5 minutes. The sections were blocked 
using TBS + 0.1% NaN3 + 0.1% Triton X-100 + 10% goat serum (blocking buffer) for 1 hour at 
69 
 
room temperature. The primary antibody was diluted in the blocking buffer, and added to 
the sections for 1 hour at room temperature or overnight at -4°C. The sections were washed 
in TBS + 0.1% NaN3 + 0.1% Triton X-100 (wash buffer) 3 x 10 minutes, before adding the 
fluorescently conjugated secondary antibody (Table 2.2) diluted in the blocking buffer for 1 
hour, and washed again using the wash buffer for 3 x 10 minutes. This process was repeated 
for the second primary and secondary antibody. A DAPI nuclear stain was added for 5 
minutes, before mounting the sections using IF mounting media. 
 
2.6.4 Golgi Plug and Stop Immuno-fluorescence: HIEC were seeded into Ibidi µ-Slide VI 0.4 
ibiTreat microslides at 3.5x104, and left for the HIEC to form a monolayer for two hours, 
before changing the media and incubating the cells overnight at 37°C. The HIEC were 
stimulated with TNF-α, TNF-α + Golgi Plug, TNF-α + Golgi Stop (Table 2.3), for 16 hours 
before removing the media, and fixing the cells using 2% PFA (paraformaldehyde) for 10 
minutes at room temperature, and proceeding with IF staining as described for HIEC. 
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Table 2.1 Primary Antibodies: Primary antibodies used during flow cytometry, IHC and IF, 
their clone, concentrations and supplier. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Antibody Clone 
Concentration used μg/ml 
Source Flow Cytometry IHC and IF 
IgG1 Mouse (MOPC21) 1.62 13 Biogen Idec 
IgG2a Mouse (P1.17) 1.85 13.6 Biogen Idec 
IgG1 Rabbit  10 AbCam 
Fn14 Mouse (MP4A8) 1.62 13 Biogen Idec 
TWEAK Mouse (MP2D10) 1.85 13.6 Biogen Idec 
CD31 Mouse (JC70A) 25 10 DAKO 
CD68 Mouse (Y1/82A) 25 10 eBioscience 
CD90 Mouse (5E10) 25 10 eBioscience 
CK18 Mouse (CD10) 30 12 DAKO 
CK19 Mouse (RCK108) 25 10 DAKO 
CD31 (Polyclonal) Rabbit - 10 AbCam 
CD20 Mouse (B-Ly1) - 10 DAKO 
CD3 Mouse (F72.38) - 10 DAKO 
FGF R1 Rabbit (D8E4) - 1:400 Cell Signalling 
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Table 2.2 Secondary and Conjugated Antibodies: secondary and conjugated antibodies, 
their clone and supplier. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Antibody Clone Source 
CD14 FITC mouse α human Miltenyi MACS 
CD14 PE mouse α human Miltenyi MACS 
CD14 APC mouse α human Miltenyi MACS 
CD66b PE mouse α human Miltenyi MACS 
CD56 PE mouse α human Miltenyi MACS 
IgG2a APC mouse α human Miltenyi MACS 
IgM FITC mouse α human Miltenyi MACS 
IgG1 PE mouse α human Miltenyi MACS 
VCAM PE mouse α human BD Biosciences 
ICAM APC mouse α human BD Biosciences 
IgG1 PE mouse α human BD Biosciences 
IgG1 APC mouse α human BD Biosciences 
Alexa Fluor 488 goat α mouse Invitrogen 
Alexa Fluor 546 goat α mouse Invitrogen 
FITC goat α mouse Southern Biotech 
TRITC goat α rabbit Southern Biotech 
Texas Red goat α mouse Southern Biotech 
Alexa Fluor 610 goat α mouse Invitrogen 
Alexa Fluor 405 goat α mouse Invitrogen 
Pacific Orange goat α mouse Invitrogen 
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2.7 Flow Cytometry 
2.7.1 Cell Surface Staining: Cells were stimulated with the appropriate cytokines for 24 hours 
(Table 2.3). The cells were then washed with PBS, and detached using Tryp-LE™ as previously 
described. The cells were subsequently washed in PBS again and centrifuged at 2000rpm for 
5 minutes. The pelleted cells were then suspended in PBS serum buffer containing PBS and 
10% FCS at 1x106 cells/ 100µl buffer. Primary antibodies (Table 2.1) were added at the 
required concentration diluted in PBS serum buffer at 4°C for 30 minutes with agitation. The 
cells were washed with 0.5ml PBS and centrifuged at 2000rpm for 5 minutes. The secondary 
fluorescently conjugated antibodies (Table 2.2) were diluted in PBS serum buffer, and added 
to each tube in a volume of 100µl, and incubated at 4°C for 30 minutes with agitation. The 
cells were washed again in PBS before fixing in 100µl of 2% PFA per tube for 20 minutes on 
ice. The cells were then washed in PBS and re-suspended in 0.5ml PBS before analysis.  
 
2.7.2 Intracellular Staining: The cells were fixed using 2% PFA on ice for 20 minutes, before 
staining with antibodies. The antibodies were diluted in permeablisation buffer (BD 
Biosciences) and left to incubate for 30 minutes at 4°C to permeablise the cell membrane. 
The cells were washed in permeablisation buffer, and re-suspended in 100µl 
permeablisation buffer with the secondary fluorescent conjugated antibody, and left to 
incubate at 4°C for 30 minutes. The samples were washed again, and re-suspended in 500µl 
PBS prior to analysis. 
 
2.7.3 Flow Cytometry Analysis: Analysis was carried out on a Dako Cyan ADP flow cytometer 
and Summit 4.3 for analysis of data. 
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Table 2.3 HIEC stimulations: Cytokines used to stimulate HIEC, their concentrations and supplier. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
             
  
 
 
 
 
 
Stimulations Concentration used (ng/ml) Source 
TNF-α 10 Peprotech 
TWEAK 100 Biogen IDEC 
IFN-γ 20 Peprotech 
FGF 0.5 Peprotech 
IL-1β 10 Peprotech 
IL-2 10 Peprotech 
IL-4 100 Peprotech 
IL-6 20 Peprotech 
IL-8 20 Peprotech 
IL-10 50 Peprotech 
IL-17A 50 Peprotech 
IL-18 100 Peprotech 
IL-21 50 Peprotech 
IL-22 50 Peprotech 
MCP-1 20 Peprotech 
TGF-β 10 Peprotech 
Golgi Plug 1:1000 BD Biosciences 
Golgi Stop 0.7:1000 BD Biosciences 
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 Table 2.4 Functional Inhibitors: Inhibitors used, their concentrations and supplier. 
 
 
 
 
 
2.8 Quantitative Real Time PCR 
2.8.1 RNA Isolation: Total RNA was isolated from HIEC and whole liver blocks using the 
RNeasy® Mini Kit (Qiagen) according to the manufacturer’s instructions. Liver blocks, 
approximately 30mg in weight were submerged in RNA later (Sigma-Aldrich) prior to RNA 
(ribonucleic acid) isolation to preserve RNA. The HIEC and PBMC (peripheral blood 
mononuclear cells) were stimulated for 24 hours prior to RNA isolation (Table 2.3), and the 
cells were detached from their flasks and pelleted by centrifugation prior to RNA isolation. If 
RNA was not isolated immediately, then the cell pellets were suspended in RNA later. DNA 
(deoxyribonucleic acid) contamination was removed from the isolated RNA, using the RNase 
Free DNase Set (Qiagen). 
 
2.8.2 cDNA Synthesis: cDNA (complementary DNA) was synthesised from 1µg of isolated 
total RNA using the 1st strand cDNA synthesis kit for RT-PCR (AMV) (Roche). 
 
2.8.3 Real Time Polymerase Chain Reaction: Primers specific to TWEAK and Fn14 were 
designed using the Primer-BLAST program using the NCBI databases. The Primers were 
purchased from Alta Bioscience (Birmingham, UK; Table 2.5). Primer probes specific to 
Inhibitor Concentration Source 
TWEAK Inhibitor (Fn14 mAb) 74 ng/ml Biogen IDEC 
NF-kB Rel A Inhibitor 10 μg/ml Calbiochem 
Erk 1/2 Inhibitor 20μM Cell Signalling 
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TWEAK (04689097001) and Fn14 (04687574001) were designed and purchased from Roche, 
and relative expression levels were calculated and compared to the housekeeping gene 
GUSB (Roche). The lightcycler 480 master-mix and system (Roche) was used for the real time 
PCR (Table 2.6). 
 
Table 2.5 TWEAK and Fn14 primer sequence: Primers used for qPCR to detect TWEAK and Fn14 
mRNA. 
 
 
 
 
 
 
  Table 2.6 Thermal profile for real time PCR: qPCR programme. 
 
 
 
 
 
 
2.9 MTT to assess cell viability  
HIEC were seeded into a 24 well plate at a density of 5.0 x 104 per well, and were stimulated 
for 24 hours in HIEC complete media.  Thereafter, the media was removed and cells were 
treated with Yellow MTT (Thiazolyl Blue Tetrazolium Blue; Sigma-Aldrich) to assess cell 
Primers Fn14 
Forward 5'-CAC-GAA-GGT-CAG-GCT-CAG-A-3' 
Reverse 5'-GAC-CGC-ACA-GCG-ACT-TCT-3' 
 TWEAK 
Forward 5'-CTC-ACT-GTC-CCG-TCC-ACA-C-3' 
Reverse 5'-ATC-GCA-GCC-CAT-TAT-GAA-GT-3' 
 
Number of Cycle: 65 Temperature °C  Time (minutes) 
Denaturing 95 1 
Annealing 60 1 
Extension 72 1 
Hold 4 5 
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viability. Each well was treated with 300µl of 0.4mg/ml MTT, made up in complete HIEC 
media, and incubated for 1 hour until the development of a purple insoluble formazan 
product was visualised.  The media was removed and 600µl of DMSO was added to each well 
to solubilise the purple formazan product.  The plate was incubated at room temperature for 
5 minutes on a plate shaker, and then read at an absorbance of 490nm. The percentage 
viability was calculated using the following formula: 
% viability = mean absorbance of sample X 100 
                     Mean absorbance of control  
 
2.10 Angiogenesis Assay  
2.10.1 Angiogenesis Assay: BD Natural Matrigel ™ (VWR) was thawed on ice at 4°C 
overnight. A 12 well plate was coated with the natural Matrigel ™ after wetting the plates 
with PBS. The Matrigel ™ was allowed to set at 37°C prior to seeding harvested HIEC at 1.4 x 
105 cells/ well in complete HIEC media, with the appropriate stimulations. The cells were 
then incubated at 37°C for 24 hours.  
 
2.10.2 Analysis: Images were taken using a Zeiss Axiovert 40C microscope and Canon 
DS126171 camera, at 0, 4, 8 and 24 hours post stimulation. Images were taken from five 
fields of view of each well. The assay was quantified by counting the average number of 
nodes with 1 or more branch points, from five fields of view of each condition at 8 hours. 
 
2.10.3 Angiogenesis and Cytokine Array: Supernatants from the Angiogenesis Assay were 
analysed using the Proteome Profiler™ Array; Human Angiogenesis Array Kit (R&D Systems; 
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ARY007), and Human Cytokine Array Panel A (R&D Systems; ARY005) according to the 
manufacturer’s instructions. 
 
2.11 Scratch Wound Assay  
2.11.1 Scratch Wound Assay: HIEC were seeded at 1.75 x 105 cells/well in complete HIEC 
media in a 6 well plate coated with 0.1% (w/v) gelatin in PBS, and left overnight. The media 
was then aspirated, and pen marks were made at the bottom of the wells before a scratch 
was made perpendicular to the pen marks. Fresh media was made containing 25µg/ml 
mitomycin C (to prevent cell mitosis) (Sigma-Aldrich), and appropriate cytokines were added. 
The media in each well was replaced by the conditioned media and incubated at 37°C. 
 
2.11.2 Analysis: Cell migration was observed by taking images at 0, 4, 8, 24 and 48 hours. 
Images were taken using a Zeiss Axiovert 40C microscope and Canon DS126171 camera. 
 
2.12 Determination of ROS accumulation, apoptosis, necrosis and autophagy  
HIEC were stimulated for 24 hours with the appropriate conditioned media. The media was 
then aspirated and kept in a separate tube and replaced with HBSS (Hanks Balanced Salt 
Solution; Sigma-Aldrich), an ROS accumulation marker: 30µM 2’, 7’- dichlorofluorescin (DCF) 
(Gibco) and an autophagy marker: 1µM monodansylcadaverine (MDC) (Gibco) were added 
to the media, and incubated at 37°C for 20 minutes with constant agitation. The cells were 
harvested using Tryp-LE™, and placed into the aspirated media from the initial step and 
washed extensively in PBS and 10% FCS. The cells were then re-suspended in Annexin-V 
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staining buffer and labelled with Annexin-V (Molecular Probes, Paisley, UK); an apoptosis 
marker, and 7-AAD (Molecular Probes, Paisley, UK); a necrosis marker, and incubated on ice 
for 15 minutes before analysis using flow cytometry. Appropriate compensation tubes were 
used for each channel the antibodies were analysed at. 
 
2.13 Peripheral Blood Mononuclear Cell Isolation 
Peripheral blood was layered upon a lympholyte (Cedarlane) gradient at a ratio of 2:1 and 
centrifuged at 2000rpm for 20 minutes with brake 0. The mononuclear layer was removed 
and washed with PBS, before centrifuging for 5 minutes at 2000rpm. The pellet was re-
suspended and washed again in PBS, before centrifuging for 10 minutes at 800rpm to 
remove platelets.  
 
2.14 Monocyte Subset Sorting 
PBMC were isolated and counted using a haematocytometer, before labelling the sample 
using fluorescently conjugated antibodies (Table 2.2). CD56 and CD66 were used for 
negative selection of neutrophils and NK cells. Separate tubes of PBMC were also set up with 
the relevant isotype controls and compensation tubes for APC, FITC and PE. The samples 
were incubated for 30 minutes at 4°C, then washed with PBS serum buffer and centrifuged 
at 2000rpm for 5 minutes, brake 3. The cell pellet was re-suspended in PBS serum buffer at 1 
x 106 cells/ml. The sample for sorting was transferred into sterile tubes using a filter (PARTEC 
Cell Trics®) to separate the preparation into a single cell suspension.  
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The MoFlow high speed cell sorter was set up using the isotype controls, and all three 
fluorescent channels were compensated. The sample was then sorted into Classical; 
CD14++CD16-, Non-classical; CD14+CD16++ and Intermediate; CD14++CD16+ subsets into 
sterile tubes containing RPMI (Sigma-Aldrich) + 10% FCS. The monocyte cloud was isolated, 
and the PE negative cloud was further sorted into the monocyte subsets (Figure 2.1). Once 
cell sorting was complete the subsets were centrifuged at 2000rpm for 5 minutes brake 3; 
re-suspended in RPMI + 10% FCS, and incubated overnight at 37°C with and without IFN-γ 
50ng/ml activation. RNA was isolated from each subset, converted to cDNA, and RT-PCR was 
used to determine TWEAK mRNA expression.  
 
 
 
 
 
 
 
 
 
2.15 Flow Assay 
 
2.15.1 Ibidi µ-Slide preparation: Ibidi µ-Slide VI 0.4 (ibi-Treat microslides) were prepared by 
incubating the slides for 30 minutes after adding rat tail collagen into each lane, ensuring the 
 
Figure 2.1 Monocyte subset sorting: Monocytes were isolated by selecting the correct cell 
gate and subsequently negatively selecting for neutrophils and NK cells (CD56 and CD66). 
The monocytes were separated in to their subsets by selective markers for CD14 and CD16. 
These were classical monocytes; CD14++CD16-, Intermediate monocytes; CD14++CD16+, 
and non-classical monocytes; CD14+CD16++. (Liaskou et al., 2013) 
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entire lane was covered. The rat tail collagen was removed and the slides were then washed 
through with sterile PBS, and then washed with HIEC complete media to ensure no residual 
rat tail collagen was remaining. 
 
2.15.2 HIEC monolayer preparation: HIEC were seeded into the coated Ibidi µ-Slides at 
3.5x104 cells/lane, and incubated for two hours to allow an HIEC monolayer to adhere, 
before changing the media and incubating overnight at 37°C. The HIEC were then stimulated 
for 24 hours with the appropriate conditions.  
 
2.15.3 Flow based adhesion assay: PBMC were isolated (Section 2.13) and counted, and re-
suspended at 106 cells/ml in endothelial media + 10% FCS. The Ibidi microslide was 
connected to a Harvard pump (Harvard Apparatus, South Natic, USA), a syringe to remove 
waste, and an electronic valve which allowed alternating perfusion of the PBMC cell 
suspension and the wash buffer (endothelial serum free media + 0.1% BSA) (Figure 2.2). The 
microslide, PBMC suspension, and wash buffer were kept incubated in a temperature 
controlled chamber to ensure optimal conditions for the duration of the assay. The PBMC 
were perfused over the stimulated HIEC at 0.05Pa for 5 minutes, and then the wash buffer 
was perfused over the HIEC layer for 3 minutes. The assay was recorded for 2 minutes by a 
microscope and camera unit, whilst changing the field of view 10 times. 
 
2.15.4 Analysis: the data was analysed by counting PBMC which have adhered and migrated 
to the HIEC monolayer, in 10 different fields per condition of a known dimension. Monocytes 
and lymphocytes were counted and easily distinguishable by their size difference, with 
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monocytes being much larger in size than lymphocytes. PBMC shape change was analysed by 
counting all PBMC which have changed shape and comparing them to PBMC which have 
remained round. All data was normalised to the total number of cells perfused per 
condition, and data was shown as cells/mm2/106 cells perfused. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.16 Western Blotting 
 
 
Figure 2.2 Flow based adhesion assay: A) The Ibidi microslide with the HIEC monolayer 
was connected to a Harvard pump, a syringe to remove waste, and an electronic valve 
which alternated between PBMC suspension and wash buffer. The whole assay was 
carried out in a heated chamber to ensure optimum experimental conditions. The slide 
was mounted on to a microscope with an internal camera which was attached to a TV 
and DVD recording unit. B) The PBMC were perfused over an HIEC monolayer for 5 
minutes at 0.05PA shear stress before subsequent analysis. 
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2.16.1 Protein Lysate Preparation: HIEC were stimulated and collected into universal tubes.  
The cells were washed with PBS and centrifuged for 5 minutes at 2000rpm brake 3. The cell 
pellet was re-suspended in Cell lytic MT™ (Sigma-Aldrich), + phosphatase and protease 
inhibitor cocktail (1:100; Cell Signalling), + DNase (Sigma-Aldrich), and incubated for 15 
minutes on a shaking platform. The lysed cells were sonicated briefly to further disrupt the 
cell membrane, and centrifuged at 13’000 rpm for 30 minutes. The supernatant containing 
the protein lysate was transferred to a chilled tube and kept at -80°C until required. 
 
2.16.2 Protein Determination Assay: A BSA calibration curve was made from a concentration 
range of 1-0.016mg/ml. The samples were diluted 1:10 in 0.85% NaCl solution, which was 
also used as a blank. 20µl of each sample and standard was loaded on to a 96 well plate in 
duplicates, and 220µl of Biuret reagent was added to each well and incubated at room 
temperature for 10 minutes. 10 µl of Folin and Ciocaulteaus (Sigma-Aldrich) reagent was 
added to each well, mixed and incubated at room temperature for 30 minutes. The plate 
was then read at 750nm absorbance. 
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Table 2.7 Western Blotting reagents: Western blotting reagents, molecular weight and supplier. 
 
 
 
 
 
 
 
 
 
 
2.16.3 SDS PAGE: 40-50µg of protein was diluted in the appropriate sample buffer (200mM 
Tris pH 6.8, 20% Glycerol, 10% SDS and 0.05% bromophenol blue), and boiled at 100°C for 10 
minutes. The resolving gel was made (Table 2.9) and poured between glass plates, and a 
layer of butanol was used to prevent oxidisation of the gel. Once the gel had set, the butanol 
was removed and the stacking gel was layered over the resolving gel, and a comb was 
inserted to create wells. Once set, the gel was placed into an electrophoresis tank, and the 
samples and molecular weight marker was loaded before running the gel at 200V, until the 
dye front reached the bottom of the plate. The separated protein was transferred to 
nitrocellulose membrane using transfer apparatus, at 100V for 60 minutes.  
 
 
 
Reagent Molecular Weight (FW) Source 
Tris Base 121.14 Sigma 
Tris HCl 157.6 Sigma 
Glycine 75.07 Sigma 
Sodium Dodecyle Sulphate 288.38 Sigma 
NaCl (Sodium Chloride) 58.44 Sigma 
Non Fat Milk - Marvel 
BSA (Bovine Albumin Serum) - Sigma 
APS (Ammonium Persulphate) 228 Sigma 
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Table 2.8 Western Blotting buffers: Buffers used for Western blotting and their constituents. 
 
 
 
 
 
 
 
 
 
 
 
Table 2.9 SDS PAGE: SDS PAGE components. 
 
 
 
 
 
 
 
 
 
Western Blotting Buffers Constituents 
Stacking Gel Buffer 1.M Tris Base pH 6.8 
Resolving Gel Buffer 1.5M Tris Base pH 8.8 
Electrophoresis Buffer 2.5mM Tris Base, 200mM Glycine, 1g SDS, 1L Distilled H2O 
Transfer Buffer 
2.5mM Tris Base, 200mM Glycine, 200ml Methanol, 800ml 
Distilled H2O 
Stripping Buffer 
100mM β-2-mercaptoethanol, 2% w/v SDS, 62.5mM Tris-HCL pH 
6.7 and Distilled H2O 
10x TBS (Tris Buffered Saline) 24.2g Tris Base, 80g NaCl, pH 7.6 
Wash Buffer TBS,  0.1% (v/v)Tween 
Blocking Buffer 100 ml TBS,  0.1% (v/v)Tween, 5g non-fat milk 
Antibody Dilution Buffer 100 ml TBS,  0.1% (v/v)Tween, 5g BSA 
 
 
Stacking Gel (ml) Resolving Gel (ml) 
4% 5% 6% 8% 10% 
Resolving Gel Buffer 0 0 2.5 2.5 2.5 
Stacking Gel Buffer 0.63 0.63 0 0 0 
Distilled H20 3.6 3.4 5.3 4.6 4 
30% acrylamide (BioRad) 0.64 0.83 2 2.7 3.3 
10% w/v SDS 0.1 0.1 0.1 0.1 0.1 
10% w/v APS 0.1 0.1 0.1 0.1 0.1 
TEMED 0.02 0.02 0.02 0.02 0.02 
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2.16.4 Ponceau Stain: To ensure successful transfer of the protein, the nitrocellulose 
membrane was placed in Ponceau S solution (Sigma), and immediately washed with tap 
water until the bands could be visualised. The membrane was then washed in tap water until 
the Ponceau stain was completely removed. The membrane was then blocked in 5% milk 
solution or 5% BSA solution for 60 minutes. 
 
2.16.5 Blotting: The primary antibody was diluted in BSA (Table 2.10), and the nitrocellulose 
membrane (Hy-bond Nitrocellulose, Amersham) was incubated overnight at -4°C in the 
solution. The membrane was then washed in TBS-Tween (0.1%) for 3 x 5 minutes on a 
shaking platform, before adding β-actin (as a positive control) diluted in BSA for 1 hour. The 
membrane was washed again in TBS-Tween (0.1%) 3 x 5 minutes before adding the 
secondary HRP conjugated antibodies (Table 2.10). The membrane was then washed finally 
in TBS-Tween (0.1%) 3 x 5 minutes, before adding the ECL reagent according to 
manufacturer’s instructions. The membrane was then placed in a cassette with X-ray film 
and developed at various time points in the dark.  
 
2.16.6 Stripping and Re-probing the Nitrocellulose Membrane: The membrane was incubated 
in stripping buffer for 30 minutes at 50°C. It was then washed 2 x 10 minutes in TBS Tween, 
before blocking the membrane and re-probing as before. 
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Table 2.10 Western Blotting antibodies: Western blotting antibodies used, their clone, 
concentration and supplier. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Clone Concentration used Source 
NF-kB Rel A Phosphorylated Rabbit (93H1) 1:100 Cell Signalling 
NF-kB Rel A Total Rabbit (D14E12) 1:100 Cell Signalling 
NF-kB Rel B Phosphorylated Rabbit 1:100 Cell Signalling 
NF-kB Rel B Total Rabbit (C1E4) 1:100 Cell Signalling 
Erk 1/2 Phosphorylated Rabbit (D13.14.4E) 1:100 Cell Signalling 
Erk 1/2 Total Rabbit (137F5) 1:100 Cell Signalling 
Src Phosphorylated Rabbit (D49G4) 1:100 Cell Signalling 
Akt Phosphorylated Rabbit (D9E) 1:100 Cell Signalling 
FAK Phosphorylated Rabbit (D20B1) 1:100 Cell Signalling 
PLCγ1 Phosphorylated Rabbit (D25A9) 1:100 Cell Signalling 
VEGFR2 Phosphorylated Rabbit (19A10) 1:100 Cell Signalling 
P38 MAPK Phosphorylated Rabbit (D3F9) 1:100 Cell Signalling 
β-actin Mouse (AC-15) 1ug/ml Sigma Aldrich 
Goat α Rabbit HRP 
conjugated P0448 1:200 DAKO 
Goat α Mouse HRP 
conjugated P0260 1:200 DAKO 
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2.17 Statistical analysis 
 Statistical analysis of data from numerical variables between two groups was carried out 
using a paired Student’s t test, when the data followed normal distribution. Mann-Whitney 
U test was performed when the data followed non-normal distribution. p-values of ≤ 0.05 
were considered statistically significant, and data was presented as *≤0.05, **≤0.01 and 
***≤0.001. All statistical analysis was carried out using Microsoft Excel and GraphPad Prism 
software. 
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CHAPTER 3 
TWEAK and Fn14 may regulate specific inflammatory responses in the liver via paracrine 
interactions of leukocytes and HIEC 
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3.1 INTRODUCTION 
Cells of the innate and adaptive immune system highly express TWEAK, indicating the critical 
role TWEAK may play in mediating inflammatory responses. Over the years, TWEAK 
activated inflammatory responses have been a focus of TWEAK and Fn14 functional 
activities. These have been extensively characterised by TWEAK and Fn14 regulated 
leukocyte infiltration and recruitment via cellular interactions, cell surface adhesion proteins, 
and chemokine and cytokine expression. TWEAK and Fn14 expression has subsequently 
been observed in several studies of inflammatory diseases such as MS, RA and LN (Winkles, 
2008). The expression of TWEAK and Fn14 mRNA and protein has also been found in a 
variety of tumours including pancreatic, ovarian and colorectal tumours, and often a variable 
response to malignancy by TWEAK and Fn14 has been observed (Feng et al., 2000; Ho et al., 
2004; Winkles, 2008). Fn14 and TWEAK protein and mRNA expression has been detected in 
normal and diseased liver in several investigations, where their expression has been found to 
be key during liver inflammatory processes and regeneration (Feng et al., 2000; Jakubowski, 
Ambrose, Parr, Lincecum, Wang, Zheng, Browning, Michaelson, Baetscher, Baestcher, et al., 
2005).  
 
The general TWEAK and Fn14 expression pattern in normal tissue is found to be low, 
however in inflamed tissue TWEAK and Fn14 expression is found to be up-regulated. This 
expression has been found to be highly regulated by many growth factors and cytokines, and 
the expression patterns of TWEAK and Fn14 always vary and are dependent on the tissue, 
conditions, and context they are present in. Thus, TWEAK and Fn14 interactions have been 
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found to be highly complex and multifunctional capabilities even within the same type of 
tissue have been described (Chicheportiche et al., 1997; Burkly et al., 2007; Winkles, 2008; 
Burkly e Dohi, 2011).  
 
This investigation aimed to understand functional regulation of TWEAK and Fn14 in chronic 
inflammatory liver disease by further characterising the expression and regulation patterns 
of TWEAK and Fn14 in HIEC. TWEAK and Fn14 expression has previously been detected in 
liver tissue in several studies but not characterised to individual liver cell populations; and 
specifically in HIEC. It is first important to understand the expression patterns of TWEAK and 
Fn14 in HIEC and in liver tissue. It is then highly essential to further characterise leukocyte 
recruitment via TWEAK and Fn14 by HIEC, as these cells mediate a host of physiological, 
immune, and pathogenic functions within the liver; and understanding these processes are 
essential for regulating these during pathological settings as an aim to develop novel 
therapeutics in future.  
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3.1.2 Aims 
The aims of this chapter were: 
 To determine TWEAK and Fn14 expression in liver tissue and in isolated HIEC. 
 To determine conditions which may activate TWEAK and Fn14 expression in 
HIEC. 
 To determine TWEAK expression in PBMC and in monocyte subsets, to further 
understand Fn14 and TWEAK interactions with HIEC during inflammation. 
 To determine if TWEAK stimulated HIEC express ICAM and VCAM adhesion 
proteins on their cell surface which may facilitate leukocyte recruitment. 
 To determine if TWEAK stimulated HIEC, contribute to leukocyte recruitment 
by TWEAK, and TWEAK in combination with other cytokines. 
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3.2 MATERIALS AND METHODS 
Materials and Methods for this chapter; refer to sections: 2.1-2.8, 2.13 - 2.15 and Tables: 
2.1-2.6.  
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3.3 RESULTS 
3.3.1 Liver tissue architecture 
We wanted to identify the different cell types and structures within the liver we were 
analysing, to do this we used IHC immunohistochemistry (IHC). Liver tissue sections were 
stained using IHC and antibodies of phenotypic markers of typically identified liver cells and 
structures, and compared these to the IgG control for all antibodies used (Figure 3.3.1a A). 
Figure 3.3.1a B shows a representative CD31 stained liver tissue section. CD31 is a marker of 
cells of an endothelial phenotype, staining in this section was observed in portal veins, 
hepatic arteries, neovessels, and surrounding sinusoidal endothelium. Figure 3.3.1a B is also 
a representative image of a portal triad which consists of a bile duct, portal vein and hepatic 
artery. CK18 is a marker for hepatocytes and biliary epithelial cells. Figure 3.3.1a C is a 
representative image of stained bile ducts and hepatocytes. CK19 is a marker for biliary 
epithelium, Figure 3.3.1b D shows staining present in epithelia and bile ducts. CD90 is a 
marker for fibroblasts which is represented in Figure 3.3.1b E. CD68 is a marker for 
monocytic cells including monocytes, macrophages and KC, Figure 3.3.1b F shows 
representative staining of this marker.  
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Figure 3.3.1a Phenotyping liver tissue: frozen liver tissue sections were stained for 
phenotypic markers of liver cells and structures. A) Shows the IgG1 control for the 
antibodies used. B) Shows CD31 staining which is an endothelium marker, staining 
was present in liver sinusoidal endothelium, neovessels, portal veins and hepatic 
arteries. C) Shows CK18 staining which was present in biliary epithelial cells and 
hepatocytes. All antibodies were developed with a DAB substrate. Images were 
taken with a Zeiss microscope and axiovision v4.4 software 200x magnification. 
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Figure 3.3.1b Phenotyping liver tissue: frozen liver tissue sections were stained for 
phenotypic markers of liver cells and structures. D) Shows CK19 staining which was 
present in biliary epithelium. E) Shows CD90 staining which was present in 
fibroblasts. F) Shows CD68 staining which was present in monocytic cells. All 
antibodies were developed with a DAB substrate. Images were taken with a Zeiss 
microscope and axiovision v4.4 software 200x magnification. 
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3.3.2 TWEAK and Fn14 expression was up-regulated in inflammatory liver disease tissue 
To determine the mRNA expression difference of TWEAK and Fn14 between normal liver 
tissue and inflammatory diseased liver tissue. We used PBC and PSC diseased liver tissue as 
models of CILD and normal liver tissue, and analysed these for mRNA expression of TWEAK 
and Fn14 using quantitative real time PCR. TWEAK mRNA expression was significantly 
(*p=0.01) up-regulated 3.5 fold in diseased liver tissue (n=6), in comparison to normal liver 
controls (n=3). Fn14 mRNA expression was also significantly (*p=0.03) up-regulated 17 fold 
in diseased liver tissue (n=6) (Figure 3.3.2 A and B respectively).  
 
Chronic inflammatory liver disease sections from explanted liver tissue were stained for 
TWEAK using an anti-TWEAK mAb (Figure 3.3.3). The sections stained included NASH, PBC, 
and ALD tissue. In the liver tissue sections analysed, TWEAK expression was observed in 
monocytic cells present in inflammatory infiltrates in close proximity to portal vessels (Figure 
3.3.3 A, E and F). Representative magnified images of positive TWEAK staining is shown in 
Figure 3.3.3 C and G. All TWEAK staining was compared to the relevant IgG2a control (Figure 
3.3.3 D and H). 
 
Fn14 expression was determined using IHC in liver tissue sections and this was compared to 
normal donor tissue (Figure 3.3.4). Liver tissue sections from normal donor (A and B) and 
diseased liver tissues including PBC (C and F) and ALD (D and E) were analysed for Fn14 
expression, this was compared to the relevant IgG1 control (Figure 3.3.4 G-I) representative 
images are shown. Fn14 expression was predominantly seen surrounding portal vessels, 
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neovessels, sinusoidal endothelium in close proximity to portal vessels, and in hepatocytes. 
Fn14 expression was also observed in ductular reactive cells (Figure 3.3.4 F). Fn14 expression 
did not appear in the same regions consistently; it was present in some neovessels and in 
certain portal vessels. One normal donor case showed a very light Fn14 stain present in the 
hepatocytes (Figure 3.3.4 A), however in the second normal donor case Fn14 was expressed 
highly in portal vessels (Figure 3.3.4 B). The staining pattern in the different diseased liver 
tissue types all showed an individual staining pattern. 
 
Fn14 distribution and expression patterns indicated that Fn14 may be involved in ductular 
and portal vessel neogenesis. It was important to further establish whether the Fn14 
expression observed, was actually present on endothelial regions of diseased liver tissue. 
Therefore dual immuno-fluorescence staining was used to co-stain diseased liver tissue 
sections with Fn14 (stained green) and CD31 (stained red) (Figure 3.3.5), ALD (Figure 3.3.5 A) 
and NASH (Figure 3.3.5 F) cases were stained. Fn14 expression was confirmed to be present 
in areas where portal vessels were present, and in hepatocytes (Figures 3.3.5 A and F), re-
confirming observations made in the IHC staining. Fn14 co-localisation with CD31 was 
present in the sections; however this co-localisation was present in select areas and not 
entirely throughout the liver tissue section as was observed with IHC staining (Figures 3.3.5 
D and I).  
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Figure 3.3.2 TWEAK and Fn14 mRNA expression was elevated in PBC and PSC 
diseased liver tissue in comparison to normal liver tissue: total RNA was isolated 
from normal liver blocks (n=3) and diseased liver blocks (PBC and PSC; n=5-6). qPCR 
was performed to detect TWEAK and Fn14 mRNA expression. TWEAK and Fn14 
mRNA expression was significantly higher in diseased liver tissue in comparison to 
normal donor liver (*p=0.01 and *p=0.03 respectively). All samples have been 
analysed as duplicates against a GUSB reference gene. Fn14 and TWEAK forward and 
reverse primer concentration 1µM/ well. Data was shown as fold difference with the 
normal donor normalised to 1. Data is shown as ± standard error. Statistical analysis 
was performed using a Mann Whitney U test. 
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Figure 3.3.3 TWEAK localises to monocytic cells in close proximity to portal vessels in 
chronic inflammatory liver diseased tissue: PBC, NASH and ALD liver tissue sections 
were stained for TWEAK. A, B, E, and F) Show corresponding TWEAK IHC staining of 
diseased liver tissue. Magnified images (x3) of TWEAK stained tissue is shown in C and G. 
TWEAK expression was confirmed within monocytic infiltrates near portal vessels. 
Staining was compared to the corresponding IgG2a controls (D and H). All antibodies 
were developed with a DAB substrate. Images were taken with Zeiss microscope and 
axiovision v4.4 software 200x magnification. 
 
 
100 
 
  
Figure 3.3.4 Fn14 localises to portal vessels and neovessels in inflamed and normal 
liver tissue: Normal liver (A and B), PBC (C and F) and ALD (D and E) liver tissue were 
stained for Fn14. G-I Shows corresponding IgG1 controls. Fn14 expression was 
confirmed to be present on hepatocytes, portal vessels, neovessels and liver sinusoidal 
endothelium. All antibodies were developed with a DAB substrate. Images were taken 
with Zeiss microscope and axiovision v4.4 software 200x magnification. 
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Figure 3.3.5 Fn14 was expressed in portal vessels in inflamed liver tissue: A and F) 
show dual immuno-fluorescent staining of portal vessels in inflamed liver tissue (ALD 
and NASH respectively) for Fn14 (FITC; green); B and G) shows the same section stained 
for the endothelial cell marker CD31 (TRITC; red); C and H) shows DAPI nuclear staining 
(Blue). D and I) shows the merged image confirming co-localisation of Fn14 to portal 
vessels. E and J) Show the control with primary antibodies substituted for isotype 
matched control IgG1. Images were taken with a Zeiss LSM 510 UV confocal microscope 
magnification 200x.  
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3.3.3 Phenotyping isolated primary HIEC  
To establish the purity of HIEC isolated for the experiments in this study, phenotypic markers 
were used. IHC was used to stain isolated HIEC preparations for the following markers: CD31, 
CK18, CK19, CD90 and CD68 (Figure 3.3.6). All staining was compared to IgG1 isotype 
matched control (Figures 3.3.6 A). Isolated HIEC stained positive for CD31 which was the 
specific marker used to isolate cells of an endothelial phenotype from whole liver 
preparations (Figures 3.3.6 B). CK18 stained predominantly negative, however some 
contamination was observed (Figures 3.3.6 C). All other markers stained HIEC negatively 
(Figures 3.3.6 D, E, F). 
 
HIEC were isolated and analysed for purity using flow cytometry. Cells were gated around 
the region where HIEC appear on the FACS plot to ensure no other cell type was included in 
the analysis (Figure 3.3.7 A). A further gate was used to isolate the region where only single 
cells were included in the analysis, to ensure accuracy of data obtained (Figure 3.3.7 B). 
CD31 was used as a positive endothelial cell marker for HIEC and only cells exhibiting ≥ 97-
100 percent positivity were used in this analysis (Figure 3.3.7 C (shown as a solid red graph) 
and G). HIEC displayed typical morphological and phenotypical characteristics of HIEC; this 
included a very low, negligible percentage of contamination from hepatocytes, BEC (CK18 
and CK19) and fibroblasts (CD90) (Figure 3.3.7 D, E, F, G). Any contamination was eliminated 
during the analysis by ensuring only CD31 positive populations were included. This further 
demonstrated that the isolation technique used to obtain HIEC, yielded cells of high purity 
with minimal contamination from other cells from the liver tissue. All data obtained for this 
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analysis was quantified against the correct isotype control for each antibody used; IgG1 
(shown as a black line). Data is shown as percentage positive HIEC and median fluoresence 
intensity (Figure 3.3.7 G) ± SEM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.6 Phenotyping isolated HIEC: Isolated HIEC from normal and diseased liver 
were stained using different liver cell phenotypic markers to determine the purity of 
HIEC. Representative images are shown. A) Shows the IgG1 control for the antibodies 
used. B) Shows CD31 staining which was present in all cells. C) Shows CK18 staining 
which was present in a small population of HIEC. D) Shows CK19 staining which was 
negative. E) Shows CD90 staining which was negative. E) Shows CD90 staining which 
was negative. F) Shows CD68 staining which was negative. All antibodies were 
developed with a DAB substrate. Images were taken with Zeiss microscope and 
axiovision v4.4 software 200x magnification. 
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Figure 3.3.7 Phenotypic analysis of HIEC to determine purity of isolation: HIEC were 
analysed using flow cytometry. A) Shows the gate used to isolate HIEC to include in the 
analysis. B) Shows the gate isolating the single cell scatter of HIEC to include in the analysis. 
The HIEC were phenotypically analysed for cell surface markers CD31 (C), CD90 (D), CK18 (E) 
and CK19 (F) to ensure that the cells used in all experiments were of an endothelial lineage. 
CD31 (Red) was used to phenotype HIEC used in this study to determine purity of isolation. 
The histograms show the IgG control (Black line) and the respective markers (red solid 
histogram). G) Shows a representative graph of the phenotypic analysis done on HIEC prior to 
use. HIEC showed almost 97.22% percentage positivity for CD31, 8.49% CD90, 2.15% CK18 
and 1.77% CK19. This was also confirmed with MFI data (n=3). All data is shown as mean ± 
SEM, representative of 3 independent experiments. No statistical analysis was performed on 
this data. 
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3.3.4 Fn14 expression on HIEC was up-regulated in response to TNF-α 
Flow cytometry was used to determine basic cell surface and intracellular protein expression 
of Fn14 and TWEAK from HIEC, in response to various inflammatory cytokines. Cell surface 
Fn14 protein expression was significantly up-regulated by TNF-α, increasing the average 
percentage positive HIEC for Fn14 from 27 to 51.8 ± SEM (***P=0.0002) (Figure 3.3.8 C and 
E). This was also shown in the median fluorescence intensity (MFI) values which significantly 
increased from 9.1 to 16.2 ± SEM (*p=0.04) (Figure 3.3.8 F). To determine mRNA Fn14 
expression; total RNA was isolated from TNF-α stimulated HIEC, and analysed for Fn14 
mRNA expression using qPCR. Fn14 expression significantly increased in reponse to TNF-α 
(**p=0.006), where relative Fn14 expression increased almost 2-fold (Figure 3.3.8 G). 
 
FGF stimulated HIEC, marginally increased Fn14 cell surface protein expression on HIEC from 
27 to 31.4 ± SEM percentage positive HIEC (*p=0.03) (Figure 3.3.8 D and E). This however, 
was not reflected in the MFI data where expression values remained the same (Figure 3.3.8 
F). IFN-γ stimulated HIEC, did not significantly effect Fn14 cell surface protein expression. 
HIEC were analysed for presence of the FGF receptor on the cell surface and and to 
determine if this presence was altered in response to TWEAK and TNF-α activation. Flow 
cytometry data did not show the presence of an FGF receptor on HIEC cell surface (Figure 
3.3.9). 
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Figure 3.3.8 Increased Fn14 protein and mRNA expression was observed when HIEC were 
stimulated by TNF-α: HIEC were stimulated with IFN-γ 50ng/ml, TNF-α 10ng/ml and FGF 
0.5ng/ml for 24 hours prior to analysis. A) Shows Fn14 cell surface expression (Red) with its 
IgG1 isotype control (Black). B) Shows HIEC stimulated with IFN-g, C) HIEC stimulated with 
TNF-α, D) HIEC stimulated with FGF. E) A significant up-regulation of Fn14 expression was 
seen when HIEC were stimulated using TNF-α in comparison to the un-stimulated control 
(***p=0.0002 n=13). A marginal increase in Fn14 expression was observed when HIEC were 
stimulated with FGF (* p=0.03, n=9). IFN-γ did not affect Fn14 expression in comparison to 
the un-stimulated HIEC control (n=9). F) Median fluorescence intensity data showed an 
increase in Fn14 expression in TNF-α stimulated HIEC (*p=0.04, n=10). FGF and IFN-γ 
stimulation did not show a difference in Fn14 MFI expression (n=6). Data is shown as ± SEM. 
G) A significant up-regulation of Fn14 mRNA expression was observed using qPCR analysis, 
when HIEC were stimulated using TNF-α in comparison to the un-stimulated control (n=5 
**p=0.006 ± SE). All samples have been analysed as triplicates against a GUSB reference 
gene. Data is shown as fold difference with the unstimulated HIEC normalised to 1. Statistical 
analysis was carried out using a paired Student’s t test. 
 
 
107 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
Figure 3.3.9 FGF receptor 2 was not present on HIEC cell surface: HIEC were left 
unstimulated (A) and stimulated with TWEAK (100ng/ml) (B) and TNF-α (10ng/ml) 
(C) for 24 hours prior to flow cytometry analysis to detect the presence of FGF 
receptor 2. D) Analysis of percentage positive HIEC showed that FGF receptor 2 was 
not expressed on HIEC. The median fluorescence intensity was also negative (n=2). 
Histograms of cell surface FGF receptor expression are shown in red, and their IgG 
controls have been shown in black. No statistical analysis was performed on these 
experiments due to a small sample number. 
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3.3.5 Passage of HIEC does not alter Fn14 expression 
Flow cytometry was used to determine Fn14 expression from HIEC across different passages; 
from passage 2 to 7. HIEC were stimulated with IFN-γ, TNF-α and FGF for 24 hours prior to 
analysis. Passage of HIEC showed no significant change in Fn14 expression across the 
majority of passages (Figure 3.3.10). Significant changes were observed in unstimulated HIEC 
Fn14 expression from passage 2 to passage 3, where a decrease of Fn14 expression 
percentage positive HIEC from 38 to 17 ± SEM was observed (*p=0.04). Significant changes 
were also observed in FGF stimulated HIEC from passage 6 to passage 7 where Fn14 
expression levels percentage positive HIEC were decreased from 27 to 21.8 ± SEM (*p=0.05). 
The general expression pattern of Fn14 from HIEC in response to IFN-γ, TNF-α and FGF 
stimulations remained the same; where TNF-α stimulation promoted Fn14 expression. Based 
on this data, all HIEC isolations were used for experiments between passage 3 to passage 6 
for consistency. 
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Figure 3.3.10 Fn14 expression did not change with passage of HIEC: HIEC were 
stimulated with IFN-γ 50ng/ml, TNF-α 10ng/ml and FGF 0.5ng/ml for 24 hours prior to 
analysis. HIEC were analysed for Fn14 expression at different passages. Significant 
decreases in expression were observed in unstimulated HIEC from passage 2 to 3, and 
FGF stimulated HIEC passage 6 to 7. No significant change was observed for Fn14 
percentage positive HIEC from passage 3 to 6. The trend of enhanced Fn14 expression 
in response to TNF-α activation continued through all experiments. Data is shown as 
mean ± SEM (Passage 2: n=2, Passage 3: n=3, Passage 4: n=5, Passage 5: n=5, Passage 
6: n=4 and Passage 7: n=2). Statistical analysis was carried out using a paired Student’s 
t test. 
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3.3.6 IL-1β stimulates HIEC increase cell surface Fn14 expression 
To further assess the inflammatory response of Fn14 on HIEC; a panel of inflammatory 
cytokines were used to stimulate HIEC, and to detect changes in Fn14 protein expression 
patterns using flow cytometry (Figure 3.3.11 and 3.3.12). HIEC were stimulated with 
recommended manufacturers concentrations of IL-1β (10ng/ml), IL-2 (10ng/ml), IL-4 
(100ng/ml), IL-6 (20ng/ml), IL-8 (20ng/ml), IL-10 (50ng/ml), IL-17A (50ng/ml), IL-18 
(100ng/ml), IL-21 (50ng/ml), IL-22 (50ng/ml), IL-23 (50ng/ml), TGF-β (50ng/ml) and MCP-1 
(20ng/ml) for 24 hours prior to analysis. IL-1β stimulation significantly promoted Fn14 cell 
surface protein expression from 48 to 70.8 percent positive HIEC ± SEM (n=6) *p=0.04. MFI 
data also showed a significant increase in Fn14 expression in response to IL-1β from 15.1 to 
21.9 ± SEM (n=6) **p=0.0007 (Figure 3.3.11).  Interestingly, IL-17A and TGF-β significantly 
decreased cell surface Fn14 expression from 39 to 26 and 29.3 mean percent positive HIEC 
respectively ± SEM (n=3) (*p=0.02 and *p=0.05) (Figure 3.3.12). MFI data showed a similar 
trend but the data was not statistically significant. All other stimulations did not significantly 
alter Fn14 protein expression on HIEC from this panel of inflammatory cytokines. 
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Figure 3.3.11 Increased Fn14 cell surface protein expression was observed when HIEC 
were stimulated with IL-1β: A) Histogram shows IgG1 control in black, Fn14 
unstimulated in red and IL-1β stimulated HIEC in green. HIEC were stimulated with IL-
1β (10ng/ml) for 24 hours prior to analysis. B) Flow cytometry data showed a 
significant up-regulation of Fn14 expression percent positive HIEC when stimulated 
using IL-1β in comparison to the un-stimulated control *p=0.04 (n=6). C) A similar 
pattern to the percentage positive expression of Fn14 was observed for the median 
fluorescence intensity data, where a significant increase in Fn14 expression was 
observed in IL-1β stimulated HIEC **p=0.007 (n=6). Statistical analysis was carried out 
using a paired Student’s t test. All data is shown as mean ± SEM. 
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Figure 3.3.12 Decreased cell surface Fn14 protein expression was observed when 
HIEC were stimulated by IL-17A and TGF-β: Histograms show IgG1 control in black, 
Fn14 unstimulated in red and all stimulations in green. HIEC were stimulated with A) 
IL-2 (10ng/ml), B) IL-4 (100ng/ml), C) IL-6 (20ng/ml), D) IL-8 (20ng/ml), E) IL-10 
(50ng/ml), F) IL-17A (50ng/ml), G) IL-18 (100ng/ml), H) IL-21 (50ng/ml), I) IL-22 
(50ng/ml), J) IL-23 (50ng/ml) and K)  TGF-β (10ng/ml) and L) MCP-1 (20ng/ml) for 24 
hours prior to analysis. M) A significant decrease in Fn14 expression was observed in 
IL-17A and TGF-β activated HIEC *p=0.02 and *p=0.05 respectively in comparison to 
the unstimulated control (n=3). N) A similar pattern to the percentage positive 
expression of Fn14 was observed for the median fluorescence intensity data. All 
other stimulations did not significantly alter Fn14 cell surface HIEC expression. 
Statistical analysis was carried out using a paired Student’s t test. All data is shown as 
mean ± SEM. 
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3.3.7 Enhanced Fn14 expression in HIEC was observed in the cytoplasm, in response to 
TNF-α, FGF, and IL-1β activation 
Protein and mRNA data showed an increase in Fn14 expression in response to TNF-α, in 
comparison to un-stimulated HIEC. Therefore, IF was used to observe cellular changes in 
HIEC when they were stimulated with TNF-α. HIEC were cultured on glass coverslips and 
stained using a mouse anti human Fn14 mAb coupled to a FITC (green) secondary. DAPI 
(blue) was used as a nuclear stain. HIEC were stimulated overnight using TNF-α prior to 
analysis. Results show two HIEC isolates represented with A, B and C from the first isolate 
and D and E fom the second (Figure 3.3.13). In unstimulated HIEC; Fn14 expression appeared 
predominantly in the cytoplasm and a punctate staining pattern was observed (Figure 3.3.13 
B and D) in comparison to the isotype control (Figure 3.3.13 A). When HIEC were stimulated 
with TNF-α, increased intensity of staining was observed in the cytoplasm (Figure 3.3.13 C 
and E). Z-stack images were taken of HIEC unstimulated and stimulated with TNF-α to 
confirm up-regulated Fn14 expression. The collated 3D images from the Z-stacks confirmed a 
significant increase in Fn14 expression in HIEC (Figure 3.3.13 B and C). 
 
HIEC were stimulated with FGF (0.5 ng/ml), and IL-1β (10ng/ml) for 24 hours prior to staining 
(Figure 3.3.14). Fn14 expression was detected in the cytoplasm of HIEC analysed, in 
comparison to the isotype IgG1 control (Figure 3.3.14 A). Fn14 cytoplasmic expression was 
slightly enhanced in response to FGF and largly enhanced with IL-1β activation (Figure 3.3.14 
C and D), in comparison to the unstimulated control (Figure 3.3.14 B).  
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Figure 3.3.13 Increased Fn14 expression was observed in the cytoplasm when 
HIEC were stimulated by TNF-α: Confocal immuno-fluorescent imaging was used to 
visualise Fn14 expression in HIEC. Two HIEC isolates are represented with B and C 
from the first isolate and D and E from the second. An anti Fn14 antibody (3.7µg/ml) 
was used to detect Fn14 expression in HIEC, this was conjugated to a FITC (green) 
secondary, DAPI (blue) was used as a nuclear stain. Cytoplasmic fluorescent staining 
was observed in B, C, D, and E in comparison to the IgG1 Isotype control (A). 3D 
representative image shown in B and C with a subsequent magnified view. Fn14 
expression significantly increased when HIEC were stimulated with TNF-α (10ng/ml) 
for 24 hours (C and E) in comparison to the unstimulated control (B and D). A 
punctate staining pattern was visible in unstimulated and TNF- α stimulated HIEC. 
Magnification 200x Zeiss LSM 780 Zen confocal microscope.  
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   Figure 3.3.14 Increased Fn14 expression was observed in the cytoplasm when HIEC 
were stimulated with FGF and IL-1β: Confocal immuno-fluorescent imaging was used 
to visualise Fn14 expression in HIEC, this was conjugated to a FITC (green) secondary, 
DAPI (blue) was used as a nuclear stain. An anti Fn14 antibody (3.7µg/ml) was used to 
detect Fn14 expression in HIEC. Cytoplasmic fluorescent staining was observed in B, 
C, and D in comparison to the IgG1 Isotype control, A. Fn14 expression increased 
when HIEC were stimulated with FGF (0.5 ng/ml), and a larger increase in Fn14 
expression was observed when HIEC were activated with IL-1β (10ng/ml) for 24 hours 
(C and D respectively) in comparison to the unstimulated control (B). Magnification 
200x Zeiss LSM 510 UV confocal microscope.  
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3.3.8 HIEC store intracellular Fn14  
We wanted to confirm if the increased Fn14 expression in response to stimulation, was from 
intracellularly stored Fn14. To do this HIEC were stimulated with IFN-γ, TNF-α and FGF for 24 
hours prior to analysis. Fn14 protein expression percentage positivity was analysed after 
permeablising the cells to detect intracellular Fn14. Significant up-regulation of Fn14 
expression was observed when cell surface Fn14 was compared to intracellular Fn14 (Figure 
3.3.15), in all stimulations and unstimulated HIEC (n=6); Unstimulated Fn14 expression mean 
percentage positivity increased from 26 to 85 ± SEM (***p≤0.001), IFN-γ stimulated HIEC 
mean percentage positive HIEC increased from 27 to 98 ± SEM (***p≤0.001), TNF-α 
stimulation increased percentage positivity from 49 to 97 ± SEM (***p≤0.001), and FGF 
increased percentage positivity from 33 to 87 ± SEM (**p≤0.01). All data was quantified 
against their individual IgG1 controls. 
 
3.3.9 HIEC transports Fn14 via the Golgi apparatus  
Our data showed significant elevation of Fn14 expression in response to TNF-α, FGF and IL-
1β activation. This was determined using flow cytometry detecting cell surface protein 
expression and observed using IF. Fn14 expression was detected in the cytoplasm and a 
granular punctate stain was observed. This was followed by data showing significant 
elevation of Fn14 protein expression when HIEC were permeablised, indicating intracellular 
stores of Fn14 protein. To determine if there are Fn14 present in the Golgi apparatus, and if 
the Golgi is involved in transport of this protein, a Golgi plug (Golgi to endoplasmic reticulum 
(ER) transport) and Golgi stop (trans-Golgi transport) was used together with TNF-α 
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activation before staining for Fn14. All staining was confirmed against an IgG1 negative 
control and a CD31 positive control (Figure 3.3.16 A and B). Enhanced Fn14 expression was 
observed in response to TNF-α activation (Figure 3.3.16 D) in comparison to the 
unstimulated control (Figure 3.3.16 C). The staining after applying the Golgi plug showed 
large accumulations of Fn14 in the HIEC analysed (Figure 3.3.16 E). The HIEC analysed after 
using the Golgi stop showed no difference in comparison to the HIEC activated with TNF-α 
without a Golgi stop (Figure 3.3.16 F). This data showed that the Golgi apparatus may play a 
significant role in storing intracellular Fn14, and aiding its release after stimulation and 
transporting Fn14 via the ER. 
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Figure 3.3.15 Increased intracellular Fn14 protein expression was observed in 
HIEC:  A and B) show histograms of cell surface and intracellular Fn14 expression 
(unstimulated) respectively in red. Their IgG1 controls have been shown in black. C) 
HIEC were stimulated with IFN-γ 50ng/ml, TNF-α 10ng/ml and FGF 0.5ng/ml for 24 
hours prior to analysis. Flow cytometry data showed significant up-regulation of 
Fn14 expression percentage positive HIEC when HIEC were permeablised to release 
intracellular Fn14 in comparison to cell surface Fn14 expression. Data was shown 
as mean ± SEM (n=6) (Unstimulated; ***p=0.0005, IFN-γ; ***p=0.000007, TNF-α 
***p=0.00015 and FGF **p=0.0017). Statistical analysis was carried out using a 
paired Student’s t test. All data is shown as mean ± SEM. 
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Figure 3.3.16 Fn14 is transported from the Golgi to the ER when activated by TNFα:  
HIEC were activated with and without TNF-α and confocal imaging and Immuno-
fluorescent staining using an anti Fn14 antibody (3.7µg/ml) was used to determine 
Fn14 expression. TNF-α plus a Golgi plug (E), and TNF-α plus a Golgi Stop (F) were used 
prior to staining with Fn14, to determine if Fn14 transport may be regulated by the 
Golgi apparatus. IgG1 was used as a negative control (A) and CD31 was used as a 
positive control (B). Fn14 expression was up-regulated in response to TNF-α (D) in 
comparison to the unstimulated control (C). Fn14 protein appears accumulated in E 
where a Golgi plug was used with TNF-α stimulation. No change in Fn14 expression 
pattern was observed where a Golgi stop was used. Magnification 200x Zeiss LSM 510 
UV confocal microscope.  
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3.3.10 TWEAK stimulated HIEC decreased cell surface Fn14 protein and Fn14 mRNA 
expression 
We wanted to determine the HIEC response to TWEAK activation and how this alters Fn14 
expression. HIEC were stimulated with TWEAK (100ng/ml) for 24 hours prior to analysis. 
Flow cytometry data revealed that TWEAK activation significantly decreased Fn14 cell 
surface expression from 32 to 22 percent positive HIEC ± SEM (n=5 *p=0.05) (Figure 3.3.17 
A). This decrease was also observed at an mRNA level where Fn14 mRNA expression 
decreased 3 fold in HIEC in response to TWEAK activation (Figure 3.3.17 B). 
 
HIEC were stimulated with TWEAK (10ng/ml) overnight prior to IF staining to detect Fn14 
expression. Unstimulated HIEC showed cytoplasmic Fn14 present. The staining pattern 
showed a punctate Fn14 stain distributed in the cytoplasm (Figure 3.3.18 B). In TWEAK 
activated HIEC, Fn14 expression was still observed in the cytoplasm, however the intensity 
decreased in particular in the previous punctately stained regions (Figure 3.3.18 C). Staining 
was compared to the relevant IgG1 control for Fn14 (Figure 3.3.18 A). 
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Figure 3.3.17 TWEAK stimulated HIEC showed a decrease in Fn14 protein and 
mRNA expression: HIEC were stimulated with TWEAK 100ng/ml for 24 hours prior to 
flow cytometry and qPCR analysis. A) Flow cytometry data showed Fn14 expression 
percentage positivity significantly decreased with TWEAK stimulation. Data is shown 
as mean ± SEM (* P=0.05, n=5). Statistical analysis was carried out using a paired 
Student’s t test. B) qPCR data showed Fn14 mRNA expression also decreased with 
TWEAK stimulation. All qPCR samples were analysed as triplicates against a GUSB 
reference gene. Fn14 forward and reverse primer concentration 1µM/ well. Data is 
shown as mean ± SE (n=3) as fold difference with unstimulated HIEC normalised to 1. 
This data was not statistically significant.  
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Figure 3.3.18 Decreased Fn14 expression was observed in the cytoplasm when 
HIEC were stimulated by TWEAK: Confocal immuno-fluorescent imaging was used 
to observe Fn14 expression in HIEC, this was conjugated to a FITC (green) 
secondary, DAPI (blue) was used as a nuclear stain. An anti Fn14 antibody 
(3.7µg/ml) was used to detect Fn14 expression in HIEC. Cytoplasmic fluorescent 
staining was observed in B and C in comparison to the IgG1 Isotype control, A. Fn14 
expression decreased when HIEC were stimulated with TWEAK (100 ng/ml) for 24 
hours (C) in comparison to the unstimulated control (B). Magnification 200x Zeiss 
LSM 510 UV confocal microscope.  
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3.3.11 PBMC and monocytes expressed TWEAK mRNA which was regulated by IFN-γ 
HIEC were consistently negative for TWEAK cell surface protein expression in comparison to 
its isotype control IgG2a. This was in un-stimulated HIEC and HIEC stimulated with TNF-α, 
IFN-γ and FGF (Figure 3.3.19 E). This was also confirmed in corresponding MFI data (Figure 
3.3.19 F). PBMC stimulated with IFN-γ were used as a positive control for TWEAK mRNA 
expression. A significant increase in TWEAK mRNA expression was observed when IFN-γ 
stimulated PBMC were compared to unstimulated PBMC *p=0.01. Data was shown as 
TWEAK mRNA fold difference with un-stimulated PBMC normalised to 1. HIEC showed little 
to no expression of TWEAK mRNA in comparison to un-stimulated PBMC (Figure 3.3.20). This 
mRNA expression data was consistent with the TWEAK protein expression data from HIEC, 
obtained using flow cytometry. Intracellular TWEAK expression was also assessed using flow 
cytometry. Increased TWEAK expression was observed when HIEC were permeablised, 
however this increase was insignificant (Figure 3.3.21), and below 10% percentage positive 
HIEC.  
 
TWEAK has been found to be expressed on monocytes, macrophages and PBMC in a number 
of studies. The data obtained from this investigation was also suggestive that TWEAK was 
not present on HIEC but may be acting in a paracrine manner with Fn14 which is 
constitutively expressed on HIEC, and TWEAK interacting via mononuclear cells, as we have 
found TWEAK mRNA present in PBMC, and this expression was elevated in response to 
inflammatory cytokine IFN-γ activation. We thus wanted to determine the presence of 
TWEAK mRNA on monocytes, in particular in different subsets of monocytes, and to 
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determine how this expression was altered in response to IFN-γ activation. This would 
enable us to beginto understand how possible TWEAK paracrine interactions with HIEC may 
be regulated. TWEAK mRNA expression was analysed in CD14+ (CD14++CD16-), CD16+ 
(CD14+CD16++) and dual positive monocyte populations (CD14++CD16+). Relative 
expression analysis showed that TWEAK mRNA was expressed the highest in CD14+ 
monocyte populations and IFN-γ activation increased TWEAK mRNA expression (Figure 
3.3.22). Dual positive monocytes and CD16+ monocytes expressed relatively low amount of 
TWEAK mRNA to CD14+ populations; however TWEAK mRNA expression was doubled in IFN-
γ activated dual positive HIEC populations, and CD16+ monocytes showed 3.5 fold decreased 
TWEAK mRNA expression when this population of monocytes was activated with IFN-γ.  
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Figure 3.3.19 HIEC do not express TWEAK protein on the cell surface: HIEC were 
unstimulated (A) and stimulated with IFN-γ 50ng/ml (B), TNF-α 10ng/ml (C) and 
FGF 0.5ng/ml (D) for 24 hours prior to flow cytometry analysis. Histograms show 
the IgG2a control in black and the TWEAK cell surface expression in red. HIEC were 
negative for TWEAK expression showing less than 2% percentage positivity. Data is 
shown as mean ± SEM; Unstimulated and TNF-α (n=8), IFN-γ and FGF (n=4). MFI 
data also confirmed this observation. Data is shown as mean ± SEM (n=3). No 
statistical analysis was performed on this data. 
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Figure 3.3.20 TWEAK mRNA expression was enhanced by IFN-γ activation in PBMC: 
qPCR data showed a significant increase in TWEAK mRNA expression in cDNA obtained 
from PBMC stimulated with IFN-γ *p=0.01. HIEC showed a low amount of TWEAK 
mRNA in comparison to PBMC. All samples were analysed as triplicates against a GUSB 
reference gene. TWEAK forward and reverse primer concentration 1µM/ well. Data 
has been shown as fold difference of mean (n=3 ± SE) with the un-stimulated PBMC 
control normalised to 1. Statistical analysis was carried out using a paired Student’s t 
test. 
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Figure 3.3.21 Enhanced intracellular TWEAK protein expression was observed in 
HIEC: C) HIEC were stimulated with TNF-α 10ng/ml for 24 hours prior to analysis. Flow 
cytometry data showed a marginal up-regulation of TWEAK protein expression 
percentage positive HIEC when HIEC were permeablised to detect intracellular TWEAK 
in comparison to cell surface TWEAK expression. Data was shown as mean ± SEM 
(n=4). Histograms show IgG2a control in black and TWEAK expression in red. A) Shows 
cell surface expression and B) shows intracellular expression. This data was not 
statistically significant. 
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Figure 3.3.22 IFN-γ promoted TWEAK mRNA expression on CD14+ and dual positive 
monocytes: Total PBMC were isolated and sorted using a high speed cell sorter in to 
CD14+, CD16+ and dual positive monocyte populations. Monocyte fractions were 
cultured for 24 hours with IFN-γ and total RNA was isolated. qPCR was used to 
determine TWEAK mRNA expression from the different monocyte subsets. Enhanced 
TWEAK mRNA expression was observed in CD14+ monocyte and dual positive monocyte 
populations with IFN-γ activation in comparison to unstimulated controls. CD16+ 
monocyte populations showed decreased TWEAK mRNA expression in response to IFN-γ 
activation.  Data is shown as relative expression from 3 different experiments ± SE. This 
data was not statistically significant. 
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3.3.12 TWEAK activated HIEC facilitate leukocyte recruitment to HIEC 
We have found TWEAK and Fn14 expression present in areas surrounding leukocyte 
infiltration and portal and neovessels in diseased liver tissue, suggesting a potential role in 
regulating inflammation and angiogenesis. Therefore we wanted to determine the role of 
TWEAK and Fn14 in leukocyte recruitment to HIEC. Initially we wanted to determine 
expression of VCAM and ICAM on TWEAK activated HIEC to understand if leukocyte 
recruitment was mediated via these adhesion proteins. TNF-α was used as a positive control, 
Fn14 expression in response to TWEAK and TNF-α stimulation was also analysed in parallel 
to ensure the data obtained was consistent with previous findings. TWEAK activated HIEC 
did not promote Fn14, VCAM and ICAM protein expression on HIEC cell surface (Figure 
3.3.23). TNF-α activated HIEC significantly increased Fn14, VCAM and ICAM expression on 
HIEC cell surface; from 28.7 to 66.2, 19.5 to 89 and 13.8 to 61.8 percentage positive HIEC 
respectively. 
 
Following this, we wanted to determine if TWEAK activated HIEC enhanced leukocyte 
recruitment, and further analysed differences between monocyte and lymphocyte adhesion 
(Figure 3.3.24 and 3.3.25). We used flow based in vitro assays to determine if TWEAK 
influenced leukocyte adhesion (Figure 3.3.25 A), migration (Figure 3.3.25 C), and 
morphological changes (Figure 3.3.25 B) of leukocytes in response to activated HIEC. TWEAK 
activated HIEC showed enhanced monocyte, lymphocyte and total PBMC adherence in 
comparison to the unstimulated control. A significant increase in monocyte adherence was 
observed in TWEAK activated HIEC from 6 to 11.5 ± SE adherent cells to HIEC/mm2/106 cells 
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perfused *p=0.04. HIEC stimulated with TWEAK and TNF-α in combination also significantly 
enhanced PBMC adherence from 15.7 to 51.4 ± SE adherent cells to HIEC/mm2/106 cells 
perfused *p=0.03. TNF-α and IFN-γ activated HIEC were used as a positive control and 
showed the largest number of adherent cells in comparison to all stimulations 64.8 ± SE 
adherent cells to HIEC/mm2/106 cells perfused. TNF-α, IFN-γ and TWEAK were used in 
combination and showed a large increase in adherent cells to HIEC, 60.3 ± SE adherent cells 
to HIEC/mm2/106 cells perfused in comparison to the unstimulated control and TWEAK 
stimulation. These increases in adherence were observed in all conditions, however this data 
was not statistically significant. Blocking TWEAK activation using Fn14 mAb showed no 
differences to TWEAK activation in all assays.  
 
Enhanced shape changing PBMC were observed when HIEC were activated with TWEAK in 
comparison to unstimulated controls from 6 to 14.2 ± SE shape changing cells to 
HIEC/mm2/106 cells perfused (Figure 3.3.25 B). TWEAK, TNF-α, and IFN-γ activation in 
combination showed the largest amount of shape changing PBMC observed 61.3 ± SE. 
Followed by TNF-α and IFN-γ 54.2 ± SE and then TWEAK and TNF-α in combination 46 ± SE. 
TWEAK activated HIEC appeared to enhance migration in response to TWEAK but only 
marginally and this finding was not statistically significant (Figure 3.3.25 C). The positive 
control of TNF-α and IFN-γ activated HIEC showed an increase in migration in comparison to 
the unstimulated HIEC from 2.6 to 22.1 ± SE migrated cells to HIEC/mm2/106 cells perfused. 
This was further enhanced in HIEC activated by TWEAK and TNF-α. The largest increase in 
migration was observed in HIEC activated with TWEAK, TNF-α and IFN-γ in combination from 
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2.6 to 24.6 ± SE migrated cells to HIEC/mm2/106 cells perfused in comparison to the 
unstimulated control.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.23 - TWEAK does not promote the expression of VCAM and ICAM on the 
cell surface of HIEC: HIEC were stimulated with TNF-α (10ng/ml) and TWEAK 
(100ng/ml) for 24 hours prior to FACS analysis. TNF-α was used as a positive control 
and unstimulated HIEC were used as a negative control. A) The percentage positive 
population of HIEC expressing Fn14, VCAM and ICAM. B) Median Fluorescence 
Intensity from HIEC expressing Fn14, VCAM and ICAM, this data was not statistically 
significant. TWEAK did not promote the expression of Fn14, VCAM and ICAM. TNF-α 
significantly enhanced Fn14, VCAM and ICAM expression on HIEC cell surface p=0.03* 
p=0.03* and p=0.04* percentage positive HIEC respectively. Data is shown as mean ± 
SEM n=4.  Statistical analysis was carried out using a paired Student’s t test. 
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Figure 3.3.24 - TWEAK activated HIEC leukocyte recruitment in a flow based adhesion 
assay: HIEC were stimulated for 24 hours with combinations of IFN-γ (50ng/ml), TNF-α 
(10ng/ml) and TWEAK (100ng/ml). Total PBMC were perfused over a monolayer of 
HIEC with a shear stress of 0.05Pa. Adherent monocytes and lymphocytes (zoomed in 
image shows size difference between monocytes and lymphocytes) were counted from 
10 fields of view and presented as cells/mm
2
/10
6
 cells perfused. Unstimulated HIEC 
were used as a negative control and TNF-α and IFN-γ in combination were used as a 
positive control.  
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Figure 3.3.25 TWEAK supports the adhesion of PBMC to HIEC in a flow based adhesion 
assay: HIEC were stimulated for 24 hours with combinations of IFN-γ (50ng/ml), TNF-α 
(10ng/ml) and TWEAK (100ng/ml). Total PBMC were perfused over a monolayer of HIEC 
with a shear stress of 0.05Pa. A) Adherent, B) shape changing and C) migrating 
monocytes and lymphocytes were counted from 10 fields of view and presented as 
cells/mm
2
/10
6
 cells perfused. Unstimulated HIEC were used as a negative control, and 
TNF-α and IFN-γ in combination were used as a positive control. Data is presented as 
mean ± SEM from 4 experiments. TWEAK significantly enhanced monocyte adherence to 
HIEC (*p=0.037). TWEAK and TNF-α stimulated HIEC significantly enhanced adherence of 
total PBMC in comparison to their unstimulated control (*p=0.0286). Data is shown as 
mean ± SE n=4. Statistical analysis was carried out using a paired Student’s t test. Data 
from experiment B and C was not statistically significant. 
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3.3.13 Summary of Results 
 TWEAK and Fn14 mRNA expression significantly enhanced in diseased liver tissue in 
comparison to normal liver tissue. 
 TWEAK was found expressed in inflammatory infiltrates in human liver tissue sections 
using IHC. 
 Fn14 was found expressed on sinusoidal endothelium, neovessels, portal vessels, and 
in ductular reactive cells in human liver tissue sections using IHC. 
 Fn14 was expressed on HIEC cell surface and enhanced in response to TNF-α, IL-1β 
and FGF stimulation. Fn14 expression was significantly decreased in response to 
TWEAK, IL-17A and TGF-β stimulation. 
 Fn14 was found stored in the Golgi apparatus in HIEC and subsequently released in 
response to cytokine stimulation to the cytoplasm, endoplasmic reticulum and cell 
surface. 
 No TWEAK was found expressed on HIEC, TWEAK mRNA was detected in total PBMC 
and significantly enhanced when stimulated with IFN-γ. 
 TWEAK activated HIEC promoted leukocyte recruitment in combination with TNF-α 
and enhanced monocyte recruitment to HIEC. 
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3.4 DISCUSSION 
Previous literature has shown low Fn14 and TWEAK expression in normal tissue, and 
enhanced expression in diseased or injured tissue. Our observations have confirmed 
enhanced TWEAK and Fn14 mRNA expression in diseased liver, in comparison to normal 
donor tissue (Figure 3.3.2). This was also consistent with previous unpublished findings from 
our lab, where IHC revealed TWEAK and Fn14 expression in normal donor liver tissue to be 
very low in comparison to diseased liver tissue. The observed low expression of TWEAK in 
diseased liver tissue analysed using IHC, was consistent with mRNA fold difference of 
expression which revealed a 3 fold increase of TWEAK in diseased liver tissue in comparison 
to the normal liver samples (Figure 3.3.2). IHC data revealed the presence of TWEAK in 
inflammatory infiltrates, highly localised to areas near portal vessels (Figure 3.3.3). A faint 
stain was also observed in hepatocytes surrounding portal vessels. Kawakita et al extensively 
studied TWEAK expression in liver tissue using IHC. They showed increased TWEAK 
expression in HCC tissue, and a higher expression observed in metastatic HCC tissue. They 
subsequently found hepatitis and cirrhotic liver tissue to be generally negative for TWEAK 
expression, but they found TWEAK to be present in lymphocyte infiltrates surrounding portal 
vessels, suggesting an inflammation mediating role (Kawakita et al., 2004). Our study 
confirmed TWEAK expression consistently found in inflammatory infiltrates, and studies 
have further shown that TWEAK can initiate secretion of other pro-inflammatory 
chemokines, cytokines and MMP’s in response to injury (Winkles, 2008). This is suggestive 
that TWEAK may be involved in co-ordinating the inflammatory response, and further 
perpetuating this response in inflammatory liver disease by enhanced TWEAK expression 
leading to further inflammatory cell recruitment. 
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Fn14 expression was found to be localised to hepatocytes, ductular reactive cells, 
neovessels, and highly localised to portal vessels (Figure 3.3.4). The expression of Fn14 
varied on a case by case basis. The first normal liver sample (Figure 3.3.4 A) showed very low 
Fn14 expression, with a faint stain throughout hepatocytes. The second normal liver sample 
(Figure 3.3.4 B) showed high expression of Fn14 and localisation to portal vessels. The liver 
disease samples all showed high expression of Fn14. The differences observed between the 
two normal donor samples may be dependent on the origin of the ‘normal’ tissue. In this 
study, normal donor tissue has been classed as tissue obtained from a normal donor surplus 
to surgical requirement, reasons including; too much fat accumulation in the tissue, and/or 
scar tissue from previously undiagnosed liver trauma. Normal tissue can also be obtained 
from normal tissue adjacent to surgically resected tumour liver samples, which are retrieved 
from patients who have undergone extensive radio and chemotherapy, which can cause 
damage to otherwise healthy liver. Enhanced Fn14 expression is usually associated with 
detrimental consequences (Burkly et al., 2007), therefore, the high expression of Fn14 in IHC 
stained liver samples in generally described normal tissue, is not surprising. The mRNA data 
however, showed a significant difference of Fn14 mRNA expression between normal and 
diseased liver tissue, showing a 17 fold increase of Fn14 mRNA in diseased liver tissue in 
comparison to the normal liver samples (Figure 3.3.2). 
 
Fn14 expression has previously been described to be present in hepatocytes surrounding 
portal vessels in wild type murine liver tissue, in comparison to Fn14 knock out mouse 
models after PHx (Karaca et al., 2014), our data confirms these Fn14 expression patterns in 
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human liver tissue, and we also observed Fn14 expression in areas of neovessels and 
ductular reactive cells. Dual IF staining showed co-localisation of Fn14 with CD31+ 
endothelium in liver tissue sections, on portal vessels and where the liver tissue was 
particularly fibrotic (Figure 3.3.5). This co-localisation was seen only in some of these areas 
and not consistently throughout the tissue section. This was a similar staining pattern 
observed by using IHC, and was suggestive of a more specific localised TWEAK and Fn14 
response in inflammatory liver conditions. There was also some auto-fluorescence observed 
in our IF data with the CD31 stain and Fn14 stain. This was present but at a lower level than 
our specific stains of CD31 and Fn14. It could also be that this was not auto-fluorescence in 
the case of Fn14 and was in fact hepatocytes which also stain for Fn14, and Fn14 staining of 
fibrotic areas as was observed using IHC. Fn14 activity in endothelial areas of the liver 
suggests that Fn14 may facilitate neovascularisation indicated by Fn14 presence in areas of 
neovessels, and Fn14 expression found highly localised to portal vessels indicates that Fn14 
may influence the influx of TWEAK positive inflammatory infiltrates leading to possible 
fibrogenic responses in the liver. This further supports current literature indicative of TWEAK 
and Fn14 involvement in the hepatic inflammatory response, repair and regeneration. 
 
We further characterised expression of TWEAK and Fn14 on HIEC isolated from liver tissue, 
and observed responses to stimulating HIEC by various cytokines and growth factors which 
have known functions in inflammatory and regenerative responses. Previous literature has 
suggested that this ligand and receptor are highly inducible. A large part of our study 
confirmed this, we showed increased expression of Fn14 at a protein and mRNA level in HIEC 
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when stimulated with TNF-α, in comparison to un-stimulated HIEC (Figure 3.3.8). This up-
regulated Fn14 expression was observed in HIEC cytoplasm using IF staining and confocal 
microscopy (Figure 3.3.13). We also showed significantly enhanced Fn14 cell surface protein 
expression in response to FGF (Figure 3.3.8) and IL-1β (Figure 3.3.11), and observed 
enhanced Fn14 expression in the cytoplasm of HIEC in response to these cytokines (Figure 
3.3.14); although the enhanced FGF response was limited. Data from this study revealed a 
significant decrease in Fn14 expression in response to TGF-β, TWEAK, and IL-17A activation 
(Figure 3.3.12 and 3.3.17). This investigation revealed no significant changes in Fn14 
expression in HIEC in response to IFN-γ, IL-2, IL-4, IL-6, IL-8, IL-10, IL-18, IL-21, IL-22, IL-23, 
and MCP-1 (Figure 3.3.12). 
 
Previous literature has shown enhanced Fn14 mRNA and protein expression in human 
gingival fibroblasts in response to IL-1β and TGF-β activation. In combination with TWEAK, 
they have shown an up-regulation of IL-8 and VEGF, facilitating inflammation (Hosokawa et 
al., 2006). Justo et al 2006 showed enhanced Fn14 expression in TNF-α and IFN-γ induced 
murine cortical tubular cell lines, which induced TWEAK dependent apoptosis (Justo et al., 
2006). These studies were in agreement with our findings of TNF-α and IL-1β activated HIEC 
inducing Fn14 expression, however our observed HIEC responses to TGF-β induction did not 
agree with these findings. In contrast, Jin et al 2004 found that TGF-β and IFN-γ had no effect 
on Fn14 mRNA and protein expression on human keratinocytes (Jin et al., 2004). This was 
consistent with our findings of IFN-γ activated HIEC which showed no effect on Fn14 
expression, however it was in contrast with our findings of TGF-β, where we showed a 
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significant down-regulation of Fn14 expression in HIEC. These varying cellular responses may 
be explained by the specific cell types and environment during detection of Fn14 responses. 
 
TWEAK activation has shown a pro-inflammatory effect in female lower genital tract 
endothelial cells in combination with IL-1β activation (Han, Mekasha e Ingalls, 2010). This 
pro-inflammatory effect was also seen with TWEAK and IL-1 activation in combination with 
TNF-α, where an enhanced expression of inflammatory cytokines was observed in chronic RA 
samples (Chicheportiche et al., 2002). IL-1β and TNF-α have been shown to have a 
synergistic effect on TWEAK in rheumatoid arthritis fibroblast-like synoviocytes enhancing 
inflammation, and have shown that they can enhance Fn14 expression (Xia et al., 2010). This 
was in agreement with our findings, where activation with IL-1β and TNF-α in HIEC, 
enhanced the Fn14 response. IL-17 has been shown to amplify inflammation observed in 
rheumatoid arthritis patients, and IL-17 induction has been observed after TWEAK 
stimulation (Park et al., 2012). There have been no studies however, investigating Fn14 
expression in response to IL-17A at present. 
 
The FGF response to Fn14 expression in HIEC was the most surprising. FGF is a known 
growth factor for endothelial cells, and Fn14 is a known FGF inducible protein. Therefore, we 
were expecting a large up-regulation of Fn14 in response to FGF activation. Our data showed 
a significant up-regulation of FGF induced Fn14 expression, however the response was very 
small, and our data only showed significant percentage positive HIEC for Fn14, and the MFI 
data was not statistically significant. IF data also showed a limited FGF response in Fn14 
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expression which was mildly up-regulated in the cytoplasm (Figure 3.3.14). Our data further 
showed the lack of an active FGF receptor present on HIEC (Figure 3.3.9), which would 
explain the limited response to FGF stimulation in these cells. This could possibly be due to 
FGF using alternative FGF receptors to induce Fn14 activation in HIEC. This will need to be 
further investigated to understand the limited FGF response on Fn14 in HIEC.  
 
Enhanced Fn14 expression observed in HIEC cytoplasm when they were stimulated, was 
suggestive of Fn14 being secreted once HIEC have been exposed to the appropriate stimuli 
such as TNF-α, FGF, and IL-β in this case. Unstimulated HIEC still showed basal Fn14 
expression on HIEC cell surface which may function to mediate normal physiological liver 
functions. Unstimulated HIEC showed a punctate staining pattern, with TNF-α stimulation, 
the staining pattern evened out and enhanced in the cytoplasm with some punctate staining 
remaining. This indicated that Fn14 may be held in compartmentalised cell structures and 
then released. We then showed that Fn14 was stored in the Golgi apparatus and released in 
response to activation, and transported via the Golgi and endoplasmic reticulum (Figure 
3.3.16). Previous reports have suggested that Fn14 is expressed in the Golgi, as well as cell 
membrane in several cells including normal human keratinocytes, HUVEC, HEK293 cells, and 
HaCat cell line. They also reported TWEAK expression present in the cytoplasm (Sabour 
Alaoui et al., 2012; Gurunathan et al., 2014). This was consistent with our observations of 
Fn14 present in the HIEC cytoplasm using IF and on HIEC cell surface using flow cytometry. 
Our study did not however reveal any TWEAK expression in HIEC. 
 
141 
 
Increase in fluorescence intensity for Fn14 expression was consistent with the increase of 
Fn14 protein expression observed at the cell surface of HIEC using flow cytometry, and 
mRNA expression using real time PCR post TNF-α stimulation of HIEC. Enhanced Fn14 cell 
surface expression was detected using flow cytometry, which may indicate the potential of 
Fn14 to be involved in protein-protein interactions on the cell surface. This is potentially 
where Fn14 may interact with its ligand TWEAK, which may become activated after an 
inflammatory response. A large increase in Fn14 protein expression was observed when HIEC 
were permeablised. This intracellular expression of Fn14 was further increased when HIEC 
were stimulated overnight with TNF-α prior to analysis (Figure 3.3.15). This data was 
consistent with the observations made of HIEC using IF where compartmentalised Fn14 
migrated out into the cytoplasm, and flow cytometry data which showed enhanced Fn14 
expression on the cell surface.  
 
Our data showed a significant down-regulation of Fn14 expression on HIEC cell surface and 
mRNA in response to TWEAK activation. We also observed down-regulated Fn14 expression 
using IF in response to TWEAK activation (Figure 3.3.17 and 3.3.18). In unstimulated HIEC, 
cytoplasmic Fn14 was present with a punctate staining pattern (Figure 3.3.18 B). In TWEAK 
activated HIEC, Fn14 expression remained in the cytoplasm but the punctate staining pattern 
was not present (Figure 3.3.18 C), and an overall slight down-regulated expression of Fn14 
observed. It has been seen in other TNFSFR’s where ligand binding has resulted in down-
regulated receptor expression, such as in TNFR1 (Higuchi e Aggarwal, 1994), and Fas 
(Algeciras-Schimnich et al., 2002); these have been shown to include receptor 
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internalisation, shedding, and DISC formation mechanisms. A previous study has described 
up-regulated expression of Fn14 in response to TWEAK activation in fibroblast like 
synoviocytes (Xia et al., 2010). Another study showed no effect of TWEAK activation on cell 
surface Fn14 expression in an endothelial cell line (Stephan et al., 2013). Our findings are in 
contrast with these studies. 
 
A recent publication has characterised the regulation of Fn14 expression in TWEAK 
dependent and independent assays (Gurunathan et al., 2014). They have found that Fn14 
expression is a tightly controlled process from synthesis and trafficking from the Golgi to the 
plasma membrane, and lysosomal mediated degradation within the cell, dependent on the 
extracellular domain of Fn14. They found that Fn14 can undergo this receptor degradation 
and turnover in a TWEAK independent manner, but the process is accelerated with the 
addition of TWEAK and further perpetuated in a dose dependent manner. This process was 
seen in all cells that they tested indicating an endogenous Fn14 process. They also 
highlighted the importance of the Golgi in synthesising and continuous trafficking of Fn14 to 
the cell surface (Gurunathan et al., 2014). Our findings are in agreement with these, as we 
also found Fn14 transport via the Golgi (Figure 3.3.16), and we found Fn14 expression on the 
cell surface using flow cytometry, and subsequent loss of Fn14 expression with TWEAK 
activation, indicating possible TWEAK accelerated Fn14 degradation within HIEC. We also 
observed down-regulated Fn14 expression in response to IL-17A and TGF-β activation in 
HIEC. It may be that these cytokines enhance TWEAK expression to the HIEC 
microenvironment and thus indirectly enhance Fn14 degradation via TWEAK interactions. 
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This will need experimental validation and we will need to determine if IL-17A and TGF-β 
activation in HIEC induce TWEAK expression. 
 
It is apparent that TWEAK and Fn14 interactions on HIEC are highly regulated by all of these 
cytokines and may be initiating a complex signalling response leading to various functions 
during inflammatory conditions in the liver. To further understand the regulation of TNF-α, 
IL-1β, FGF, IL-17A, and TGF-β of TWEAK and Fn14 responses during inflammatory liver 
disease in comparison to normal donor samples, it would be essential to observe changes in 
TWEAK and Fn14 mRNA from normal and diseased liver tissue in response to activation, and 
to observe and characterise these changes using IHC, before making further conclusions. Our 
observations of TWEAK and Fn14 regulation have been made in HIEC, which have not been 
characterised before. The potential implications these stimulations will have on Fn14 activity 
in HIEC may be determined by functional assays, which will help to develop a better 
understanding of the roles that Fn14 may play in endothelial cells of the liver.  
 
To further characterise TWEAK and Fn14 interactions on HIEC it was important to 
understand which various cell types of PBMC were expressing TWEAK. TWEAK expression 
was first discovered on macrophages, and subsequent studies have confirmed TWEAK 
expression on haematopoietic and immune cells. Monocytes are precursors of macrophages, 
and monocyte subsets have been shown to differentiate into macrophages and dendritic 
cells, depending on the physiological environment. Recruited monocytes from blood have 
been shown to contribute to the fibrogenic response in chronic liver inflammation, whilst KC 
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have been shown to play only a minor role in the fibrogenic response (Karlmark et al., 2009). 
Previous unpublished data in our lab had shown 11% TWEAK percentage positive expression 
in isolated CD14+ve PBMC. Other work in our lab has also shown high percentage positivity 
of TWEAK protein expression in mesenchymal stem cells and activated hepatic stellate cells 
(Annika Wilhelm; Personal Communication). Throughout this study no TWEAK protein 
expression was observed on HIEC cell surface (Figure 3.3.19). This was shown with and 
without known stimuli which have previously been found to activate TWEAK expression; 
such as IFN-γ. In confirmation of our TWEAK protein expression data on HIEC, little to no 
expression of TWEAK mRNA was observed in HIEC in comparison to PBMC TWEAK mRNA 
expression (Figure 3.3.20). An increase in TWEAK expression was however observed when 
HIEC were permeablised; this further increased when HIEC were permeablised after TNF-α 
stimulation of the HIEC overnight (Figure 3.3.21). This increase in TWEAK expression was 
large in comparison to cell surface TWEAK protein expression which was negative. However 
enhanced TWEAK expression was only 8% of HIEC analysed, which was still relatively very 
low expression to Fn14 expression. There have been previous studies indicating the 
expression of TWEAK in endothelial cell lines (Stephan et al., 2013), but no data has 
suggested TWEAK expression observed in endothelial cells of a primary lineage, specifically 
HIEC.  
 
To further understand the regulation of TWEAK expressing monocytes and macrophages, we 
determined the expression of TWEAK in the classical (CD14+), and non-classical (CD16+ and 
dual positive) monocyte populations isolated from total PBMC. Our data showed that 
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TWEAK may be responsive during inflammatory cytokine stimulation of CD14+ and dual 
positive monocytes (Figure 3.3.22). We found that classical CD14+ monocytes expressed the 
highest amounts of TWEAK, and when these were stimulated with IFN-γ this expression 
further enhanced. This was followed by dual positive and CD16+ monocyte populations 
which showed equal amounts of basal TWEAK expression. When these were activated with 
IFN-γ; CD16+ monocytes showed decreased TWEAK expression and dual positive monocytes 
showed enhanced TWEAK expression. Liaskou et al 2013 showed that CD14+ monocytes 
were recruited in response to chronic inflammation in the liver, and they differentiated into 
dual positive subsets, enhancing the immune response, inflammation, and fibrosis (Liaskou 
et al., 2013). Our data would support this as TWEAK mRNA expression was up-regulated in 
response to inflammatory cytokine activation, and has been previously shown to promote 
the fibrogenic response during chronic inflammation. The data obtained from this 
experiment showed a trend in TWEAK expression patterns in the different monocyte 
subsets. However we cannot draw conclusions from this data as further functional assays 
would be required to determine the responses of TWEAK activation in the different 
monocyte sub-populations.  
 
Leukocyte recruitment in response to liver insult and injury has been observed in 
inflammatory liver disease tissue, and TWEAK expression has been found highly localised to 
these areas. Subsequently the inflammatory responses of TWEAK and its putative receptor 
Fn14 has been shown to be manipulated by the expression of adhesion proteins during 
inflammatory disease (Hosokawa et al., 2006; Stephan et al., 2013). Our data showed no 
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enhanced expression of ICAM and VCAM on HIEC cell surface in response to TWEAK 
activation in comparison to the unstimulated control (Figure 3.3.23). There was however, 
basal expression of ICAM and VCAM present on HIEC, which may be sufficient to support the 
TWEAK activated enhanced leukocyte adhesion observed. Our TWEAK data was not in 
agreement with several studies which have characterised the enhanced expression of ICAM 
and VCAM on endothelial cells in response to TWEAK activation (Chen et al., 2013; Stephan 
et al., 2013).  
 
We characterised TWEAK activated HIEC responses to leukocyte recruitment using a flow 
based adhesion assay and found that TWEAK activated HIEC significantly promoted 
monocyte adhesion (Figure 3.3.25), however the response was small in comparison to 
positive controls. Lymphocyte and total PBMC were un-responsive to TWEAK activated HIEC, 
however when HIEC were activated with TWEAK in combination with TNF-α, significantly 
enhanced total PBMC adhesion was observed. We subsequently observed no significantly 
enhanced responses to total PBMC shape change or migration in response to TWEAK 
activation of HIEC (Figure 3.3.25). Our data which showed that TWEAK alone or in 
combination with TNF-α may enhance leukocyte adhesion to HIEC, is in agreement with 
previous findings from this investigation which found the presence of TWEAK localised to 
areas of leukocyte infiltrates in chronic inflammatory liver disease tissue (Figure 3.3.3). This 
data although limited, was also in agreement with several studies which have investigated 
and found that TWEAK can promote the recruitment of leukocytes (Yin et al., 2013; Sanz, 
Aroeira, et al., 2014). Our previous data also showed that monocyte subsets isolated from 
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PBMC showed enhanced TWEAK expression in response to inflammatory cytokine IFN-γ 
(Figure 3.3.22). This data indicated that inflammatory conditions can promote the expression 
of TWEAK and subsequently TWEAK activation can promote leukocyte infiltration which 
enhances the inflammatory response, and TWEAK further enhances inflammatory responses 
of other pro-inflammatory cytokines including TNF-α and IFN-γ; indicating a positive 
inflammatory mediating TWEAK dependent pathway. This data was in agreement with our 
hypothesis which highlighted the potential of TWEAK to promote and sustain acute and 
chronic inflammation by utilising key processes. Our data further showed that blocking 
TWEAK activity using Fn14 mAb had no effect on leukocyte adhesion and migration to HIEC. 
The rate of adherence remained consistently the same as with TWEAK activation alone. This 
may be a signalling pathway specific response and will need to be further investigated 
before making any more conclusions. A recent study by Salzmann et al 2013, showed that 
Fn14 mAb’s can regulate NF-kB mediated responses, but cannot fully mimick activities of 
natural Fn14 in response to its ligand TWEAK in its soluble and membrane bound form. 
Therefore the responses of Fn14 mAb to TWEAK activation may vary in a signalling 
dependent manner, and may explain the lack of response to blocking TWEAK using Fn14 
mAb that we observed. Salzmann et al showed that Fn14 bound to FcγR is a more efficient 
mechanism of mimicking natural Fn14, as this mAb activated the full range of activities 
observed of natural Fn14 (Salzmann, Seher, et al., 2013). Therefore in future to determine If 
TWEAK activated responses are indeed mediated by Fn14, Fn14 mAb bound to FcγR will be a 
superior way of determining this, as it is not dependent on NF-kB signalling. 
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It has been reported that in cases of chronic inflammatory liver diseases, lymphoid follicles 
can form from portal tract infiltrate organisation. These are formed from B and T 
lymphocytes, DC, and neovessels which have a high endothelial venule phenotype (Grant et 
al., 2002). These follicles function to sustain lymphocyte recruitment and retain them using 
the high endothelial vessels.  Lymphoid follicles develop in response to chronic immune 
stimulation such as inflammatory cytokines like TNF-a. The presence of lymphoid follicles 
have been observed in chronic inflammatory liver diseases such as PBC and PSC, and other 
chronic inflammatory diseases such as SLE and RA (Grant et al., 2002; Neyt et al., 2012). Our 
findings show that there may be a significant role for TWEAK and Fn14 in the possible 
maintenance, organisation and development, of portal lymphoid aggregation during 
inflammation and liver disease. We showed this by the presence of TWEAK in inflammatory 
infiltrates in close proximity to portal vessels. We further found that TWEAK activated HIEC 
may promote the adhesion of leukocytes in particular monocytes to HIEC which can mimic 
specific inflammatory responses in settings of chronic inflammatory liver disease. Fn14 
expression was highly up-regulated surrounding portal vessels and neovessels. We further 
showed that Fn14 cell surface expression in HIEC was highly variable in response to pro-
inflammatory cytokines and growth factors, and no significant TWEAK expression was 
present on HIEC. Therefore we can suggest that TWEAK and Fn14 may be facilitating PALT 
formation in inflammatory liver disease, and paracrine mechanisms of action by TWEAK and 
Fn14 may be regulating cellular responses in the liver endothelium. This may be by 
transportation of TWEAK by certain immune cells such as IFN-γ activated monocytes from 
circulation, to the site of liver injury or disease, and interactions with Fn14 present on the 
cell surface of HIEC. It would seem that TWEAK may further promote inflammation by 
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facilitating the recruitment of leukocytes to the site of liver injury and disease and can help 
sustain this inflammation via interactions with specific cytokines and chemokines.  
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CHAPTER 4 
 
TWEAK Activated HIEC Promote Endothelial New Vessel Formation and Stimulate a 
Tailored Immune and Angiogenic Cytokine Response to Inflammation 
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4.1 INTRODUCTION 
4.1.1 Angiogenesis 
Angiogenesis is the formation of new blood vessels from pre-existing vessels. It is a critical 
process required to regulate normal biological function such as embryonic development, 
wound healing, regeneration of the uterus during menstruation, regulating blood pressure, 
the immune system, and inflammation (Otrock et al., 2007). Angiogenesis is initiated in 
response to ischaemic conditions, and responds by enhanced vasodilation which increases 
vascular permeability, allowing angiogenic proteins free passage for functional interactions 
(Figure 4.1). This process is followed by degradation of the extracellular matrix surrounding 
existing vessels, this is carried out by activated proteins such as plasminogen and MMP9. 
Endothelial cells then proliferate and migrate towards activated pro-angiogenic stimuli such 
as VEGF, and position into the stroma formed. The endothelial cells then form a lumen, and 
the basement membrane reforms. Endothelial progenitor cells then undergo maturation and 
differentiation, and recruitment of vascular smooth muscle cells and pericytes occurs. These 
cells adhere to form tubular structures, and blood flow is resumed (Rundhaug, 2003; Ma et 
al., 2007). All of these processes are tightly regulated by growth factors and angiogenic 
cytokines such as plasma proteins and integrins, which act in processes such as cellular 
interactions, and positioning and scaffolding of endothelial cells. For normal angiogenesis, 
the correct balance of pro and anti angiogenic factors is essential. (Brooks, 1996; Coulon et 
al., 2011).  
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HIF (hypoxia inducible factor) accumulation is a response to the ischaemic conditions which 
initiate angiogenesis and further stimulates angiogenic growth factors such as VEGF and FGF 
(De Spiegelaere et al., 2010). The VEGF family are key mediators of angiogenesis and 
vasculogenesis, and induce angiogenic functions via interactions with VEGFR2 in a nitrox 
 
Figure 4.1 Angiogenesis: Angiogenesis is initiated by vessel destabilisation followed by 
permeablisation of the vessel walls to allow passage of angiogenesis regulating factors, and 
followed by breakdown of the ECM. Vessel formation is progressed by endothelial cell 
proliferation and migration to the stroma formed, and initiation of cell-cell contact and tube 
formation. Vessel formation is then completed by mesenchymal proliferation and migration, 
pericyte differentiation and stabilisation. All of these processes are regulated by 
angiogenesis promoting and inhibiting factors at different stages of vessel formation, as 
highlighted in the image (Coulon et al., 2011). 
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oxide signalling pathway dependent manner (Coulon et al., 2011). FGF family members are 
also key promoters of the angiogenic response, as well as promoting mitogenesis they 
respond to arterial formation more so than VEGF which respond to capillary formation 
(Klein, Roghani e Rifkin, 1997). PDGF and angiopoietins also positively regulate angiogenesis 
by aiding promotion of endothelial cell migration and proliferation (Risau et al., 1992; Kim et 
al., 1999). Inhibitors of angiogenesis are also critical for the regulation of normal 
physiological conditions. These include; thrombospondins which regulate endothelial cell 
migration and apoptosis. They are responsible for decreasing MMP expression which leads 
to inhibition of VEGF expression to regulate angiogenesis (Dawson et al., 1997). Endostatin 
also inhibits growth factors and regulates endothelial cell apoptosis during angiogenesis 
(Dhanabal et al., 1999). Angiostatins decrease the activation of the Erk signalling pathway 
which is activated by FGF and VEGF, and induce endothelial cell apoptosis (Claesson-Welsh 
et al., 1998; Coulon et al., 2011). As well as these mediators; integrins play key roles in 
positively and negatively regulating angiogenesis, and cadherins which are responsible for 
endothelial cell interactions and the passage of molecules across endothelium during 
angiogenesis (Lampugnani et al., 1992; Serini, Valdembri e Bussolino, 2006; Coulon et al., 
2011).  
 
Pathological implications can occur when angiogenesis is deregulated, these often occur 
during diabetes, psoriasis, rheumatic diseases, and tumour growth and metastasis (Paleolog, 
2002; Martin, Komada e Sane, 2003; Otrock et al., 2007), for example; when there is 
insufficient angiogenesis in a diabetic patient during wound healing, impaired or limited new 
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vessel formation can occur. This can lead to an inadequate inflammatory response to the 
inflicted wound, and a poor oxygen and nutrient supply; leading to impaired wound healing 
processes. In contrast, when there is excessive angiogenesis in diabetic patients, this can 
lead to other complications such as retinopathy, and kidney disease (Tahergorabi e Khazaei, 
2012). There have been associations made between diabetes lead cardiovascular disease 
where de-regulated vessel formation is a key target of pathogenesis; for example, during 
coronary atherosclerosis, collateral vascular formation is required, this process in diabetic 
patients who have de-regulated angiogenesis is severely impeded (Sasso et al., 2005). 
Angiogenesis is also vital for the progression of tumour growth. Small dormant tumours 
when activated have the ability to recruit mature blood vessels to initiate angiogenic 
processes allowing infiltration of vessels to the tumour. This provides blood flow and all the 
required components for the tumour to grow, for example VEGF which is highly expressed in 
tumours (Coulon et al., 2011).  
 
4.1.2 Liver regeneration and angiogenesis 
During the pathogenesis of liver disease, excessive inflammation is the initiation of a host of 
complications such as liver fibrosis, cirrhosis, steatosis, and occasionally tumour formation. 
When liver damage occurs, inflammatory cells and mediators regulate liver recovery, and 
the liver inflammatory process is also key to the regulation of angiogenesis. VEGF, HGF, and 
other pro-angiogenic factors as discussed have been found up-regulated during liver 
regeneration (Fernández et al., 2009; Coulon et al., 2011). Basic FGF is required for HIEC to 
proliferate, and bFGF and VEGF together are known to facilitate the increase of liver weight 
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post resection, and both of these growth factors are essential for angiogenesis . Hepatic 
stellate cells are closely linked to HIEC and have been known to regulate vessel stabilisation, 
maturation, and sinusoidal remodelling via interactions with HIEC and release of growth 
factors, such as VEGF (Lee et al., 2007). Hepatocytes and HIEC have been found to induce 
HSC proliferation during PHx, and HSC in their active form can release angiogenic 
chemokines (Michalopoulos, 2007)(Michalopoulos, 2007). Progenitor cells have also been 
found to expand and differentiate into HSC and IHEC at the neovascularisation site, in 
response to growth factors and chemokine activation during liver regeneration (Beaudry et 
al., 2007). Other resident liver cells can contribute to angiogenesis in the liver. KC release 
cytokines, reactive oxygen species, and platelet activating factors which can regulate 
angiogenesis (Horie et al., 1997). Mast cells can release angiogenesis inducing mediators 
such as VEGF, and they contribute to endothelial cell proliferation to form liver sinusoids 
(Levi-Schaffer e Pe'er, 2001)(Levi-Schaffer e Pe'er, 2001).  
 
4.1.3 Liver disease and angiogenesis 
Cirrhosis of the liver in response to inflammation induced fibrosis is strongly associated with 
abnormal angiogenic processes in the liver, and neoangiogenesis is often associated with 
liver disease progression (Coulon et al., 2011). Briefly; cirrhotic scar formation can lead to 
the compression and loss of function of hepatic vessels, accompanied by fibrotic septa 
formation, and sinusoidal capillarisation. This leads to impaired blood flow and insufficient 
oxygen delivery around the liver which requires neo angiogenesis (Le Couteur et al., 1999). 
Specifically HSC migration towards the basement membrane of HIEC cause the narrowing 
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and distortion of vessels by collagen deposit formation leading to fibrosis mediated 
sinusoidal dysfunction (DeLeve et al., 2006). Several studies have characterised the pro-
angiogenic role of HSC during pro fibrosis and angiogenesis, for example during hypoxic 
conditions, enhanced VEGF and angiopoietin 1 expression via HIF-1α have been observed in 
human and rat HSC (Aleffi et al., 2005; Novo et al., 2007). Wound healing during fibrogenic 
CLD leads to the expression of fibrosis inducing factors which also have pro-angiogenic 
functions including growth factors, cytokines and MMP’s including VEGF, FGF and TGF-β. 
Enhanced gene expression of ECM remodelling factors and angiogenesis are also enhanced 
in CLD including integrins and adhesion molecules (Fernández et al., 2009). Portal 
hypertension can cause severe complications during liver disease, as enhanced collateral 
vessel formation can be observed in these cases which can route portal blood flow into 
systemic circulation. This can cause abnormal liver metabolic functions and abnormal 
clearance of toxins, leading to complications such as sepsis and portosystemic 
encephalopathy (Hoofring, Boitnott e Torbenson, 2003). Subsequently enhanced VEGF 
expression has been observed in splanchnic organs of portal hypertensive animals linking 
portal hypertention and angiogenic processes (Fernandez et al., 2004). New vessel formation 
within the liver is also key to promoting the inflammatory response during inflammatory 
liver disease. This is achieved by enhanced expression of inflammatory cytokines and 
adhesion molecules, which contribute to angiogenesis mediated acute to chronic liver 
inflammation (Jackson et al., 1997).  
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4.1.4 TNFSF ligands and receptors and angiogenesis 
TNFSF ligands and receptors have been implicated in pro and anti angiogenic function and 
regulation in several studies, in particular during chronic inflammatory liver disease. TNF-a 
has been shown to induce angiogenesis in an in vivo rat cornea model (Leibovich et al., 
1987). Alternatively, Fajardo et al 1992 showed TNF-α to have pro and anti-angiogenic 
responses, where TNF-a inhibited proliferation of endothelial cells in vitro, whereas TNF-α 
promoted in vivo vessel formation in mice corneas. This effect was thought to be 
concentration, species and conditions dependent, where low doses induced angiogenesis 
and higher doses induced a cytotoxic effect (Fajardo et al., 1992). TNF-α has been shown to 
induce endothelial cell angiogenesis via other angiogenesis mediators in a VEGFR2, PDGF, 
and NF-kB dependent mechanism (Sainson et al., 2008). TNF-α has previously shown tumour 
suppressive activities via targeting of adhesion receptor Integrin alpha V beta 3. Integrin 
alpha V beta 3 normally funtions to promote tumour progression, however when targeted 
by TNF-α, this was shown to disrupt angiogenesis (Ruegg et al., 1998). TNF-α expressed in 
macrophages has also been shown to activate the MAPK-Erk signalling pathway, which has 
been implicated in angiogenesis regulation as well as cell migration and apoptosis (Reddy, 
Nabha e Atanaskova, 2003). 
 
Fas-L and its receptor have been also been found to have both anti and pro-angiogenic 
activities. In RA, Fas has shown anti-angiogenic functions where Fas induced apoptosis of 
endothelial cells which expressed VEGF165. Subsequently, migration of endothelial cells was 
also inhibited in response to Fas activation (Kim et al., 2007). Excised neovascular 
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membranes from patients of age related macular degeneration, showed Fas positive 
neovessels surrounded by Fas-L positive retinal epithelial cells. Fas and Fas-L inhibition 
showed enhanced in vivo murine corneal neovascularisation, suggesting that Fas and Fas-L 
regulate retinal neovascularisation (Kaplan et al., 1999). Fas with interactions with Fas-L has 
been shown to induce inflammatory angiogenesis in an in vivo murine model, where 
subcutaneous delivery of anti Fas mAb resulted in infiltration of endothelial cells and 
monocytes and macrophages, followed by neutrophils and mast cells after 
neovascularisation. This was not observed in subsequent Fas mutant mice (Biancone et al., 
1997).  
 
CD40-L has shown potential to induce angiogenesis by promoting the expression of pro-
angiogenic cytokines such as IL-8, VEGF and HGF from human intestinal microvascular 
endothelial cells (Danese et al., 2007). A similar study showed that VEGF mediated CD40 
regulated promotion of inflammation induced angiogenesis in a study on SCID (severe 
combined immuno-deficiency) mice with skin grafts. They showed CD40 expression on 
endothelial cells and monocyte/macrophages, and CD40-L expression induced expression of 
key angiogenesis proteins (Reinders et al., 2003). CD40-CD40-L interactions have also been 
shown to promote in vitro tube formation coupled to MMP expression, which are both key 
components of neovascularisation (Mach et al., 1999). CD40 has been shown to enhance 
expression of platelet activating factor on HUVEC. Expressed platelet activating factor 
mediated in vitro endothelial cell migration and vessel formation. CD40-CD40L also 
contributed to interactions between endothelial and smooth muscle cells during 
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angiogenesis (Russo et al., 2003). Furthermore, CD40 was shown to promote 
neovascularisation and Kaposi’s sarcoma tumour survival and growth, and an in vivo 
neovascularisation model showed inhibited tumour neo-angiogenesis in response to CD40 
inhibition (Biancone et al., 1999). 
 
4.1.5 TWEAK and angiogenesis 
TWEAK and Fn14 have both been described as pro-angiogenic in a number of studies. Lynch 
et al 1999 were the first to describe TWEAK as angiogenic, as they found TWEAK induced 
endothelial cell angiogenesis and proliferation. They showed that TWEAK induced HUVEC 
and several microvascular endothelial cell, and smooth muscle cell proliferation which was 
found to be independent of VEGF and other angiogenesis inducing genes and receptors; 
shown by PCR quantification and VEGF neutralising antibodies. TWEAK angiogenic function 
was further characterised in an in vivo rat cornea model, where induced neovascularisation 
by TWEAK was found to be comparable to known angiogenesis inducing growth factors; 
VEGF and FGF2 (Lynch et al., 1999). Wiley et al 2001 described the TWEAK receptor (Fn14) as 
being a key regulator of TWEAK mediated angiogenesis in several in vitro and in vivo assays. 
They found Fn14 can initiate a proliferation inducing signal in HUVEC, and Fn14 was found to 
be highly regulated by growth factor stimulation including FGF2 in smooth muscle cells. In in 
vivo rat balloon angioplasty models, Fn14 mRNA was found up-regulated at the site of 
arterial injury, whereas in uninjured rat arteries Fn14 expression was found to be low. 
Endothelial migration assays revealed Fn14-Fc fusion proteins could inhibit endothelial cell 
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migration induced by PMA and EGF, and Fn14-Fc fusion protein inhibited FGF induced in vivo 
corneal angiogenesis by 50%, determined by vascular area and density (Wiley et al., 2001).  
 
TWEAK has also been described as having mitogenic activities during cases of liver injury. 
Progenitor cell expansion during liver regeneration is a key process to facilitate liver growth 
and neovessel formation in the liver. In Fn14 knock out mouse models and by using a TWEAK 
mAb, progenitor cell and BEC proliferation in TWEAK transgenic mice, was significantly 
reduced (Jakubowski, Ambrose, Parr, Lincecum, Wang, Zheng, Browning, Michaelson, 
Baetscher, Wang, et al., 2005). A similar response was observed in a CDE liver injury model 
where TWEAK acted as a mitogen for liver progenitor cells, suggesting TWEAK has 
involvement during hepatic injury and regeneration (Tirnitz-Parker et al., 2010).  
 
Unlike other TNFSF members, TWEAK has been described to be a direct inducer of 
angiogenesis. This is unlike TNF itself which has only been known to indirectly stimulate 
angiogenesis through other angiogenesis inducing factors such as EGF, and has been known 
to degrade tumours by necrosis of blood vessels, rather than promoting vascularisation of 
tumours. TWEAK was found to directly induce endothelial cell proliferation and angiogenesis 
in an in vivo rat cornea model without the activation of other angiogenesis or proliferation 
inducing factors (Lynch et al., 1999). Alternatively other investigations showed TWEAK 
regulated other angiogenesis inducing factors such as FGF, as was demonstrated by Wiley et 
al in their in vivo mice cornea model, which showed that FGF-2 induced angiogenesis could 
be partially reduced by blocking Fn14 activity (Wiley et al., 2001). This has been further 
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confirmed in vitro where TWEAK was shown to promote mitogenic activities of VEGF and 
FGF in HUVEC which was inhibited by Fn14-Fc fusion protein (Donohue et al., 2003). It has 
also been shown that TWEAK activated HUVEC also contributed to the enhanced expression 
of ICAM, E-selectin, and inflammatory cytokines IL-8 and MCP-1, indicating that TWEAK may 
functionally mediate inflammation and angiogenesis via endothelial cells (Harada et al., 
2002).  
 
It has also been suggested that TWEAK promoted angiogenesis may be achieved solely by 
the regulation of angiogenesis promoting growth factors; bFGF and VEGF. TWEAK was 
shown to promote VEGF induced HUVEC survival, bFGF induced proliferation, wound repair, 
and capillary sprout formation. It was shown that TWEAK alone could not significantly 
promote these processes in endothelial cells, and further suggested that TWEAK may have a 
dual role in angiogenesis as has been described for TNF-α. They showed that TWEAK can 
promote or suppress angiogenesis dependent upon experimental conditions and other 
angiogenic mediators present; such as TWEAK promoting endothelial proliferation induced 
by bFGF, and on the other hand suppression of morphogenic responses induced by VEGF by 
TWEAK (Jakubowski et al., 2002)(Jakubowski et al., 2002)(Jakubowski et al., 2002). This study 
was in contrast to the findings of Lynch et al 2001, however there were suggestions that the 
differences in TWEAK response was dependent upon the environment during experiments, 
as Lynch et al were detecting TWEAK responses during inflammatory conditions post surgery 
in the rat cornea model, which were not present during the study of Jakubowski et al 2002, 
but injury conditions were present in the other studys which showed indirect TWEAK 
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activated angiogenesis. This further demonstrates the highly regulated range of functions 
that TWEAK can mediate which are context and environment dependent. 
 
As well as TWEAK being described as a direct inducer of angiogenesis, the expression of 
TWEAK has been found in a number of human primary tumours indicating TWEAK may 
directly regulate tumour angiogenesis. It was found that TWEAK over-expression in nude 
athymic mice certainly enhanced tumour growth; producing highly vascularised tumours. 
The expression of Fn14 was found on vascular endothelial cells (HEK293) indicating that 
TWEAK may indeed regulate tumour angiogenesis by a paracrine mechanism (Ho et al., 
2004).  TWEAK mRNA and protein expression has also been found up-regulated in 
hepatocellular carcinoma where TWEAK was found to promote HCC cellular proliferation in 
an NF-kB dependent manner. Increased Fn14 expression was also found on HCC cell surface 
and in normal cells analysed, in normal cells Fn14 expression was found to be low (Kawakita 
et al., 2004).  
 
TWEAK and Fn14 interactions have been found to regulate inflammatory mediated 
angiogenesis in a number of investigations, comparable to known growth factors such as 
VEGF and FGF which highly induce and regulate angiogenic functions and have been 
characterised extensively. There is a need to find novel and innovative mechanisms of 
regulating angiogenesis for therapeutic purposes in normal and diseased liver as the liver 
utilises angiogenic processes to regenerate itself, and is an ideal target to further investigate 
in relation to TWEAK mediated angiogenic regulation for future therapeutic intervention, in 
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particular to disect the mechanisms of angiogenesis regulation at a cellular level in the liver 
via TWEAK and Fn14. 
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4.1.6 Aims 
The aims of this chapter were: 
 To determine if TWEAK promoted HIEC proliferation, migration and tube formation. 
 To determine if TWEAK mediated angiogenesis in HIEC was dependent on Fn14. 
 To determine if TWEAK activated HIEC promoted angiogenic cytokine responses 
during chronic inflammatory liver disease. 
 To determine if TWEAK and Fn14 responses during liver disease contributed to PALT 
formation. 
 
 
 
 
 
 
 
 
 
 
 
165 
 
4.2 MATERIALS AND METHODS 
Materials and methods for this section; refer to: 2.1-2.5, 2.10, 2.11, and Tables: 2.1, 2.3 and 
2.4. 
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4.3 RESULTS 
4.3.1 TWEAK does not enhance HIEC proliferation and cell motility 
We wanted to establish functional relationships between TWEAK and HIEC and if TWEAK 
stimulation would enhance HIEC angiogenic potential. To do this, it was important to 
establish whether TWEAK promotes HIEC proliferation, chemokinetic cell motility, and 
tubule formation. Ki-67 staining was used to observe HIEC proliferation. HIEC were cultured 
with and without the presence of recombinant TWEAK protein. Cell preparations were fixed 
on to Poly-L lysine coated slides, and subsequently stained for Ki-67; a nuclear cell 
proliferation marker. Positive cells and negative cells were counted and the percentage of Ki-
67 positive cells was calculated which gave an indication of the proliferative capacity of HIEC. 
Relative proliferation between unstimulated and TWEAK stimulated samples was 
determined. TWEAK activated HIEC showed 1.3 fold increase in proliferation in comparison 
to unstimulated controls (Figure 4.3.1), but the data was not statistically significant.  
 
To determine the role of TWEAK in driving HIEC motility, scratch wound assays were 
performed. A scratch was made on confluent HIEC cultured on gelatine. At 0 hours the 
wound was considered 100% open and then the wound was analysed at 4, 8, and 24 hours; 
until it was completely closed. At 4 hours, TWEAK alone marginally enhanced cell motility in 
comparison to the un-stimulated control, as TWEAK decreased the wound to 72.6%, and the 
unstimulated control decreased the wound to 77.4% (Figure 4.3.2 B). This was further 
improved in combination with TNF-α, as the wound decreased to 70.5%. TNF-α alone 
promoted the most cell motility by decreasing the wound to 67.5%. At 8 hours the wound 
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closure for all treatments was approximately the same. By 24 hours a difference was 
observed between treatments, as TWEAK, and TWEAK in combination with TNF-α, 
completely closed the wound. The unstimulated control had 2.3% wound remaining, and 
TNF-α alone had 4.5% wound remaining (Figure 4.3.2 B). This data was not statistically 
significant, therefore no enhancement of TWEAK or TNF-α stimulated HIEC motility was 
observed. 
 
We wanted to determine if any TWEAK stimulated wound closure seen in HIEC was 
mediated by Fn14. To do this, scratch wound assays were performed with TWEAK with the 
presence of anti-Fn14 mAb, and TWEAK and IgG1 control for the Fn14 mAb (Figure 4.3.2 C). 
Interestingly, using an Fn14 mAb enhanced TWEAK activated wound closure rather than 
inhibiting it. At 4 hours the unstimulated control closed the wound to 77.4%, TWEAK 
activated HIEC had closed the wound marginally faster at 72.6%, TWEAK (+ Fn14 mAb) 
closed the wound much faster at 48.6% wound remaining, and the TWEAK (IgG1 control for 
Fn14 mAb) had closed the wound to 56.9%. This trend continued at 8 hours post activation 
where the unstimulated control closed the wound to 51.6%, TWEAK activated HIEC had 
closed the wound faster at 47%, TWEAK (Fn14 mAb) closed the wound much faster at 14% 
wound remaining, and the TWEAK (IgG1) had closed the wound to 39.7%. By 24 hours all 
wounds had closed apart from the unstimulated control which had 2.3% remaining open. 
Statistical analysis performed on this data showed it was not significant. 
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Figure 4.3.1 - TWEAK stimulation did not significantly enhance HIEC proliferation: 
HIEC were cultured with (B) and without TWEAK (A) (100ng/ml), and cell 
preparations were fixed on to slides. Unstimulated HIEC were used as a negative 
control. HIEC were stained for Ki-67 (a nuclear proliferation marker) to determine 
the proliferative capacity of HIEC after TWEAK stimulation. C) TWEAK stimulated 
HIEC activated cell proliferation 1.3 fold in comparison to the unstimulated control. 
Data is shown as relative proliferation of unstimulated HIEC and TWEAK stimulated 
HIEC (n=4 ± SE). This data was not statistically significant. 
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Figure 4.3.2 - TWEAK stimulation did not promote HIEC cell motility: A) HIEC were 
cultured on gelatine coated plates and scratch wound analysis was performed. HIEC 
were stimulated with TNF-α (10ng/ml) and TWEAK (100ng/ml) (Image shows TWEAK 
activated HIEC motility). Unstimulated HIEC were used as a negative control and TNF-α 
stimulated HIEC were used as a positive control. Images were taken after initialising 
the scratch at 0, 4, 8, and 24 hours. B) TWEAK activated and TWEAK and TNF-α 
activated HIEC were most active at closing the wound. Data is shown as mean 
percentage (n=5 ± SE). C) Scratch wound analysis was performed in the presence of 
TWEAK, TWEAK (Fn14 mAb to block Fn14 activation) and TWEAK (IgG control) to 
determine if TWEAK enhanced wound closure is dependent on Fn14 activation. Images 
were taken after initialising the scratch at 0, 4, 8, and 24 hours. Data is shown as mean 
percentage (n=3 ± SE). Blocking TWEAK activation using Fn14 mAb comparatively 
enhanced wound closure. This data was not statistically significant. 
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4.3.2 TWEAK promoted HIEC in vitro tube formation via Fn14 
To determine whether TWEAK plays an active role in promoting HIEC angiogenesis; 
Matrigel™ tube formation assays were performed. HIEC were cultured on natural Matrigel™ 
for 8 hours and activated with TWEAK, TNF-α, TWEAK and TNF-α in combination, TWEAK + 
Fn14 mAb (to block Fn14 activation), TWEAK + IgG1 control for Fn14 mAb, and FGF as a 
positive control. Images for analysis were taken from five fields of view at 8 hours and 
assessed for node formation. A node was counted as having a central point with ≥ 1 branch 
(Figure 4.3.3 B; indicated with red mark). TWEAK activated HIEC significantly enhanced 
angiogenic tube formation in comparison to unstimulated HIEC; from 39 nodes in 
unstimulated HIEC to 52 nodes in TWEAK stimulated HIEC. Data was shown as mean of 16 
experiments ± SEM ***p=0.00011 (Figure 4.3.3 C). The tube formation observed in HIEC 
stimulated by TWEAK was comparable to FGF which showed an average number of 49.8 
nodes in 5 experiments *p=0.02. TNF-α, and TWEAK and TNF-α in combination did not alter 
tube forming potential in HIEC significantly (n=6).  
 
To determine if the TWEAK promoted tube formation in HIEC was true and mediated by 
Fn14; an anti Fn14 mAb was used to block Fn14 activity in the angiogenesis assay in TWEAK 
stimulated HIEC. The anti Fn14 mAb significantly reduced node formation to lower than 
basal levels, with an average number of 35 nodes in 10 experiments. This data in comparison 
to TWEAK stimulated HIEC (52 average nodes) was significantly lower **p=0.002.  This 
confirmed that TWEAK was indeed responsible for the increased angiogenic potential 
observed in vitro and that this may be mediated in an Fn14 dependent manner. TWEAK in 
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addition to the IgG1 control showed a decrease in node formation in comparison to the 
TWEAK activated samples. Node formation in TWEAK (IgG) was higher than TWEAK (Fn14) 
samples averaging at 40.2 and 35.3 nodes respectively (n=5). 
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Figure 4.3.3 - TWEAK stimulated HIEC promote endothelial tube formation 
comparable to the tube formation potential of FGF: A) Representative image of HIEC 
in culture. B) HIEC were cultured on Matrigel™ for 8 hours and stimulated with TWEAK 
(100ng/ml), TNF-α (10ng/ml), TWEAK with Fn14 mAb to block TWEAK activity 
(74ng/ml), and FGF (0.5ng/ml). Node formation was used to calculate angiogenic 
potential by counting the number of nodes (Red mark) with each condition from five 
fields of view. Unstimulated HIEC were used as a negative control, TWEAK (IgG1) was 
used as a negative control for TWEAK (Fn14), and FGF was used as a positive control 
(n=5). C) HIEC cultured on matrigel showed a significant increase in node formation 
when stimulated with soluble TWEAK, and FGF for 8 hours (***p=0.000011 (n=16), 
and *p=0.02 respectively (n=5). No significant increase in node formation was 
observed when cells were stimulated with TNF-α (10ng/ml) and TWEAK and TNF-α co-
stimulation (n=6). A significant decrease in node formation was observed when Fn14 
activity was blocked (**p= 0.002385) indicating TWEAK stimulated tube formation was 
dependent on Fn14 (n=10). Data is shown as mean ± SEM. Statistical analysis was 
carried out using a paired Students t test. 
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4.3.3 TWEAK may initiate specific angiogenic and inflammatory responses during 
inflammatory liver disease 
Supernatants collected from the angiogenesis assay conducted on HIEC isolated from normal 
donor liver tissue (Case 1), was assessed for angiogenic and inflammatory cytokine 
production. TWEAK activation mildly elevated a small range of inflammatory and angiogenic 
cytokines including MCP-1, TGF-β1, PDGF, MIF, Serpin E1 and FGF acidic in comparison to 
the unstimulated control. Some cytokines were down-regulated in response to TWEAK 
activation including Activin A, MMP-8, CXCL16 and EGF (Figure 4.3.4 C and D). Liver tissue 
sections from the same donor liver were haematoxylin and eosin stained to assess the 
histology of the tissue. The histology was grossly normal with mild inflammation in the portal 
tract which is a common feature in donor tissue (Figure 4.3.4 A and B). Liver tissue sections 
from this case were stained for Fn14 expression. Fn14 was expressed generally in 
hepatocytes and a distinctive expression pattern was observed surrounding portal vessels 
(Figure 4.3.4 F and G) in comparison to its isotype control IgG1 (Figure 4.3.4 E). 
 
Assessment of angiogenic and inflammatory cytokines expressed from TWEAK stimulated 
HIEC, isolated from a case of chronic inflammatory diseased PBC liver tissue (Case 2) showed 
a more marked elevation of cytokines. MCP-1 increased 12 fold with TWEAK stimulation. An 
increase was also observed in VEGF, Prolactin, IL-8, Angiopoietin-1 and CXCL16 expression. 
TWEAK activation down-regulated PDGF (which was up-regulated in the normal donor 
sample) and TIMP-4 (Figure 4.3.5 C). The matched liver tissue histology showed heavy 
inflammatory infiltrates present in the portal tract surrounding portal vessels and granuloma 
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formation (Figure 4.3.5 A and B). Fn14 expression in corresponding liver tissue sections 
showed Fn14 highly expressed in areas surrounding inflammatory infiltrates. Staining was 
observed in hepatocytes, ductular reactive cells, and specifically surrounding portal vessels 
(Figure 4.3.5 D and E). This staining was compared to the corresponding isotype control IgG1 
(Figure 4.3.5 F). 
 
A second case of HIEC isolated from PBC liver presented a wide range of angiogenic and 
inflammatory cytokines elevated in response to TWEAK activation (Case 3). In contrast to 
other cases this case did not show a presence or elevation of MCP-1. A decrease was 
observed in Endothelin, Vasohibin, MIF and Persephin, with TWEAK activation (Figure 4.3.6 C 
and D). The corresponding liver tissue showed a large inflammatory infiltrate and 
disorganised vessel formation (Figure 4.3.6 A and B). The liver tissue also showed scattered B 
and T cells with no cellular organisation (Figure 4.3.8 A and B). Fn14 expression was 
examined in liver tissue sections from this case and Fn14 expression patterns also showed 
disorganised un-specific staining. Staining was observed in hepatocytes, and scattered 
staining around portal vessels (Figure 4.3.6 F and G). This staining was compared to the 
corresponding isotype control (Figure 4.3.6 E). 
 
Another case of HIEC isolated from PBC liver (Case 4) showed specific increases in angiogenic 
and inflammatory cytokines. MCP-1 was up-regulated 6 fold when the HIEC were stimulated 
with TWEAK; and also PDGF, MMP-8, CXCL16, EGF and IL-8 were up-regulated in comparison 
to the unstimulated control (Figure 4.3.7 C). Marked decrease was observed in Endoglin, 
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Serpin F1, Prolactin, Platelet factor 4 and Thrombospondin 1 in response to TWEAK 
activation. The corresponding liver tissue showed a high degree of organisation where well 
defined granulomas were present in close proximity to portal vessels (Figure 4.3.7 A and B). 
These showed highly organised PALT with marginated T and B cells (Figure 4.3.8 C and D). 
Fn14 expression was examined in liver tissue sections from this case. They showed 
distinctive Fn14 staining in portal and neo vessels in close proximity to the well defined 
granulomas (Figure 4.3.7 D and E, Figure 4.3.8 E and F) in comparison to their isotype control 
(Figure 4.3.7 F). 
 
Expression patterns were observed when data from the individual cytokine arrays was 
pooled together. The expression patterns of a panel of cytokines remained relatively 
unchanged between normal donor and chronic liver disease samples, with and without 
TWEAK activation in isolated HIEC (Figure 4.3.9). These included angiogenesis promoting and 
inhibiting cytokines; Angiogenin, DPPIV, EGF, Endoglin, HGF, IGFBP1, 2 and 3, MMP-9, PDGF-
AA, Pentraxin 3, Platelet factor 4, Thrombospondin 1, and TIMP-1. A panel of cytokines in 
response to TWEAK activation in liver diseased samples increased in expression in 
comparison to the normal donor with and without TWEAK activation (Figure 4.3.10). This 
included; Angiopoietin 1 and 2, Angiostatin, CXCL16, EGVEGF, IL-8, MCP-1, MMP-8, PDGF-
AB/BB, Prolactin, TIMP-4, uPA and VEGF. MCP-1 expression was enhanced 5 fold when HIEC 
were stimulated with TWEAK in comparison to the unstimulated HIEC. CXCL16 in the normal 
donor was down-regulated when stimulated with TWEAK. In contrast TWEAK stimulation in 
diseased HIEC samples significantly enhanced CXCL16 expression *p=0.04. Angiopoietin-1 
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expression was unchanged in the normal donor HIEC sample, however when HIEC from the 
diseased liver samples were stimulated with TWEAK, a large significant increase in 
Angiopoietin-1 expression was observed *p=0.04. MMP-8 expression in the normal donor 
sample was decreased in response to TWEAK activation. This expression was increased 2 fold 
in response to TWEAK activation in chronic inflammatory liver disease samples, although the 
response was much milder in 2/3 samples. IL-8 and VEGF expression in the normal donor 
remained relatively unchanged in response to TWEAK activation. In the chronic liver disease 
samples, TWEAK activation enhanced IL-8 and VEGF expression 2 fold and 1.3 fold 
respectively. Other cytokines which were enhanced in response to TWEAK activation in 
diseased liver tissue HIEC, were expressed only in certain cases and not in all cases (Table 
4.1). 
 
Expression of cytokines was observed to be down-regulated in response to TWEAK activation 
in diseased liver samples, in comparison to the normal donor sample with and without 
TWEAK activation (Figure 4.3.11 A). These included Endothelin, FGF acidic, LAP TGFβ1, 
Persephin, Thrombospondin 2 and Vasohibin. Expression of Artemin and Activin A was only 
observed in the normal donor (Case 1) and down-regulated with TWEAK activation (Figure 
4.3.11 B). Descriptions of each of these angiogenic cytokines are given in Appendix 1. 
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Figure 4.3.4 - Angiogenic and cytokine array profiles of isolated normal donor HIEC 
stimulated with TWEAK, correlate with the histopathological features of hepatic 
inflammation present in the tissue from which they were isolated (Case 1): A and B) 
Shows tissue sections from donor liver with mild inflammation represented by a 
moderately elevated presence of inflammatory cells within the portal tract. C) Shows an 
angiogenic cytokine array of HIEC isolated from the corresponding tissue. 8 hour TWEAK 
stimulation of HIEC moderately elevated some angiogenic cytokines in comparison to the 
unstimulated control. D) An inflammatory cytokine array from the same supernatant 
revealed up-regulation of macrophage inhibitory factor and Serpin E1 in response to 
TWEAK activation. F and G) Shows Fn14 IHC staining of corresponding liver tissue. Fn14 
expression was confirmed in the liver tissue, mild staining was observed throughout the 
hepatocytes and localised heavily surrounding portal vessels. E) Shows the IgG1 control 
for the Fn14 antibody. Antibodies were developed with a DAB substrate. Images were 
taken with Zeiss microscope and axiovision v4.4 software 200x magnification 
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Figure 4.3.5 - Angiogenic cytokine array profile of isolated PBC HIEC stimulated with 
TWEAK, correlate with the histopathological features of hepatic inflammation present in 
the tissue from which they were isolated (Case 2): A and B) A degree of organisation was 
observed in tissue from this liver where large inflammatory infiltrates were observed in 
close proximity to portal vessels and neovessels. C) Shows the angiogenic cytokine profile 
of HIEC isolated from tissue A and B. The angiogenic cytokine array showed specific up-
regulation of MCP-1, Prolactin, IL-8, angiopoietin 1 and CXCL16. This showed that there 
was a well-defined array of angiogenic cytokine induction following TWEAK stimulation in 
HIEC isolated from the corresponding tissue. D and E) The Fn14 staining pattern was 
observed to be present in portal vessels, neovessels, and hepatocytes. The staining also 
appeared to be focused on areas near inflammatory aggregates in close proximity to 
portal vessels. F) Shows the IgG1 control for the Fn14 antibody. All antibodies were 
developed with a DAB substrate. Images were taken with Zeiss microscope and axiovision 
v4.4 software 200x magnification 
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Figure 4.3.6 - Angiogenic cytokine array profile of isolated PBC HIEC stimulated with TWEAK, 
correlate with the histopathological features of hepatic inflammation present in the tissue 
from which they were isolated (Case 3): A and B) Shows tissue from a case of PBC liver with 
severe inflammation and disorganised vessel formation. C and D) The corresponding 
angiogenic and inflammatory cytokine arrays from supernatants from HIEC stimulated with 
TWEAK after 8 hours shows a higher expression and range of inflammatory and angiogenic 
cytokines. The array expression was broader in the diseased liver tissue sample than the 
normal donor. F and G) Shows Fn14 IHC staining of corresponding liver tissue. Fn14 expression 
was confirmed in the liver tissue but without a degree of organisation. E) Shows the IgG1 
control for the Fn14 antibody. All antibodies were developed with a DAB substrate. Images 
were taken with Zeiss microscope and axiovision v4.4 software 200x magnification. 
 
 
180 
 
 
 
 
 
 
 
 
 
 
Figure 4.3.7 - Angiogenic cytokine array profile of isolated PBC HIEC stimulated with 
TWEAK, correlate with the histopathological features of hepatic inflammation present in 
the tissue from which they were isolated (Case 3): C) Shows the angiogenic cytokine profile 
of HIEC isolated from tissue A and B. A high degree of organisation was observed in tissue 
from this liver where well defined granulomas were present in close proximity to portal and 
neovessels. This showed highly organised PALT with marginated T and B cells (see Figure 
4.3.8) with vessels in close proximity. The angiogenic cytokine array also showed well 
defined specific angiogenic cytokine induction of MCP-1, PDGF, EGF and CXCL16 following 
TWEAK stimulation in HIEC isolated from the corresponding tissue. D and E) Shows Fn14 IHC 
staining in corresponding liver tissue. The Fn14 staining pattern was observed to be present 
in portal and neovessels, and hepatocytes. The staining was heavily localised on areas near 
lymphoid aggregates in close proximity to portal vessels. F) Shows the IgG1 control for the 
Fn14 antibody. All antibodies were developed with a DAB substrate. Images were taken 
with Zeiss microscope and axiovision v4.4 software 200x magnification. 
 
  
181 
 
 
Angiogenesis Protein 
Normal 
Donor 
Case 1 
PBC 
Case 2 
PBC 
Case 3 
PBC 
Case 4 Angiogenesis Protein 
Normal Donor 
Case 1 
PBC 
Case 2 
PBC 
Case 3 
PBC 
Case 4 
Activin A + - - - IL-8 + + + + 
ADAMTS-1 - - - - LAP(TGF-B1) + - + - 
Angiogenin + + + + Leptin - - - - 
Angiopoietin-1 + + + + MCP-1 (CCL2) + + - + 
Angiopoietin-2 + - + - MIP-1a - - - - 
Angiostatin/Plasminogen + + + + MMP-8 + + + + 
Amphiregulin - - - - MMP-9 + + + + 
Artemin + - + - NRG1-β - - - - 
Coagulation Factor III - - - - Pentraxin 3 (PTX3) + + + + 
CXCL16 + + + + PD-ECGF + - - - 
DPPIV + + + + PDGF-AA + + + + 
EGF + - + + PDGF-AB/BB + + + + 
EG-VEGF + - + + Persephin + - + - 
Endoglin + + + + Platelet factor 4 + + + + 
Endostatin/ Collagen XVIII - - - - PIGF + - + - 
Endothelin-1 - + + + Prolactin + + + + 
FGF acidic + - + - Serpin B5 - - - - 
FGF basic - - - - Serpin E1 + + + + 
FGF-4 - - - - Serpin-F1 + + + + 
FGF-7 - - - - TIMP-1 + + + + 
GDNF - - - - TIMP-4 - + + + 
GM-CSF - - - - Thrombospondin-1 + + + + 
HB-EGF - - + - Thrombospondin-2 - - + - 
HGF + + + + uPA - - + - 
IGFBP-1 + + + + Vasohibin - - + - 
IGFBP-2 + + + + VEGF + + + + 
IGFPB-3 - + + + VEGF-C - - - - 
IL-1β - - - -      
       
Table 4.1 Angiogenesis cytokine profiles: This table summarises TWEAK stimulation responses of HIEC in the angiogenesis cytokine array. The + represents 
up-regulation and the – represents down-regulation of cytokine. Data is shown as a HIEC response to TWEAK in comparison to unstimulated HIEC. 
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Figure 4.3.8 - Portal associated lymphoid aggregates show zonal organisation of CD3 
positive T cells around CD20 positive B cells, Fn14 expression is found surrounding 
these areas: A and B show B and T cell infiltrates respectively scattered throughout the 
inflamed port tract without cellular organisation. These sections were taken from the 
PBC liver with HIEC angiogenic cytokine profile Figure 4.3.6; Case 3. C and D show highly 
organised marginated B and T cell lymphoid aggregates. These sections were taken 
from a PBC liver with HIEC angiogenic profile Figure 4.3.7; Case 4. Comparatively Fn14 is 
expressed surrounding granulomas within inflamed liver tissue taken from case 2 and 4. 
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Figure 4.3.9 – Angiogenesis cytokine expression remained unchanged in response to 
TWEAK activation in inflammatory liver disease: This figure shows pooled data from the 
4 angiogenesis arrays. Angiogenesis proteins expressed in the normal donor sample with 
and without TWEAK activation, and in chronic inflammatory diseased livers with and 
without TWEAK activation remain relatively unchanged. IGFBP-3 and MMP-9 were not 
expressed in the normal donor sample, they were only expressed in the diseased liver 
samples. Data is shown as mean ± SE from 4 experiments; n=1 normal donor, n=3 
diseased liver. No statistical analysis was performed on this data. 
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Figure 4.3.10 - Angiopoietin-1, CXCL16 and MCP-1 were enhanced in response to 
TWEAK activation in chronic inflammatory liver disease: This figure shows pooled 
data from the 4 angiogenesis arrays. Angiopoietin-1 expression was significantly 
enhanced in response to TWEAK in Chronic inflammatory disease liver in comparison to 
unstimulated HIEC *p=0.04. CXCL16 was down-regulated in normal donor tissue in 
response to TWEAK. This was then significantly up-regulated in response to TWEAK 
activation in diseased liver samples *p=0.03. C) MCP-1 expression was enhanced 5 fold 
in response to TWEAK from 3 out of the 4 arrays analysed. IL-8, MMP-8 and VEGF were 
also enhanced in response to TWEAK activation in HIEC isolated from diseased tissue. 
This data was not statistically significant. Data is shown as mean ± SE from 4 
experiments; n=1 normal donor, n=3 diseased liver. Statistical analysis was carried out 
using a paired Students t test. 
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Figure 4.3.11 – Angiogenesis protein expression decreased in response to TWEAK 
activation in chronic inflammatory liver disease: A) Figure shows pooled data from the 4 
angiogenesis arrays. Angiogenesis proteins – FGF acidic and LAP (TGF-β1) expression 
increased in the normal donor sample with TWEAK activation. Endothelin-1, 
Thrombospondin-2 and Vasohibin were not expressed in the normal donor sample. 
Persephin 1 only mildly decreased in response to TWEAK activation in the normal donor 
tissue. In chronic inflammatory diseased livers TWEAK activation showed decreased 
angiogenic protein expression. B) Angiogenesis proteins – Activin A and Artemin expression 
decreased in response to TWEAK activation in the normal donor tissue. In chronic 
inflammatory diseased livers no angiogenesis protein expression was observed. Data is 
shown as mean ± SE from 4 experiments; n=1 normal donor, n=3 diseased liver. This data 
was not statistically significant. 
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4.3.4 Summary of Results 
 TWEAK stimulated HIEC significantly enhanced angiogenic node formation in a tube 
formation assay. This was regulated via Fn14 which was determined by using Fn14 
mAb to block TWEAK activation. 
 TWEAK activated HIEC showed specific angiogenic cytokine responses which were 
isolated from inflamed liver tissue. Notably CXCL16, angiopoietin-1, MCP-1, IL-8 and 
VEGF were found enhanced as a TWEAK stimulated HIEC angiogenic response. 
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4.4 DISCUSSION 
Our data has shown that TWEAK activated HIEC via Fn14 may play a functional role in 
directing liver inflammation induced angiogenesis, which may lead to promoting liver 
regeneration. These findings are in agreement with several studies where TWEAK has been 
described as pro-angiogenic (Lynch et al., 1999; Wiley et al., 2001; Ho et al., 2004). We 
showed that TWEAK could directly mediate tube formation, as inhibition of TWEAK by Fn14 
mAb reduced angiogenic potential in the presence of VEGF and HGF supplemented media 
(Figure 4.3.3). The angiogenic potential observed was comparable to FGF induced tubule 
formation in HIEC, which has previously been shown by Lynch et al 1999 in a TWEAK induced 
in vivo rat cornea model comparable to VEGF and bFGF (Lynch et al., 1999). 
 
TNF-α activated HIEC have shown potential to induce Fn14 expression (Chapter 3), therefore 
we wanted to determine if TNF-α would also regulate TWEAK and Fn14 HIEC angiogenic 
responses. TNF-α and co-stimulation with TWEAK was used to observe tube formation 
responses. We showed no increase in angiogenic tube formation potential of HIEC, although 
a response of TNF-α in combination with TWEAK was expected. TNF-α has been previously 
described as both an indirect inducer of angiogenesis, and in some cases has been shown to 
inhibit endothelial cell proliferation and angiogenesis (Fajardo et al., 1992). From our data it 
can be assumed that TNF-α does not facilitate or promote angiogenesis through TWEAK in 
HIEC, or there may be a possible cytotoxic effect by using these two cytokines in parallel, 
which suppresses the ability of TWEAK to induce tubule formation. Our data is in agreement 
with Lynch et al 1999 where it has been shown that TWEAK can independently induce an 
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angiogenic effect without the influence of other growth factors and angiogeneis inducing 
cytokines (Lynch et al., 1999).  
 
To understand the mechanisms by which TWEAK can promote angiogenesis for future 
therapeutic intervention via HIEC, it would be desirable to further characterise this function 
by determining the involvement of other growth factors such as VEGF. To do this, TWEAK 
activated HIEC may be blocked with an anti-VEGF mAb, or growth factor free Matrigel™ and 
serum starved media would be used in these assays to determine if TWEAK induced tubule 
formation is indeed mediated by VEGF. Similarly other pro-angiogenic factors and mediators 
in combination with TNF-α will need to be investigated to observe any angiogenic potential 
in HIEC using TNF-α. 
 
Our data also showed non responsive proliferative and migratory capacity of TWEAK 
activated HIEC (Figure 4.3.1 and 4.3.2). An interesting observation was made during the cell 
motility assays, they showed that TWEAK activated HIEC blocked using an Fn14 mAb, 
showed a large enhancement of wound closure in comparison to TWEAK activated HIEC. In 
contrast, the tube formation assays in response to Fn14 inhibition of HIEC activated with 
TWEAK, showed significantly down-regulated node formation (Figure 4.3.3). As discussed in 
Chapter 3, this may be a HIEC signalling dependent response.  
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A key observation from this study was that TWEAK appeared to generate a tailored immune 
response to varying liver tissue histology. The sample number for these experiments were 
small, but preliminary observations were made in response to TWEAK activated HIEC which 
could indicate the potential of TWEAK activated angiogenesis regulation. All of the 
inflammatory disease samples used in this study for angiogenesis cytokine array studies, 
were from PBC livers. The histology of each of these cases revealed that each sample had a 
distinct tissue histological pattern with varying degrees of inflammatory infiltrate, and 
cellular and structural organisation. In response to each sample, TWEAK initiated a specific 
angiogenic and inflammatory cytokine activation cascade. When data from these arrays 
were pooled together, a specific regulatory pattern of TWEAK activation in PBC diseased 
tissue could be observed. Some angiogenic factors showed no response to chronic liver 
disease and TWEAK activation (Figure 4.3.9), these included pro and anti-angiogenesis 
inducing factors. Other angiogenesis proteins were found to be decreased in response to 
TWEAK activation (Figure 4.3.11). The most compelling finding was the enhanced expression 
of angiogenic cytokines in response to TWEAK activation in isolated HIEC from chronic liver 
disease samples in comparison to normal donor sample, where enhanced expression was 
observed in specific cases or in all liver disease cases investigated (Table 4.1), as this 
indicated that TWEAK positively regulated angiogenic responses during liver disease via HIEC 
(Figure 4.3.10). This has previously been described by Lynch et al 1999 where enhanced 
TWEAK angiogenic responses were observed in inflammatory conditions and alternatively 
Jakubowski et al 2002 showed a limited angiogenic response under normal conditions. For 
the purpose of this discussion I will only discuss angiogenesis proteins which showed a 
distinctive pattern of expression in all four arrays analysed (Table 4.1).  
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Generally, the Donor case (Case 1) showed a mild elevation of cytokines in response to 
TWEAK activation, which was also a reflection of the liver tissue histology of the sample 
(Figure 4.3.4). The PBC diseased samples all showed a higher degree of cytokine induction in 
response to TWEAK. There were however variations in the range of cytokines elevated or 
decreased in response to TWEAK.  The two cases where the liver tissue histology showed a 
higher degree of organisation (Figure 4.3.5 and 4.3.7); specifically distinct inflammatory 
infiltrates in close proximity to portal and neovessels, and granuloma formation were 
observed. TWEAK activation elevated MCP-1 expression in these cases. MCP-1 expression 
was observed in the donor sample, however the response to TWEAK was mild. The sample 
where no organisation was observed in the histology of the liver tissue, MCP-1 expression 
was not observed either in the unstimulated supernatant or the TWEAK stimulated 
supernatant (Figure 4.3.6). 
 
MCP-1 is a CC chemokine which is a key regulator of monocytes and macrophages, memory 
T cells, and natural killer cell recruitment and migration. MCP-1 has been shown to regulate 
the inflammatory response in disease and also can act as a direct mediator of angiogenesis 
independent of its inflammatory response, and directly contribute to tumour progression 
(Salcedo et al., 2000). Subsequently, MCP-1 expression has been found to be related to the 
formation of granulomas in settings of chronic inflammation (Flory, Jones e Warren, 1993; 
Conti e DiGioacchino, 2001). MCP-1 has been shown to be involved in chronic inflammatory 
liver disease progression via inflammatory cell recruitment. Kanda et al 2006 showed MCP-1 
expression related to hepatic steatosis (Kanda et al., 2006). Czaja et al 1994 showed patients 
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with chronic inflammatory liver disease had increased expression of MCP-1 in comparison to 
patients with no liver disease (Czaja et al., 1994). Zamara et al 2007 showed a decrease in 
liver damage caused by inflammatory infiltrates and oxidative stress in MCP-1 knock out 
mouse models (Zamara et al., 2007).  
 
There have been several studies where TWEAK has activated MCP-1 expression in response 
to disease and angiogenesis. Angiogenic responses to TWEAK activation have shown an 
elevation in MCP-1 expression, Harada et al showed an increase of MCP-1 expression in 
response to TNF-a, TWEAK and CD40L in HUVEC. This process was shown to be regulated by 
Fn14 and NF-kB (Harada et al., 2002). TWEAK was also shown to increase expression of MCP-
1 at an mRNA and protein level in a human ovarian cancer cell line (Gu et al., 2013). 
Subsequently anti-TWEAK Ab has shown a decrease in MCP-1 expression in a lupus nephritis 
mouse model (Zhao et al., 2007). Our data was in agreement with these findings that TWEAK 
may be regulating the inflammatory angiogenic response via MCP-1 during chronic liver 
disease, and in particular MCP-1 may be regulating granuloma formation in the liver tissue. 
Our finding although was not statistically significant, a 5 fold increase in MCP-1 expression 
was observed in response to TWEAK in two of the diseased HIEC isolates where granulomas 
were present. 
 
Other up-regulated angiogenesis inducing cytokines in response to TWEAK activation in all 
chronic liver disease samples included Angiopoietin 1, CXCL16, MMP-8, IL-8, and VEGF 
(Figure 4.3.10). Angiopoietin 1 (Ang-1) is a known potent regulator of angiogenesis and has 
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been shown to be active during liver regeneration. Enhanced expression of VEGF and Ang-1 
mRNA post partial hepatectomy were observed, and it was thought that these proteins 
regulated angiogenesis processes during liver regeneration, as expression of these gradually 
decreased over time (Sato et al., 2001). Taura et al 2008 showed that HSC initiated 
angiogenesis by releasing Ang-1. Subsequently, they found Ang-1 up-regulated in fibrotic 
livers, and this up-regulation was mediated by TNF-a in an NF-kB dependent manner (Taura 
et al., 2008). Ang-1 expression has been found to be up-regulated on pyogenic granulomas 
which have severe neovascularisation, and are an example of inflammatory induced 
angiogenesis (Yuan, Jin e Lin, 2000). We have made a novel observation where TWEAK and 
Ang-1 may regulate angiogenesis dependent on one another in settings of chronic 
inflammatory liver disease. This regulation was only observed in the inflammatory PBC liver 
disease samples, as the normal donor sample did not induce Ang1 expression in response to 
TWEAK activation (Figure 4.3.10).  
 
CXCL16 is the ligand to the CXCR6 chemokine receptor which can be expressed as a 
transmembrane and soluble protein (Ludwig e Weber, 2007). CXCL16 functions to recruit 
lymphocytes and has been found to be expressed by B and T lymphocytes, endothelial cells, 
and hepatocytes (Matloubian et al., 2000; Hofnagel et al., 2002; Shashkin et al., 2003). 
CXCL16 expression has been found to be regulated by inflammatory cytokines such as TNF-α 
and IFN-γ (Garcia et al., 2007). CXCL16 has been shown to stimulate proliferation of 
endothelial cells and smooth muscle cells and cancer cells. CXCL16 has been found to be 
implicated in liver disease where expression of CXCL16 has been associated with steato-
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hepatitis and liver fibrosis. Expression of CXCL16 was observed in regenerative nodules 
within the liver, and has been shown to play a critical role during lymphocyte migration 
across liver endothelium (Richard Parker 2013; Personal Communication). CXCL16 has been 
shown to stimulate HUVEC proliferation and induce tubule formation in vivo (Zhuge et al., 
2005), it has also been shown to recruit endothelial progenitor cells in the synovium of 
rheumatoid arthritis and during the formation of blood vessels (Isozaki et al., 2013). TWEAK 
has been found to regulate the expression of CXCL16 in renal tubular cells in an NF-kB 
dependent manner where the expression of MCP-1, ICAM and Rantes was also up-regulated 
(Izquierdo et al., 2012). Our data showed significantly enhanced CXCL16 expression in PBC 
diseased liver isolated HIEC when they were activated by TWEAK. It appears that TWEAK 
activation may induce an inflammation mediated angiogenesis response via CXCL16 during 
CLD. 
 
We also observed up-regulated IL-8 and VEGF expression in chronic liver diseased samples in 
response to TWEAK activation. IL-8 is a member of the chemokine family which has been 
shown to regulate tumour growth, organisation and metastasis. It has been shown to be a 
regulator of angiogenesis in several studies (Heidemann et al., 2003). IL-8 activated 
endothelial cells showed enhanced capillary tube formation and proliferation. Subsequent 
inhibition of apoptosis of endothelial cells was observed in IL-8 activated cells with up-
regulated anti-apoptosis gene expression and MMP production; all facilitating the 
angiogenesis process (Li et al., 2003). IL-8 has subsequently been shown to induce 
angiogenesis via Erk and P13K (phosphoinositide 3 kinase) signalling pathways in intestinal 
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microvascular endothelial cells (Heidemann et al., 2003), and subsequently mediate 
angiogenesis via other angiogenesis promoting factors such as EGFR (Kyriakakis et al., 2011). 
Up-regulated IL-8 expression in response to TWEAK has been observed in several studies. 
Chicheportiche were the first to describe the ability of TWEAK to induce IL-8 cytokine 
induction in tumour cell lines (Chicheportiche et al., 1997). They then showed that TWEAK 
activation may contribute to chronic arthritis pathogenesis by the induction of inflammatory 
cytokines, including up-regulated IL-8 expression in supernatants from TWEAK activated 
human dermal fibroblasts and synoviocytes (Chicheportiche et al., 2002). Subsequently it 
was shown that TWEAK activation may contribute to airway inflammatory responses by the 
induction of IL-8 in human bronchial epithelial cells in response to TWEAK activation (Xu et 
al., 2004). Our data showed that IL-8 expression was up-regulated in response to TWEAK 
activated HIEC from inflammatory liver disease samples, and may specifically contribute to 
angiogenic and pro-inflammatory responses during chronic liver disease. 
 
VEGF is a highly characterised angiogenesis mediating factor. TWEAK activated angiogenesis 
positively or negatively regulated via VEGF induction has been observed in several studies. 
VEGF has been shown to induce Fn14 mRNA expression in endothelial cells, and 
subsequently VEGF was shown to contribute to pathogenic angiogenesis in combination with 
TWEAK, suggesting that TWEAK and VEGF may promote endothelial cell responses in 
combination (Donohue et al., 2003). Alternatively, anti-VEGF antibodies showed no effect or 
inhibition of proliferation of endothelial cells in response to TWEAK activation (Lynch et al., 
1999), and TWEAK activation was shown to inhibit morphogenic responses activated in 
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endothelial cells by VEGF (Jakubowski et al., 2002), indicating that the TWEAK angiogenic 
response via VEGF is context dependent. Our data showed that TWEAK activation in 
inflammatory liver disease may induce angiogenesis and this process may require up-
regulated VEGF expression. VEGF up-regulation in response to TWEAK activation in the 
diseased samples was relatively mild in comparison to other cytokine expression. So it may 
be that TWEAK activation may trigger the angiogenesis potential of HIEC, and VEGF 
expression may be induced to complete the process of tubule formation and angiogenesis 
signalling required during inflammatory liver disease.   
 
A key finding from this study was the distribution patterns of Fn14 expression in the 
different tissues which were analysed for angiogenic protein expression. The Donor case 
which showed mild elevation of cytokines in response to TWEAK activation, also showed 
Fn14 expression mildly elevated throughout the tissue and more concentrated surrounding 
portal vessels (Figure 4.3.4 E and F). The chronic inflammatory liver disease samples all 
showed a higher degree of cytokine induction in response to TWEAK activation accompanied 
by elevated Fn14 expression in corresponding liver tissue, and subsequent variations in 
expression. The two cases where the liver tissue histology showed a higher degree of 
organisation (Figure 4.3.5 and 4.3.7), confirmed by B and T cell staining (Figure 4.3.8 C, D, E 
and F); distinct inflammatory infiltrates in close proximity to portal and neovessels, and 
granuloma formation, Fn14 expression in these cases was increased in these areas. The 
sample where no organisation was observed in the histology of the liver tissue (Figure 4.3.6 
and 4.3.8 A and B), Fn14 expression in this case also showed no organised pattern (Figure 
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4.3.6 E and F). These findings correlated with the cytokine responses we observed of HIEC 
isolates to TWEAK activation, which showed subsequent organised cytokine responses, and 
disorganised wide-ranging cytokine responses according to the tissue histology and Fn14 
distribution patterns. This suggests that TWEAK activated responses may be highly 
regulated, complex and tailored responses to the requirements of the tissue environment, 
however as the sample number for these experiments was small and the need for further 
experiments with regards to each cytokine induction will need to be performed, we can only 
speculate on the potential of this data. 
 
The individual responses observed in the cases of liver samples, showed that TWEAK 
initiated a specific cytokine response where structural organisation, and heavy inflammatory 
infiltrate were observed further enforced by Fn14 expression in liver tissue. In particular the 
cases where granuloma formation was observed in close proximity to portal and neovessels. 
Other data has suggested that CD68 positive macrophages and stromal organiser cells are 
involved in the formation of lymph nodes in mice, and this process may be dependent on the 
activation of the NF-kB pathway (Jorge Caamano; Personal Communication), which has 
subsequently been shown to be an important signalling pathway in several studies looking at 
the functional roles of TWEAK and Fn14. This information together with data obtained from 
this study may suggest a specific role of TWEAK and Fn14 in tertiary lymph node 
development. To investigate this hypothesis, TWEAK and Fn14 knock out mouse models will 
be essential to analyse in comparison to wild type tissue in an in vivo granuloma formation 
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model such as induced p.acnes liver injury model (Nishioji et al., 1999), whilst determining 
the regulatory signalling pathways.  
 
We have found that TWEAK regulation of chronic inflammatory liver disease via HIEC is a 
complex and highly regulated process, and to understand this completely a lot of further 
work will be required. The data from the angiogenesis cytokine arrays and IHC was limited, 
and to specifically make significant findings further experiments are essential. However we 
can conclude from the data obtained; that TWEAK may contribute to hepatic angiogenesis 
via HIEC tubule formation. TWEAK may also regulate these functions via Fn14. TWEAK 
activation can trigger a specific inflammatory and angiogenic response during chronic liver 
disease, which makes TWEAK a highly attractive target for future therapeutic purposes of 
liver injury and disease.  
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CHAPTER 5 
TWEAK and Fn14 signal via Erk and NF-kB Rel A during HIEC functional responses 
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5.1 INTRODUCTION 
5.1.1 TNFSF Signalling 
TNFSF members activate complex signalling pathways during functional responses via 
interactions between TNF ligands and receptors. TNF ligands are known to bind one or more 
receptor and initiate wide ranging functions such as apoptosis, cellular proliferation, 
differentiation and survival. The receptors can be sub-classified into two groups; the first 
group of receptors possess a 45 amino acid death domain required to induce cell death, and 
the second group of receptors do not possess the death domain; these typically function via 
TRAFs. TRAFs associate with specific motifs in the TNF receptors, and have been found to 
activate various signalling pathways including NF-kB and the MAPK pathways. There are six 
mammalian functional TRAFs described in TNFSF responses. The NF-kB signalling pathway is 
found largely activated in many TNF ligand-receptor functional responses, and is mostly 
defined as mediating the pro-inflammatory response of TNF family members (Aggarwal, 
2003; Aggarwal, Gupta e Kim, 2012). 
 
5.1.2 TWEAK and Fn14 Signalling 
TWEAK ligand with its receptor Fn14 has been described as a multifunctional system linked 
to the activation of various transcription factors, including NF-kB; Rel A and Rel B, MAPK Erk 
1/2, p38 and Jnk pathways, and the AKT signalling pathway (Figure 5.1) (Winkles, 2008; 
Fortin et al., 2009). Fn14 has a conserved 28 amino acid TRAF binding sequence (P-I-E-E-T) in 
its cytoplasmic tail, which can bind TRAF 1, 2, 3, and 5, activating signalling cascades (Brown 
et al., 2003). It has been reported that Fn14 contains many transcription factor binding sites 
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such as AP-1 and NF-kB in its promoter region (Tran et al., 2006). Zheng et al 2008 described 
unpublished findings of a KAFF sequence situated adjacent to the P-I-E-T-T motif in the Fn14 
cytoplasmic tail, to be responsible for NF-kB activation. They described NF-kB activation 
present in Fn14 P-I-E-T-T deletion mutants, and subsequent abrogation of NF-kB signalling 
was observed when the KAFF sequence was deleted, indicating that this sequence may be 
responsible for NF-kB signalling via TWEAK (Zheng e Burkly, 2008). 
 
Whilst numerous publications have reported TWEAK and Fn14 dependent signalling, Fn14 
signalling independent of TWEAK has also been documented in cases where Fn14 has been 
highly up-regulated, and specifically during the activation of NF-kB. Fn14 activation has been 
shown to induce cellular responses such as cell migration, invasion, and survival. It is thought 
that Fn14 signalling independent of TWEAK is dependent on the ability of Fn14 to bind TRAFs 
(Han et al., 2003; Tran et al., 2005). In a study investigating mouse intestinal epithelial cell 
injury models, Fn14 expression was up-regulated and found to activate signalling pathways 
leading to reduced inflammation in TWEAK knock out mice (Dohi et al., 2009). In non-small 
cell lung cancer (NSCLC), Fn14 over expression induced EGFR signalling leading to enhanced 
NSCLC cell migration and invasive capacity in vitro and metastasis in vivo. (Whitsett et al., 
2012). Ligand independent signalling pathway activation via TRAFs, has also been observed 
in other TNFR’s such as CD40 and BAFF-R which have been shown to activate NF-kB via TRAF 
association (Xu e Shu, 2002; Fotin-Mleczek et al., 2004). It has been suggested that these 
processes may be due to receptor trimerisation, leading to activated signalling pathways via 
TRAF association, as this has been observed in other TNFR which do not possess a death 
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domain (Winkles, 2008). Brown et al 2013 showed Fn14 signalling independent of TWEAK by 
the use of Fn14 deletion mutants which do not have the ability to bind TWEAK, and found 
that Fn14 can activate NF-kB in transfected cells. They also observed that this process may 
be regulated by Fn14 dimerisation, which may occur on the cell surface via the Fn14 
cytoplasmic domain (Brown et al., 2013).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 TWEAK and Fn14 activated transcription factors: TWEAK and Fn14 
interactions on the cell surface can activate various signalling pathways via TRAF 
binding. TRAF interactions induce kinase phosphorylation to activate signalling 
pathways leading to gene transcription. Various transcription factors can be activated 
in the nucleus to induce gene expression which mediate specific functions. This figure 
illustrates the signalling pathway activation via TWEAK and Fn14 interactions to induce 
NF-kB and AP-1 regulated functions. (Blanco-Colio, 2014) 
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5.1.3 TWEAK-Fn14 signalling via NF-kB 
TWEAK and Fn14 interactions however lead to the majority of activated signalling pathways 
observed. The canonical NF-kB signalling pathway (Rel A) is the most common activated 
pathway during TWEAK induced responses. NF-kB when activated, binds DNA leading to 
gene expression to regulate normal biological functions, and pathological functions, as well 
as being an important mediator of the innate and adaptive immune responses, 
tumourigenesis, cell fate, and lymphoid organ development. The NF-kB signalling pathway is 
well characterised as a critical immune system regulator as it is highly responsive to external 
stimuli such as growth factors, cytokines, and functional receptors (Bonizzi e Karin, 2004). 
There are five NF-kB members which dimerise and function to recognise the kB site; Rel A 
(p65), Rel B, c-Rel, p50-p105 and p52-p100 (Figure 5.2). The IkB (inhibitor of kB) complex 
binds to NF-kB dimers and prevents nuclear translocation, keeping the NF-kB complex 
dormant in the cytoplasm. The canonical pathway is activated by the phosphorylation of the 
IkB complex; the p50-p65 subunit of IkB is translocated to the nucleus, inducing 
phosphorylation of the p65 subunit and leading to the degradation of the IkB complex 
(Hayden e Ghosh, 2004).  
 
The canonical NF-kB pathway is critical during the regulation of liver functions as it regulates 
normal liver homeostasis, patho-physiological functions, and regulation of inflammation 
(Sun e Karin, 2008). It is essential for normal embryonic development, as has been shown in 
in vivo knock out mouse models, where NF-kB deletion was shown to trigger fatal liver cell 
apoptosis (Beg et al., 1995). IkBα phosphorylation in response to TWEAK activation has been 
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observed in a number of studies, and has been shown to have a rapid onset often within the 
first hour of TWEAK activation (Harada et al., 2002; Brown et al., 2003).  
 
 
 
 
 
 
 
Figure 5.2 The NF-kB signalling pathway: The canonical NF-kB pathway is induced 
by various stimuli. The activation results in the phosphorylation and degradation of 
IκBα. The RelA-p50 complex translocates to the nucleus to activate the 
transcription of target genes. The non-canonical pathway is the activation of IKKα 
by the NF-κB-inducing kinase (NIK) after stimulation. Phosphorylation of the p100 
subunit leads to the processing of the p100 subunit in to p52, which can lead to the 
activation of p52-RelB. This induces the transcription of target genes (Viennois, 
Chen e Merlin, 2013).  
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The non-canonical pathway is activated by the translocation of the p52-RelB complex to the 
nucleus, via the processing of p100 into p52. This is key to stabilising the NF-kB inducing 
kinase (NIK) via the activation of the IKKα (IkB kinase alpha) (Hayden e Ghosh, 2004). Studies 
have found the non-canonical NF-kB pathway functional in response to TWEAK induction, 
often in combination with Rel A activation. Saito T et al 2003 showed in mouse derived 
fibroblasts activated by a CD8 –TWEAK fusion protein, that the canonical and non-canonical 
signalling pathways were activated in a biphasic manner. Rel A signalling was seen very early 
on after TWEAK activation by 15 minutes, and Rel B signalling was activated after 8 hours of 
TWEAK activation (Saitoh et al., 2003). This time course dependent signalling response of 
NF-kB Rel A and Rel B has also been seen in TWEAK activated renal tubular cells (Sanz et al., 
2010). TNF-α activation in these cells only showed Rel A activation, suggesting that the 
TWEAK response activating Rel A and Rel B was a specific event of TWEAK induced functional 
responses. This biphasic activation of NF-kB pathways may be a clue in understanding the 
role of TWEAK during chronic inflammatory diseases, where for the sustained up-regulation 
of TWEAK, Rel B may be critical to inducing the prolonged inflammatory response. 
 
There have been reports of variable activation of soluble and membrane TWEAK signalling 
pathways in the same cell type and conditions as has previously been observed for TNF-α. 
Both soluble and membrane TWEAK have been found to activate the Rel A signalling 
cascade, and membrane bound TWEAK has been shown to have a heightened activation of 
Fn14 mediated Rel A and TRAF 2 degradation, in comparison to soluble TWEAK. In contrast, 
soluble and membrane bound TWEAK equally activated the non-classical Rel B pathway 
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(Roos et al., 2010). They suggested that this variable regulation may be important to 
understanding the wide variety of responses of TWEAK activation during the immune 
response. 
 
5.1.4 TWEAK-Fn14 signalling via MAPK 
MAPK’s have been shown to regulate gene expression and cell fate functions, such as 
proliferation, differentiation, apoptosis and stress responses. The MAPK’s can be activated 
by a range of stimuli such as inflammatory cytokines, mitogens, and osmotic stress (Pearson 
et al., 2001). The MAPK family members are highly conserved serine-threonine protein 
kinases which can be regulated by phosphorylation events (Theodosiou e Ashworth, 2002). 
The classical MAPK include the Erk 1/2 pathway which can activate transcription factors via 
the Ras-Raf-MEK-Erk cascade. This pathway is predominantly activated by growth and 
differentiation factors. The MAPKs also consist of the Erk 5, p38 MAPK and the Jnk signalling 
pathways which are predominantly activated by stress and growth factor signals (Figure 5.3) 
(Roberts e Der, 2007).  
 
MAPK signalling pathways have been found activated during TWEAK induced responses in a 
number of studies. These include the p38 regulation of lupus nephritis via PBMC (Zhi-Chun et 
al., 2012), ERK 1/2 activation in mouse osteoblastic functions and renal inflammation (Ando 
et al., 2006; Rayego-Mateos et al., 2013), Erk 1/2 activation during TWEAK activation of 
C2C12 myoblasts (Dogra et al., 2007), and Jnk pathways in endothelial cell activation 
(Donohue et al., 2003). It has been shown that all three pathways can also be simultaneously 
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activated upon TWEAK activation in myoblasts and fibroblasts regulating various functions 
(Kumar et al., 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
TWEAK activated complex functional responses have been found to induce activation of 
multiple signalling pathways. Donohue et al showed activation of Rel A, Erk and Jnk during 
TWEAK stimulation of HUVEC during angiogenic functions (Donohue et al., 2003). Similarly a 
study on mouse osteoblastic cells activated with TWEAK, showed differential signalling 
dependent functional activity, including AKT which was required for RANTES production and 
 
Figure 5.3 The MAPK signalling pathway: The MAPK signalling pathways are activated in 
response to cytokines, growth factors and stress. There are four major MAPK signalling 
events; Erk, p38, Jnk, and Erk 5. The MAPKs activate a signalling cascade mediated by 
phosphorylation of protein kinases leading to the activation of transcription factors 
(Pearson et al., 2001)  
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Fn14 expression, and Erk which was required for bone morphogenic protein 2 induced 
differentiation of osteoblastic cells (Ando et al., 2006). TWEAK activated myotubes from 
skeletal muscle tissue showed activation of both classical and non-classical NF-kB and p38, 
Erk and Jnk MAPK’s together functioning to regulate pathological skeletal muscle wasting via 
MMP9 (Li et al., 2009).  
 
5.1.5 TWEAK-Fn14 other signalling pathways 
There have been reports of other TWEAK activated signalling pathways determining 
functional outcomes. TWEAK and IFN-γ mediated apoptosis was found to be JAK/STAT (janus 
kinase/ signal transducers and activators of transcription) signalling dependent in tumour 
cells (Chapman et al., 2013). NF-kB signalling mediated by TWEAK in human neuroblastoma 
cells were found to be dependent on GSK3β (glycogen synthase kinase 3 β) signalling (De 
Ketelaere et al., 2004). TGF activated kinase 1 in cultured myoblasts and fibroblasts have 
been found to regulate NF-kB and p38 MAPK and Jnk signalling pathways. They also showed 
that TWEAK inhibited the AKT and Erk signalling pathways (Kumar et al., 2009). TWEAK and 
Fn14 mediated glioma cell migration and invasion has been found to be dependent on the 
Rho GTPase (guanosine triphosphatase) family member signalling pathways (Fortin et al., 
2012). These studies show that TWEAK and Fn14 interactions are highly regulated. The 
ability of TWEAK to induce a specific signalling cascade during a functional response, is key 
to the varying functional capabilities observed for TWEAK and Fn14 between cells and 
cellular environments. 
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5.1.6 TWEAK-Fn14 signalling with TNFSF members 
TWEAK regulated signalling of other TNFSF members has also been documented in several 
studies. As Fn14 does not have a death domain, pro-apoptotic functions via TWEAK 
activation have been difficult to explain. There have been suggestions that TWEAK may be 
indirectly inducing apoptosis via TNF-α, which was found to be stimulated by NF-kB 
activation (Schneider et al., 1999). It was later found that TWEAK and Fn14 interactions 
induce degradation of TRAF2-CIAP1 (cellular inhibitor of apoptosis 1) complexes which lead 
to TNF-α induced apoptosis in immortalised cells (Vince et al., 2008). This was subsequently 
found to be due to a RIP-1 (receptor interacting protein 1) – FADD (Fas associated death 
domain) – caspase 8 complex formation in response to TWEAK activation (Ikner e Ashkenazi, 
2011). TWEAK has also been found to interfere with CD40-CD40L induced signalling via NF-
kB and MAPK. It was found that TWEAK activated cells prevented CD40-CD40L interactions, 
leading to impaired signalling via TRAF-2, thus indicating that TWEAK has the ability to 
regulate CD40 related functions (Salzmann, Lang, et al., 2013). 
 
5.1.7 TWEAK-Fn14 VEGFR2 mediated signalling 
TWEAK has been described as a potent mediator of angiogenesis in vitro and in vivo in 
several studies (Lynch et al., 1999; Ho et al., 2004). There have been subsequent studies 
investigating the angiogenic potential of TWEAK in endothelial cells, specifically to determine 
if TWEAK mediated angiogenic functions are VEGF dependent. Some studies have reported 
VEGF independent angiogenic functions of TWEAK (Lynch et al., 1999), and some studies 
have reported VEGF mediated angiogenic functions. TWEAK was found to up-regulate VEGF 
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expression in human ovarian cancer cells to promote tumour metastasis in an NF-kB 
signalling dependent manner (Dai et al., 2009). TWEAK was also reported to inhibit VEGF 
mediated morphogenic responses in endothelial cells, and alternatively in the same cells was 
found to promote FGF induced angiogenic responses (Jakubowski et al., 2002).  
 
We have reported that TWEAK induced angiogenesis via a tube formation assay in HIEC. This 
angiogenic potential has been found to be more potent than FGF induced tube formation 
(Chapter 4). It was essential to understand and determine if TWEAK activated HIEC activated 
VEGFR2 downstream signalling pathways to induce inflammatory mediated angiogenesis. 
The angiogenic potential in endothelial cells observed via VEGF is a complex and highly 
regulated process, and a deeper understanding of the downstream activated signals is 
essential to understand the potential of TWEAK activation contributing to subsequent VEGF 
signalling. There have been no reports of TWEAK activated responses via this signalling 
pathway yet. However as previously discussed, certain downstream signalling pathways of 
VEGR2 have been activated in TWEAK functional responses such as p38 MAPK, Erk 1/2 and 
AKT. 
 
VEGFR2 is a major receptor which mediates VEGF functions. VEGFR2 mediated signalling has 
been implicated during endothelial cell proliferation, migration and sprouting of capillarised 
endothelial cells in vitro. In vivo, VEGFR2 has functions during development and 
neovascularisation (Karkkainen e Petrova, 2000). VEGFR2 signalling is controlled during 
angiogenesis by the activation of other downstream signalling pathways including the 
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MAPKs; p38 and Erk 1/2, AKT, Src, FAK (focal adhesion kinase), and PLCγ1 (phospholipase C γ 
1) (Figure 5.3) (Carmeliet, 1999; Claesson-Welsh, 2003; Olsson et al., 2006). P13K dependent 
AKT signalling has been found activated by various angiogenic growth factors to regulate 
blood vessel growth and homeostasis. This signalling pathway is widely activated in response 
to various stimuli in endothelial cells. It has been found to possess anti-apoptotic and pro-
angiogenic activities which have been found to be regulated by VEGF signalling (Shiojima e 
Walsh, 2002) Erk 1/2 up-regulation has also been described to abrogate apoptosis, and 
enhance pro-angiogenic functions such as cell proliferation in endothelial cells. It has been 
described to do this by enhanced VEGF expression via an activator protein 2 complex binding 
to the promoter region of VEGF (Berra, Pagès e Pouysségur, 2000). Subsequently other 
studies have also described VEGF induced activation of Erk 1/2 and AKT signalling cascades 
during in vivo angiogenic responses (Zhu, MacIntyre e Nicosia, 2002). P38 MAPK has been 
found to mediate angiogenesis via VEGF. In vitro regulation of VEGF and FGF by p38 in 
tumour cells was found, and in an in vivo neovascularisation mouse model, p38 inhibition 
reduced VEGF induced angiogenic functions (Tate et al., 2013).  
 
FAK is a focal adhesion kinase which is known to mediate signalling via growth factors and 
integrin activation, and the regulation of angiogenic processes, for example; regulating 
endothelial cell migration via matrix metalloproteinase induction. It has also been found to 
regulate cell growth, survival, migration, and differentiation of endothelial cells (Rizzo, 
2004). In vivo FAK knock out mouse models have shown decreased tumour growth and 
angiogenesis. In vitro deletion of FAK in endothelial cells have shown decreased VEGF 
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induced AKT phosphorylation leading to enhanced apoptosis and suppressed proliferation 
(Tavora et al., 2010). PLCγ1 signalling has been implicated in regulating angiogenesis. During 
phosphorylation of VEGFR2, the p85 subunit of PLCγ1 binds protein tyrosine phosphatase 
Tyr1175. It has been shown in HIEC that PLC γ1 has been found to be essential for activating 
VEGF mediated signalling (Takahashi et al., 2001). In an in vivo arterial defect zebra fish 
model, PLC was found to function downstream to VEGF receptors during embryonic 
development and arterial formation (Lawson et al., 2003). P13K-PLCγ1 has also been found 
to regulate FGF2 dependent tubule formation in endothelial cells. P13K-PLCγ1 were also 
found to mediated FGF activated AKT signalling pathways (Maffucci et al., 2009). There have 
been no studies yet which have found TWEAK directed regulation of signalling via FAK and 
PLCγ1 during the mediation of endothelial cell responses. 
 
The Src family of kinases (SFK) has been found to respond to a range of stimuli in the ECM 
including growth factors and adhesion proteins. The SFK have been shown to activate 
downstream signalling pathways such as the MAPKs (Courtneidge et al., 1993). Src has been 
shown to be required for VEGF mediated angiogenesis for embryonic development in in vivo 
mouse and chick models where Src was found to provide protection against apoptosis 
(Eliceiri et al., 1999). TWEAK and Fn14 activated cell migration and invasion via TRAF2 
signalling in gliomas, has been described to be a response mediated by the Src homology 3 
domain containing guanine nucleotide exchange factor (Fortin Ensign et al., 2013).  
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TWEAK and Fn14 interactions lead to diverse functions which is a result of complex signalling 
pathways governing these responses. To understand TWEAK and Fn14 contributions to 
chronic liver inflammation and liver regeneration, it is highly important to understand 
signalling pathways contributing to these functions via HIEC and TWEAK interactions. This 
will allow us to better understand how we can manipulate this system for future 
therapeutics towards inflammatory liver disease. 
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Figure 5.3 The VEGFR2 signalling pathway: VEGFR2 signalling is a common activated 
transcription pathway for the regulation of angiogenesis. It is required to mediate 
VEGF functions in endothelial cells including survival, proliferation and migration. This 
pathway is regulated by downstream signalling events mediated by the recruitment of 
various adaptor proteins (Olsson et al., 2006) 
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5.1.8 Aims 
The aims of this chapter were: 
 To characterise activation of NF-kB Rel A and Rel B signalling pathways in TWEAK 
activated HIEC.  
 To determine if TWEAK activated HIEC function via downstream signalling pathways 
of VEGFR2 to further understand HIEC angiogenic regulation. 
 To determine if TWEAK activated HIEC signalling pathways also mediate HIEC Fn14 
expression on HIEC. 
 To determine if TWEAK and Fn14 regulation of HIEC angiogenesis and cell migration 
was regulated by specific cell signalling pathways. 
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5.2 MATERIALS AND METHODS 
Materials and methods for this chapter; please refer to sections: 2.1-2.4, 2.7, 2.10, 2.11, and 
2.16, and Tables 2.1-2.4, 2.7 - 2.10. 
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5.3 RESULTS 
5.3.1 TWEAK activated HIEC phosphorylate Erk 1/2 
To establish the signalling pathways which may be regulating TWEAK activated HIEC 
functions, in particular during potential TWEAK activated angiogenesis, we first 
characterised signalling pathways activated down-stream to VEGFR2, which are common 
pathways activated during angiogenesis. These include: AKT, FAK, PLC-γ1, p38 MAPK, Erk 1/2 
and Src.  
 
Protein lysates were obtained from TWEAK activated HIEC at various time points, and 
Western blotting analysis was performed. Unstimulated HIEC were used as a negative 
control, and TNF-α was used as a positive control to compare TWEAK activation. TWEAK 
activated HIEC did not activate by phosphorylation AKT, FAK, PLC-γ1, p38 MAPK, and Src 
signalling pathways in comparison to the unstimulated control (Figure 5.3.1). No 
phosphorylation was observed in TNF-α activated HIEC either. All data was compared to 
endogenous total β-actin, to ensure correct protein loading. 
 
Initial data obtained, showed that TWEAK activated HIEC, phosphorylated Erk 1/2 at 4 hours 
after stimulation with TWEAK; showing a 3.5 fold increase of phosphorylation in comparison 
to the unstimulated HIEC (Figure 5.3.2 A). TWEAK activated HIEC at 2 hours and 24 hours 
showed no activation of Erk 1/2 in comparison to the unstimulated control. TNF-α on the 
other hand showed Erk 1/2 activation in HIEC after 2 hours of stimulation, with a 3 fold 
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increase in phosphorylation in comparison to the unstimulated control. After 24 hour TNF-α 
activation, HIEC showed an 18 fold increase in Erk phosphorylation.  
 
The general phosphorylation patterns observed across all blots was analysed, and we found 
that TWEAK activated HIEC at 4 hours showed consistent enhanced phosphorylation of Erk 
1/2. However TNF-α activation did vary between liver samples. In accumulated densitometry 
quantification, TNF-α activated HIEC revealed a large up-regulation of phosphorylated Erk 
1/2 at 24 hours post stimulation (Figure 5.3.2 A), which was found to be from one outlier 
data set (Blot not shown). This large up-regulation was not found in any other Western blot. 
Therefore in the densitometry quantification graph, TNF-α activated HIEC at 24 hours 
showed a large up-regulation of phosphorylated Erk 1/2 in comparison to all other 
conditions. All data was quantified and normalised from the mean densitometry of 3 
experiments. 
 
Further Erk 1/2 data was obtained in order to determine if the Erk 1/2 activation was true 
and a response of TWEAK activation, by the use of a pharmacological inhibitor PD98059 to 
inhibit Erk activation. Phosphorylated Erk levels were compared to endogenous total Erk 
levels. Accumulated data confirmed previous findings that TWEAK stimulated HIEC, 
significantly activated the Erk 1/2 pathway at 4 hours post stimulation, in comparison to the 
unstimulated control (Figure 5.3.2 B). Accumulated data showed a significant 7.91 fold 
increase (*p=0.03, n=7). TNF-α was used as a positive control in parallel to TWEAK which 
showed a 1.9 fold increase in Erk phosphorylation at 4 hours post stimulation n=7. 
218 
 
Phosphorylation of Erk 1/2 decreased two fold when the Erk 1/2 signalling pathway was 
blocked in TWEAK activated HIEC ± SEM (n=4). TNF-α activated HIEC which showed a 1.9 fold 
increase in Erk phosphorylation in comparison to the unstimulated control, decreased to 0.5 
fold when Erk was inhibited in TNF-α activated HIEC. Unstimulated HIEC remained 
unchanged with Erk inhibition. Phosphorylated Erk 1/2 was compared to endogenous total 
Erk 1/2 levels in HIEC. Under the same conditions as for phosphorylated Erk protein lysates, 
endogenous total Erk levels remained consistent and unchanged across all conditions (n=3) 
(Figure 5.3.2 B). All data was normalised to its relative total β-actin control and then 
normalised to the unstimulated HIEC control. 
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Figure 5.3.1 TWEAK activated HIEC angiogenic transcription factor activation: HIEC 
were treated with TWEAK and TNF-α for 2, 4, and 24 hours prior to protein lysate 
extraction and Western blotting analysis. TNF-α was used as a positive control to 
TWEAK, and unstimulated HIEC were used as a negative control. Western blotting 
analysis was used to determine if TWEAK activated HIEC, phosphorylate PLC-γ1, VEGFr, 
Src, AKT, FAK and p38 MAPK. Densitometric analysis detected no TWEAK activated 
phosphorylation in these transcription factors. All data was normalised to its relative β-
actin control and then normalised to the unstimulated control. 
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Figure 5.3.2 TWEAK activated HIEC signal via the Erk 1/2 pathway: HIEC were treated 
with TWEAK and TNF-α for 2, 4 and 24 hours prior to protein lysate extraction and 
Western blotting analysis. Replicate HIEC were inhibited with PD98059 (an Erk 1/2 
inhibitor) prior to stimulation with TWEAK and TNF-α. A) Representative image of 
Western blot for phosphorylated Erk 1/2 and β-actin control. Graph shows 
densitometric analysis of replicate Western blots from HIEC protein isolates. Data 
represents n=3. B) TWEAK activated HIEC significantly phosphorylated Erk 1/2 at 4 
hours post stimulation (*p=0.03). Unstimulated, TWEAK and TNF-α stimulated HIEC at 
4 hours represents n=7. Total Erk data was n=3. All data was normalised to its relative 
β-actin control and then normalised to the unstimulated control (represented as the 
relative density of 1 ± SE). Statistical analysis was carried out using a paired Student’s t 
test. 
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5.3.2 TWEAK activated HIEC enhance phosphorylation of the NF-kB Rel A pathway 
TWEAK activated cells have been shown to activate NF-kB Rel A signalling in a number of 
studies, in particular TWEAK inflammatory and angiogenic responses. Therefore, we wanted 
to determine if this signalling pathway is active during TWEAK activated HIEC functional 
responses. Initially we used TWEAK activated HIEC at time points previously used at 2, 4, and 
24 hours. However no response of Rel A activation was detected (data not shown). Previous 
studies have shown that Rel A activation is a very early response, therefore earlier TWEAK 
activation time points were used at 15, 30, and 60 minutes. We determined that TWEAK 
activated this pathway in HIEC comparison to the unstimulated HIEC control; at 30 minutes, 
showing a 1.7 fold increase in Rel A phosphorylation (Figure 5.3.3 A). This activation was 
comparable to TNF-α activated Rel A responses which showed a 1.5 fold increase. We also 
wanted to determine if TWEAK and TNF-α activated HIEC in combination altered Rel A 
activation responses. The TWEAK and TNF-α activation had a similar response to the TNF-α 
activation alone, but a slightly lower response of Rel A activation in comparison to the 
TWEAK response at 30 minutes. This data set showed a slight differential reading of 
endogenous total Rel A protein across different HIEC samples. It was not consistently 
expressed in the varying stimulations as was expected. 
 
The raw data from Rel A activation experiments showed higher activation of Rel A at 30 
minutes post TWEAK activation, and on occasion at 60 minutes post TWEAK activation (data 
not shown). Therefore, to test Rel A inhibition of TWEAK activated HIEC, a time point of 45 
minutes post TWEAK and TNF-α activation was used (Figure 5.3.3 B). When the NF-kB Rel A 
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signalling pathway was inhibited using a pharmacological inhibitor, phosphorylation of Rel A 
in unstimulated HIEC showed an unexpected 2 fold increase. TWEAK activated HIEC at 45 
minutes showed a 5.6 fold increase in Rel A phosphorylation in comparison to the 
unstimulated control. This phosphorylation decreased almost to basal levels when Rel A was 
inhibited. HIEC activated with TNF-α for 45 minutes, showed an 8.7 fold increase in Rel A 
phosphorylation in comparison to the unstimulated HIEC. This showed a weaker down-
regulation of phosphorylated Rel A (to 6.8 fold NF-kB phosphorylation) when the Rel A 
inhibitor was used. All Rel A activation data showed a trend in TWEAK activated responses 
during this investigation, however the data was not statistically significant after 
densitometric quantification. Data was tested against the total NF-kB Rel A levels for 
comparison. Endogenous Rel A was consistent and unchanged in response to stimulation 
and inhibition (Figure 5.3.3 B). 
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Figure 5.3.3 TWEAK activated HIEC signal via the NF-kB Rel A pathway: HIEC were 
treated with TWEAK and TNF-α prior to protein lysate extraction and Western blotting 
analysis. Replicate HIEC were treated with an NF-kB inhibitor 1 hour prior to stimulation 
with TWEAK and TNF-α. TNF-α was used as a positive control to TWEAK, and 
unstimulated HIEC were used as a negative control. A) Representative image of Western 
blot for phosphorylated NF-kB, total NF-kB and β-actin control, and densitometric 
analysis of replicate Western blots from HIEC protein isolates. B) Representative image 
of Western blot for phosphorylated NF-kB, total NF-kB and β-actin control with NF-kB 
inhibitor, and densitometric analysis of replicate Western blots from HIEC protein 
isolates. Data represents n=3. All data was normalised to its relative β-actin control and 
then normalised to the unstimulated control (represented as the relative density of 1 ± 
SE). This data was not statistically significant. 
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5.3.3 TWEAK activated HIEC do not phosphorylate NF-kB Rel B  
It has been reported that TWEAK activates the non-canonical NF-kB pathway during certain 
functional responses. We wanted to determine if TWEAK also signals via this pathway in 
HIEC. Previous reports have suggested that TWEAK activation phosphorylates Rel B at later 
time points and Rel B phosphorylation is sustained over long time points. We had seen a 
very early signalling response via Rel A and a later response via Erk 1/2, therefore we tested 
various time points of TWEAK activation on HIEC for signalling responses via Rel B. We 
analysed 15, 30, and 60 minutes and 2, 4, and 24 hour activation, we also analysed TNF-α 
activation of HIEC after 60 minutes. We found no activation of Rel B across these time points 
of TWEAK activated HIEC (n=3) (Figure 5.3.4). In the blots analysed we only detected a single 
band in one data set which was found in an unstimulated HIEC control. The data was 
compared to endogenous total Rel B and β-actin. All Western blots were tested against 
endogenous β-actin protein to ensure even loading and accurate analysis. 
 
 
 
 
 
 
 
 
225 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3.4 TWEAK activated HIEC do not signal via the NF-kB Rel B pathway: HIEC 
were treated with TWEAK (100ng/ml) for the indicated time points, prior to protein 
lysate extraction and Western blotting analysis. Unstimulated HIEC were used as a 
negative control. A representative image of Western blot for phosphorylated NF-kB Rel 
B, total Rel B and β-actin control is shown. Data was normalised to its relative β-actin 
control and then normalised to the unstimulated control n=4. 
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5.3.4 Erk and Rel A signalling may determine Fn14 expression patterns on HIEC 
Fn14 protein expression has been found on cell curface HIEC and subsequently found to be 
regulated by various inflammatory and growth factor cytokines. To determine if their 
expression patterns were mediated by NF-kB Rel A and Erk dependent signalling, these 
pathways were inhibited using pharmacological inhibitors, prior to detecting cell surface 
Fn14 expression on HIEC using flow cytometry (Figure 5.3.5 A and B). Erk inhibition 
significantly reduced Fn14 protein expression on HIEC cell surface from 24.3 to 21.3 
percentage positive HIEC ± SEM *p=0.02. NF-kB inhibition on the other hand significantly 
increased Fn14 protein expression on HIEC cell surface from 24.3 to 35.4 percentage positive 
HIEC ± SEM **p=0.006. This trend was also refelcted in the MFI data (**p=0.01).  
 
Following this data, we further wanted to assess whether changes in Fn14 expression on 
HIEC cell surface in response to various stimuli, were also dependent on NF-kB and Erk 
signalling. HIEC were stimulated with IL-1β, TNF-α, and FGF, and Erk and NF-kB inhibitors 
prior to Fn14 cell surface expression analysis (Figure 5.3.5 C, D and E). IL-1β, TNF-α and FGF 
activated HIEC previously had shown a significant increase in Fn14 cell surface expression in 
comparison to unstimulated controls. This data set confirmed up-regulated Fn14 cell surface 
protein expression in response to these cytokines. In response to Erk inhibition basal Fn14 
expression only marginally reduced, and NF-kB inhibition showed high induction of Fn14 
protein expression. 
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We found that Erk and NF-kB inhibition of IL-1β activated HIEC showed down-regulated Fn14 
cell surface expression on HIEC from 42.9% in uninhibited HIEC, to 24.84% in Erk inhibited 
HIEC, and 29.19% in NF-kB inhibited HIEC ± SEM (Figure 5.3.5 C). Erk inhibition down-
regulated Fn14 expression more than NF-kB inhibition. TNF-α activated HIEC also showed 
down-regulated Fn14 cell surface protein expression from 43.7% in uninhibited HIEC, and 
24.1% in response to Erk, and 20.08% in response to NF-kB inhibition ± SEM (Figure 5.3.5 D). 
In this case both inhibitors showed an equal down-regulation of cell surface Fn14 expression. 
In response to FGF, HIEC activation up-regulated Fn14 cell surface expression from 20.7% to 
41.1% HIEC ± SEM (Figure 5.3.5 E). In response to Erk inhibition the FGF response was 
blocked, and Fn14 cell surface expression reduced to basal levels showing 18.95%, and NF-kB 
inhibition reduced to 31.4% Fn14 cell surface expression ± SEM. This data however was not 
staitically significant. 
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Figure 5.3.5 Fn14 cell surface expression on HIEC may be dependent on Erk and 
NF-kB signalling: HIEC were cultured in the presence of Erk and NF-kB inhibitors, IL-
1β, TNF-α, and FGF for 24 hours prior to analysis. HIEC were analysed for Fn14 
expression. A and B) Erk inhibition significantly reduced Fn14 positive HIEC *p=0.02 
and significantly increased Fn14 positive HIEC with NF-kB signalling inhibitor 
**p=0.006. MFI data showed a similar pattern however NF-kB signalling significantly 
increased Fn14 expression **p=0.01. C, D and E) IL-1β, TNF-α, and FGF activated 
Fn14 expression was inhibited by Erk and NF-kB inhibitors, this data was not 
statistically significant. All data is represented as ± SEM n=3. Statistical analysis was 
carried out using a paired Student’s t test.  
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5.3.5 TWEAK mediated angiogenic potential was regulated via Erk and NF-kB Rel A 
signalling transduction 
In order to further understand the signalling mechanisms mediating TWEAK activated HIEC 
angiogenesis, we performed the matrigel tube formation assay and scratch wound migration 
assays with pharmacological inhibitors to NF-kB Rel A and Erk signalling in addition to TWEAK 
activation. 
 
HIEC cell motility in response to TWEAK activation was tested to see if this was regulated by 
Erk and NF-kB Rel A dependent mechanisms (Figure 5.3.6). In comparison to TWEAK 
stimulated HIEC, TWEAK activated HIEC with Erk pathway inhibited showed a slower 
progress of wound healing at 4 hours (TWEAK alone – 72.6% Erk inhibited -79%)  and 8 hours 
(TWEAK alone- 47% Erk inhibited – 68.2%). By 24 hours both wounds had healed fully. NF-kB 
inhibition had no marked effect on the speed of wound healing, it appeared to close the 
wound slightly faster than the TWEAK activated HIEC at 4 hours (TWEAK alone – 72.6% NF-
kB inhibited- 68.7%) and 8 hours (TWEAK alone – 72.6% NF-kB inhibited – 43.4%). Erk 
inhibition alone showed a similar progression of wound closure to the unstimulated control, 
however failed to completely close the wound, remaining open after 24 hours. NF-kB 
inhibition alone had no effect on the normal progression of wound healing in comparison to 
the unstimulated control. All differences observed in these wound healing assays were not 
statistically significant, but showed a trend across all assays.  
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Erk and NF-kB Rel A inhibition significantly reduced tube formation in HIEC activated with 
TWEAK (**p=0.01 and **p=0.007 respectively) (Figure 5.3.7). Erk inhibition reduced TWEAK 
activated node formation in HIEC from 50.2 to 12.7 nodes ± SEM. NF-kB inhibition reduced 
TWEAK activated node formation to 34.8 nodes ± SEM. Erk inhibition alone almost 
completely abrogated node formation (7.2 nodes) in comparison to the unstimulated control 
**p=0.01, whereas NF-kB inhibition alone reduced node formation in comparison to the 
unstimulated control (33.8 to 24.2 nodes). 
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Figure 5.3.6 TWEAK does not significantly promote HIEC cell motility in an NF-kB or 
Erk mediated pathway: HIEC were cultured on gelatine coated plates. Scratch wound 
analysis was performed in the presence of TWEAK and inhibitors to Erk and NF-kB, to 
determine if these signalling pathways regulated HIEC cell motility. Unstimulated HIEC 
were used as a negative control. Images for analysis were taken after initialising the 
scratch at 0, 4, 8, and 24 hours. Data is shown as mean percentage ± SE (n=3). Erk 
inhibition delayed wound healing which was enhanced in response to TWEAK 
activation. This data was not statistically significant. 
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Figure 5.3.7 TWEAK activated tube formation in HIEC may be mediated by signalling via 
the Erk 1/2 and NF-kB pathways: HIEC were cultured on natural matrigel and stimulated 
with TWEAK, Erk 1/2 inhibitor and NF-kB inhibitor. Unstimulated HIEC were used as a 
negative control. Node formation was used to calculate angiogenic potential by counting 
the number of nodes with each condition from five fields of view. HIEC cultured on 
matrigel showed a significant increase in node formation when stimulated with soluble 
TWEAK (100ng/ml) for 8 hours (*p=0.02). This node formation was significantly 
decreased when the Erk 1/2 (**p=0.01) and NF-kB (**p=0.007) signalling pathways were 
inhibited. Node formation was also significantly decreased in unstimulated HIEC in 
response to Erk inhibition (**0.008). All data is represented as ± SEM (n=6). Statistical 
Analysis was carried out using a paired Student’s t test. 
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5.3.6 Summary of Results 
 TWEAK stimulated HIEC induce signal transduction via Erk1/2 and NF-kB Rel A. 
 NF-kB Rel A and Erk 1/2 signalling pathways may regulate Fn14 cell surface HIEC 
expression, and TWEAK stimulated HIEC angiogenesis.  
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5.4 DISCUSSION 
Our study revealed that TWEAK activated HIEC may signal via Erk 1/2 and NF-kB Rel A. Rel A 
signalling is the most studied transcription factor for TWEAK functions. A common trend 
observed in studies where TWEAK has activated Rel A, is that signal transduction occurs 
rapidly, and NF-kB phosphorylation occurs usually within the first hour of TWEAK activation 
(Donohue et al., 2003; Kumar et al., 2009). Our findings agreed with these investigations and 
revealed that TWEAK activated HIEC also phosphorylated Rel A within the first hour, and 
subsequent phosphorylation was not detected after this time point (Figure 5.3.3). TWEAK 
activated HIEC showed a 5.6 fold increase in Rel A phosphorylation in comparison to the 
unstimulated HIEC, which was markedly reduced after Rel A inhibition. These findings 
however were not statistically significant (Figure 5.3.3 B).  
 
The TNF-α activated HIEC showed a more enhanced NF-kB Rel A phosphorylation response 
than TWEAK activated HIEC, but showed a weaker response to Rel A inhibtion. It has been 
reported before, that TNF-α can induce a more potent NF-kB response in cancer cell line 
apoptosis, in comparison to TWEAK activated apoptosis in the same cells (Schneider et al., 
1999). Our data is in agreement with these findings that HIEC NF-kB signalling responses are 
enhanced in response to TNF-α activation than TWEAK activation, however there is potential 
that TWEAK and TNF-α may co-regulate inflammation via HIEC. The TNF-α response was 
observed in earlier time points and was sustained through later time points, indicating TNF-α 
may regulate sustained Rel A mediated inflammation via HIEC. 
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In this investigation we were determining the potential of TWEAK activation in HIEC 
functional responses, which are endothelial cells known to function in liver regenerative and 
pathogen clearance responses in the liver. NF-kB signalling is known to activate a range of 
immune and inflammatory functions which are observed in a wide range of cells. 
Subsequently, NF-kB has been described as a critical regulator of the TNFSF inflammatory 
functions (Aggarwal, 2003). Our data suggests NF-kB signalling may regulate TWEAK 
activated functions, and is most likely indicative of mediating proinflammatory responses via 
this signalling pathway as an early response to TWEAK activation in HIEC.  
 
We detected no VEGFR2 activation in HIEC (Figure 5.3.1). We analysed HIEC activated with 
TWEAK at earlier time points of 15, 30, and 60 minutes (data not shown), and later time 
points of 2, 4, and 24 hours, all of these time points were negative for VEGFR2 activation. 
Previous literature has suggested that TWEAK angiogenic responses are independent of 
VEGF signalling. Donohue et al 2003 showed TWEAK and VEGF activated endothelial cells, 
and enhanced cell proliferation in vivo, and Erk 1/2 activation was found to be the signalling 
pathway mediating this response. They further wanted to determine if this response was 
perpetuated by VEGF and TWEAK co-treatment. TWEAK and VEGF activation in endothelial 
cells did not show an additive effect on Erk 1/2 phosphorylation (Donohue et al., 2003). Our 
data is in agreement with these findings that TWEAK does not activate angiogenic functions 
via VEGF signalling responses, but it does via Erk 1/2 and Rel A signalling pathways. We 
previously observed up-regulated VEGF expression from TWEAK activated HIEC (Chapter 4). 
Erk is a downstream activated transcription factor to VEGFR2, therefore Erk activation may 
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be a secondary response to VEGF activation via TWEAK in HIEC, or VEGF activation by TWEAK 
may be an Erk mediated response. 
 
We detected phosphorylation of Erk 1/2 signalling during TWEAK activation of HIEC at 4 
hours post stimulation (Figure 5.3.2). Other studies have shown that TWEAK activation 
phosphorylated Erk 1/2 at earlier activation time points; usually within the first hour (Ando 
et al., 2006; Dogra et al., 2006; Echeverry et al., 2012). The Erk pathway is often activated in 
response to growth factors and has been shown to induce functions relative to angiogenesis 
(Roberts e Der, 2007). The late but significantly enhanced onset of this pathway is indicative 
of key processes preceeding the Erk response in TWEAK activated HIEC, which may trigger 
endothelial cell regulation in the liver. 
 
We described TWEAK activated HIEC promoting angiogenic functions (Chapter 4), and when 
NF-kB Rel A and Erk pathways were blocked using pharmacological inhibitors during the 
angiogenesis tube formation assays, a significant reduction in node formation was observed 
(Figure 5.3.7), where a larger Erk 1/2 inhibitory response was observed in TWEAK activated 
HIEC in comparison to NF-kB inhibition. Erk inhibition of unstimulated HIEC showed a large 
reduction in node formation suggesting that Erk alone may be largely regulating angiogenic 
tubule formation, therefore TWEAK inhibition data has to be taken with caution from this 
assay. When we blocked Erk and NF-kB Rel A during scratch wound assays in the presence of 
TWEAK, we observed that Erk inhibition delayed cell motility which was initially promoted by 
TWEAK (Figure 5.3.6) but this data was not statistically significant, and NF-kB inhibition in 
237 
 
these assays had no effect on HIEC cell motility activated by TWEAK. This data was 
suggestive that the overall angiogenic potential observed with TWEAK activation in HIEC was 
mediated by both the Rel A and Erk signalling pathways, however Erk seemed to have a 
more specific response to angiogenic functions than NF-kB. This data was in agreement with 
previous studies observing TWEAK activated Erk endothelial cell angiogenic responses. Erk 
phosphorylation has previously been observed in HEK293 cell lines and HUVEC during 
tumour growth, which requires angiogenesis promoting processes (Ho et al., 2004). More 
specific TWEAK responses in endothelial cells via Erk activation have also been observed in 
cutaneous vasculitis studies, where human dermal microvascular endothelial cells showed 
enhanced Erk phosphorylation in response to TWEAK activation (Chen et al., 2013), and 
HUVEC proliferation was observed to be regulated by TWEAK via Erk phosphorylation 
(Donohue et al., 2003). Our data indicates that TWEAK may initiate an inflammatory 
response in HIEC during early activation which triggers signalling pathway activation of NF-kB 
Rel A. This may be followed by pro-inflammatory mediated angiogenesis which may be co-
ordinated by Erk 1/2 phosphorylation later during TWEAK activated HIEC responses.  
 
The TWEAK data for Erk activation in HIEC was consistent in all samples however, the TNF-α 
activated HIEC showed differing results between samples. TNF-α activated HIEC initially 
showed Erk phosphorylation upregulated at 2 hours post activation, showing a 2.9 fold 
increase in comparison to unstimulated controls. The degree of phosphorylation in response 
to TNF-α was comparable to TWEAK activated HIEC which showed a 3.5 fold increase from 
unstimulated HIEC. TNF-α activated Erk reduced at 4 hours post stimulation and a large up-
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regulation was observed at 24 hours, which we found was due to an outlier data set (Figure 
5.3.3 A). In our second data set where we observed Erk responses to TWEAK and TNF-α in 
the presence of Erk inhibitors in HIEC, we found that TNF-α activated Erk phosphorylation in 
HIEC at 4 hours post stimulation. This response was 2 fold less than the TWEAK activated Erk 
phosphorylation. It is apparent that TWEAK and TNF-α may co-regulate complex signalling 
mechanisms in HIEC and more specifically this may be an isolate specific response, therefore 
there is a need to further explore the potential of these in mediating specific HIEC functional 
responses via Erk and NF-kB. 
 
FAK, PLC-γ1, Src, AKT, and p38 MAPK transcription factors were not phosphorylated in 
response to TWEAK activated HIEC (Figure 5.3.1). This data was in consistency with previous 
known investigations of TWEAK mediated responses, which have not characterised 
activation of VEGFR2 and downstream signalling cascades of FAK, Src, and PLCγ1. AKT 
signalling has been seen activated in a growing number of studies in response to TWEAK 
activation, including myoblasts, fibroblasts, and renal tubular cells (Kumar et al., 2009; Sanz 
et al., 2009). p38 MAPK phosphorylation in response to TWEAK has also been observed in a 
number of studies, including studies observing PBMC interactions with TWEAK in lupus 
nephritis regulation, and TWEAK enhanced skeletal muscle degeneration (Li et al., 2009; Zhi-
Chun et al., 2012). Our investigation in TWEAK activated HIEC did not agree with these 
findings and were consistently negative for p38 signalling activation. In some of the data 
intial phosphorylation of PLC-γ1 in unstimulated HIEC protein lysates was observed, this 
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appeared to disappear post TWEAK activation suggesting that TWEAK might be inhibiting 
this pathway. Further studies would be requires to confirm this. 
 
During this study we did not find TWEAK phosphorylated Rel B in HIEC at early or later time 
points (Figure 5.3.6). Previous studies which have shown activation of Rel B signalling 
pathways during TWEAK induction, have noted that Rel B activation occurs later during 
TWEAK activation and remains activated for long periods of time (Sanz et al., 2010), and 
linked to a prolonged inflammatory mediating process by Rel B. From this investigation, we 
can suggest that TWEAK may be activating HIEC signalling pathways specific to endothelial 
cell proliferation and angiogenesis in response to rapid inflammatory NF-kB responses. HIEC 
may not be the critical mediators of a specific prolonged inflammatory response in the liver 
which would potentially be mediated by Rel B following TWEAK activation, and would 
explain the lack of activation of this signalling pathway. It will also be beneficial to observe 
Rel B activation in HIEC with varying TWEAK concentrations, as it has been previously 
reported that low concentrations of TWEAK have shown induction of Rel B phosphorylation 
in comparison to high concentrations of TWEAK which activated the Rel A signalling pathway 
(Roos et al., 2010).  
 
We further found Fn14 cell surface expression from HIEC was regulated by Rel A and Erk. We 
found that Erk inhibition significantly reduced basal Fn14 expression, and NF-kB inhibition 
significantly up-regulated Fn14 expression on HIEC cell surface (Figure 5.3.5), indicating 
positive and negative regulation of TWEAK activation on HIEC via Fn14. Up-regulated TWEAK 
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and Fn14 expression has often been linked to detrimental pathological consequences. NF-kB 
is a signalling pathway which is critical to the proinflammatory and immune response, and 
NF-kB inhibition on HIEC showed up-regulated Fn14 expression. This may be suggestive of  
NF-kB regulating Fn14 and TWEAK responses during inflammatory and pathological 
environments, where it may function to neutralise the pathological inflammatory response 
orchestrated by TWEAK. Erk inhibition reduced Fn14 expression on HIEC. Erk activation is 
linked to proliferative responses, and it may positively up-regulate Fn14 expression on HIEC 
to induce angiogenic responses via TWEAK in response to chronic inflammation in the liver. 
 
In response to Erk and NF-kB inhibition we found changes in expression pattern of Fn14 in 
response to TNF-α, FGF and IL-1β cytokine activation (Figure 5.3.5). We found up-regulated 
Fn14 expression on HIEC cell surface in response to cytokine activation, and found that Erk 
and NF-kB inhibition reduced Fn14 expression but showed different effects between each 
cytokine. TNF-α activated HIEC responded to NF-kB inhibition more than Erk inhibition, this 
supports the pro-inflammatory functions of TNF-α and NF-kB activation in combination. FGF 
activated HIEC were the most responsive to Erk inhibition, supporting the pro-angiogenic 
functions of FGF and Erk. They reduced Fn14 expression two fold in comparison to 
uninhibited HIEC. Finally IL-1β which showed a higher response to Erk inhibition may also 
contribute to inflammatory angiogenesis. These effects were not statistically significant 
therefore we can only comment on the potential this data might have. This data confirmed 
that TWEAK and Fn14 signalling in HIEC is a highly complex, multi-faceted process which will 
require a significantly deep understanding of all processes and interactions of this system 
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and further work to understand how these signalling pathways completely regulate TWEAK 
activated HIEC. We can conclude that TWEAK activated HIEC, signal via pro-angiogenic and 
pro-inflammatory Erk 1/2 and NF-kB Rel A signalling pathways to mediate HIEC functions in 
the liver.  
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Chapter 6 
TWEAK activation regulates HIEC cell fate  
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6.1 INTRODUCTION 
TWEAK and Fn14 have been described as a highly regulated ligand and receptor system and 
have been implicated in cellular responses including ROS (reactive oxygen species) 
production, necrosis, apoptosis and autophagy. 
 
6.1.1 Apoptosis 
Apoptotic cell suicide is a highly complex process which is designed to remove damaged or 
infected cells which may be detrimental to normal physiological function. Apoptosis is 
characterised in the cell as DNA fragmentation, degradation of the cytoskeletal and nuclear 
proteins, membrane blebbing, and morphological and biochemical changes. There are two 
major apoptosis inducing pathways; the extrinsic pathway and the intrinsic pathway. The 
extrinsic apoptosis pathway is regulated by TNFR activation (Figure 6.1). Some TNFR’s 
possess the death domain in their cytoplasmic tail, which mediate a death signal from the 
cell surface to intracellular signalling pathways. TNF ligand and receptor association can bind 
functional adaptor proteins FADD, which form a death inducing signalling complex (DISC). 
This activates initiator caspases (caspase 8, 9 and 10) which leads to the execution phase by 
the subsequent activation of effector caspases (caspase 3, 6 and 7). This process induces the 
cleavage of death substrates leading to apoptosis. The intrinsic apoptosis pathway is 
activated by non-receptor mediated stimulation, leading to an intracellular signalling 
cascade which directly influences targets within the cell. The intrinsic pathway is regulated 
by the mitochondria which induces the release of cytochrome C and other apoptosis 
inducing proteins in response to stress. Apoptosis inducing stimuli can activate Bcl2 family 
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members which can regulate pro-apoptotic functions such as cytochrome C release. Once 
the apoptosome is formed, initiator caspases are activated leading to effector caspase 
activation and subsequent apoptosis. (Elmore, 2007; Portt et al., 2011). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1 The Extrinsic Apoptosis inducing pathway: TNFSF ligands bind their 
receptors on the cell surface. This interaction induces activation of the death domain via 
TRAF associated death domain binding (TRADD) and subsequent Fas associated death 
domain binding (FADD). These interactions lead to the formation of the death inducing 
signalling complex which activates initiator caspases, including caspase 8 and 10. These 
caspases can directly lead to the execution phase by activation of effector caspases to 
induce apoptosis. The initiator caspases can activate Bcl2 family members such as Bid to 
activate the execution phase via the mitochondrial pathway (Guicciardi e Gores, 2005).  
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6.1.3 Autophagy 
Whilst apoptosis is described as programmed cell death type I. Autophagy is described as 
programmed cell death type II. Autophagy is the process of lysosomal mediated self-
degradation. Autophagy is required to maintain normal function and development, such as 
apoptotic cell clearance during embryogenesis, and providing cell protection during stress 
responses. Stress responses include nutrient starvation which results in degradation of un-
required proteins to provide amino acids which form essential proteins for survival. 
Autophagy also provides protection from pathogens and is a regulator of the immune 
response. Autophagy is critical for the degradation and removal of faulty proteins and 
damaged organelles, and with the presence of autophagosomes, autophagy can mediate 
programmed cell death. There are three types of classified autophagy; macroautophagy, 
microautophagy, and chaperone mediated autophagy (CMA) (Figure 6.2). Macroautophagy 
is the most widely characterised autophagy function, it involves the processing of target 
cellular content, by isolation into the double membraned autophagosome. The 
autophagosome then fuses to the lysosome which initiates degradation. Microautophagy 
involves the direct engulfment of cytoplasmic components by the lysosome. CMA is the most 
complex and highly selective form of autophagy, CMA recognises an Hsc70 (heat shock 
protein 70) binding sequence present in the protein (KFERQ), the protein binds Hsc70 and a 
suitable chaperone, and forms a complex. This complex then binds lysosomal surface protein 
LAMP2 (lysosomal associated membrane protein 2), and the target protein then translocates 
to the lysosome without the Hsc70 and chaperones, and is subsequently degraded 
(Mizushima, 2007; Glick, Barth e Macleod, 2010).  
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Autophagy has been highly characterised in studies of the liver where it was described in rat 
liver cells which were treated with glucagon. These cells displayed large numbers of 
lysosomes, some of which contained other organelles such as the mitochondria (De Duve e 
 
Figure 6.2 Autophagy: There are three classified autophagy pathways. A) 
Macroautophagy is the most characterised autophagy pathway, it requires the 
engulfment of target content by the phagophore to form the autophagosome. The 
autophagosome fuses to the lysosome which leads to subsequent degradation of the 
target proteins. B) Microautophagy requires the direct engulfment and degradation of 
the target proteins by the lysosome. C) Chaperone mediated autophagy is a highly 
specific and complicated autophagy pathway. It requires the specific binding of the 
Hsc70 protein and a suitable chaperone which binds the LAMP2 protein on the 
lysosome cell surface. The target protein is translocated in to the lysosome for 
subsequent degradation (Yin, Ding e Gao, 2008).  
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Wattiaux, 1966). Since this discovery we now understand that autophagy is an essential 
process to maintain normal liver homeostasis and a key response during stress activation.  
 
6.1.4 Necrosis 
Programmed cell death III is necrosis. Necrosis is a response to extreme stress conditions 
such as tissue injury or ischemic conditions. Apoptotic cell death has been described as a 
process which can be beneficial, whereas necrosis is a process which is usually associated 
with detrimental consequences such as tissue damage and fatality (Figure 6.3) (Festjens, 
Vanden Berghe e Vandenabeele, 2006). As a more developed understanding of necrosis is 
emerging, it is found to be a regulated process which can be independent of apoptotic cell 
death, although both processes share key features of cell death which is mediated by 
mitochondrial permeablisation (Golstein e Kroemer, 2007). Necrosis and autophagy have 
been found to be initiated when apoptotic cell death is defective or absent. Necrosis can be 
activated in response to mitochondrial dysfunction which leads to the production of ROS and 
cell swelling, as opposed to cell shrinking during apoptosis. Cell swelling is closely followed 
by the accumulation of membrane blebs (Portt et al., 2011). The mechanistic process 
involves depletion of ATP in response to metabolic stress. This is followed by Calcium ion up-
regulation from external and ER sources which leads to the activation of calpains. Calpains 
are proteins which lead to lysosomal rupture and the subsequent activation of cathepsins 
which mediate cellular destruction. Cellular destruction is characterised by the irreversible 
plasma membrane breakdown which leads to leakage of enzymes from the cell and 
disrupted ion and electrical exchange. Necrosis can initiate the local inflammatory response 
248 
 
as it may activate the innate immune system by the subsequent release of factors by the 
necrotising cells (Golstein e Kroemer, 2007; Portt et al., 2011).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3 Necrosis and Apoptosis: Necrosis and apoptosis are cell death pathways 
which can be activated by the same stimuli such as ischaemia, oxidative stress and 
toxicity. Necrosis can also be activated by mechanical injury, and apoptosis can be 
activated by TNFSF member binding and activation on the cell surface. Necrosis is 
characterised by the loss of ATP and cell swelling. This leads to damaged cytoplasmic 
organelles, cell lysis and subsequent initiation of the inflammatory response. Apoptosis 
on the other hand requires ATP to induce cell death. A cell undergoing apoptosis will 
require membrane blebbing, cell shrinking, chromatin condensation, and caspase 
activation. The cell will undergo fragmentation with the cellular content still intact. These 
apoptotic bodies will be targeted by phagocytosis for clearance and the inflammatory 
response will not be activated. http://clinicalscienceblogcindy.wordpress.com/ 
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6.1.5 Reactive Oxygen Species 
Reactive signalling intermediates include ROS, reactive nitrogen species (RNS), carbon 
monoxide, and hydrogen sulphide intermediates. ROS are chemically reactive molecules 
which contain oxygen. The mitochondrion electron transport chain is responsible for 
producing the most ROS. Oxygen contains two unpaired electrons orbiting the outer electron 
shell, when oxygen is reduced by the addition of more electrons, reactive oxygen species are 
formed; these include superoxides, hydrogen peroxide, hydroxyl radicals and ions, and nitric 
oxides (NO). ROS are complicated molecules which can be expressed in all types of cells 
where they can influence various functions in different targets. ROS mediate normal 
physiological functions including cell signalling, apoptosis, gene expression and homeostasis 
regulation. ROS are also implicated in a number of pathological functions including 
inflammatory responses, ischaemia, cancer and ageing (Muriel, 2009; Nathan e Cunningham-
Bussel, 2013).  
 
During oxidative stress, ROS expression is highly up-regulated whilst antioxidant expression 
is down-regulated, leading to damage to cell structures. ROS function during inflammation 
can induce cellular cytotoxicity, generation of pro-inflammatory mediators, and sensitisation 
of cells towards inflammation. The mitochondria can mediate TNF induced apoptosis signal 
transduction by the production of ROS; including NF-kB, MAPK and AP1 (Garg e Aggarwal, 
2002). Several TNFSF members have been implicated in ROS production in endothelial cells. 
In cerebral microvascular endothelial cells, NOX4 (a NADPH oxidase) has been shown to 
regulate cell fate in TNF-α activated cells; in particular during apoptosis and oxidative stress. 
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NOX4 NADPH derived ROS were shown to adapt to carbon monoxide mediated enhanced 
cell survival when activated by TNF-α via signalling through AKT, Erk, and p38 signalling 
pathways (Basuroy et al., 2011). Soluble CD40-L has been shown to regulate endothelial cell 
dysfuntion via regulation of reactive signalling intermediates. It was shown that soluble 
CD40-L decreased endothelial nitric oxide synthase, NO, and superoxide production, and 
enhanced NOX activity in human coronary artery endothelial cells. These processes were 
induced via p38, Erk, and NF-kB dependent signalling pathways (Chen et al., 2008).  
 
6.1.6 Cell fate responses during liver disease 
Programmed cell death and ROS have been implicated in normal physiology of the liver as 
well as during chronic liver disease. Liver injury is often triggered by inflammatory cell 
products. For example; hepatocellular injury induced by toxins show enhanced ROS 
production and inflammatory cell cytokines. During liver disease, TNF mediated apoptosis is 
known to play a significant role during liver disease pathogenesis (Schattenberg, Galle e 
Schuchmann, 2006). Briefly; in carbon tetra chloride injury models, NF-kB and Jnk signalling 
pathways were shown to mediate liver injury, TNF induced apoptosis (TNFIA) was shown to 
induce hepatocyte death (Czaja, Xu e Alt, 1995). Hepatocyte immunity to apoptosis was 
subsequently observed in TNF receptor and ligand null mice (Morio et al., 2001). In cases of 
NASH, over expression of a pro oxidising agent cytochrome (Cyt) P450 2E1 was observed in a 
MAPK signalling dependent mechanism in humans and mouse models. In response to Cyt 
P450 2E1 overexpression in these cases, induced TNFIA was observed to be dependent on 
the up-regulation of ROS in the liver tissue. Subsequent decreased TNFIA in antioxidant 
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treated hepatocytes was observed in NASH models (Liu et al., 2002; Schattenberg et al., 
2004). HCC cell lines have shown inherent resistance to TRAIL induced apoptosis and down-
regulated expression of TRAIL receptors. Subsequently in HCC cases defective apoptotic 
signalling has been shown to enhance cellular proliferation (Shin et al., 2002). During viral 
hepatitis infection apoptosis inducing proteins (such as HBV x) are up-regulated in 
hepatocytes to protect them from infection (Su e Schneider, 1997), and defective apoptosis 
has been shown to be one of the causes of HCC development post viral infection (Yoo e Lee, 
2004). It has over the years become apparent that apoptosis and necrosis are two different 
pathways leading to the same outcome; which is cell death. In cases of liver disease, cells 
which undergo apoptosis in an ATP dependent manner, follow a necrotic pathway when ATP 
is depleted from metabolic processes. For instance, during liver ischaemia reperfusion injury 
in hepatocytes, glycine and fructose administration prevents necrotic cell death by 
enhancing ATP and preventing ATP depletion mediated membrane destruction. This process 
leads to the activation of apoptosis, mediated by caspase activation. Subsequently apoptosis 
was shown to be inhibited by depletion of ATP (Kim et al., 2003; Malhi, Gores e Lemasters, 
2006).  
 
Defective autophagy in liver cells is a key to disease progression in the liver, for instance 
during ischaemia reperfusion liver injury, autophagy markers show a specific autophagic 
response where they are found to be up-regulated or decreased depending on the context 
and conditions (Rautou et al., 2010). During cases of ALD and non-alcoholic fatty liver 
disease, several studies have shown autophagy inhibition. Enhanced uptake of ethanol may 
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result in inhibition of autophagy by decreased autophagic vacuoles demonstrated by rats fed 
on a high ethanol diet, decreased catabolism of proteins (Pösö e Hirsimäki, 1991), and 
enhanced protein accumulation (Baraona et al., 1975). In NAFLD mouse models of chronic 
obesity and insulin resistance defective autophagy has been demonstrated by sustained lipid 
availability, and down-regulated autophagy indicators in the liver (Singh et al., 2009; 
Codogno e Meijer, 2010). During hepatitis C infection, autophagy can play an infection 
enhancing role. Accumulated autophagic vacuoles were observed in HCV infected 
hepatocytes, however these were found to be functionally redundant as the virus can evade 
detection by the autophagosome and prevents subsequent autolysosomal formation. The 
virus actually has been found to use the autophagy process to enhance its own replication by 
triggering cells to produce required proteins for viral enhancement (Dreux et al., 2009).  
 
Reactive oxygen species accumulation has been shown to contribute to liver disease. For 
instance during ALD, oxidative stress is induced by alcohol consumption. This leads to 
enhanced ROS and RNS production and the peroxidisation of DNA, protein, and lipids. 
Enhanced ROS production has been shown to contribute to necrosis and apoptosis of 
hepatocytes, and enhanced fibrosis by the activation of HSC (Bataller et al., 2003; Muriel, 
2009). ROS contribution to malignancy is well documented. Specifically chronic inflammation 
paired with oxidative stress is a large contributing factor to the cause of liver cirrhosis which 
can subsequently lead to HCC by the persistent up-regulation of oxidative stress and 
inflammation (Marx, 2004; Seitz e Stickel, 2006).  
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6.1.7 TWEAK mediated cell fate responses 
TWEAK activated responses to ROS production and programmed cell death have been 
investigated extensively since the initial discovery that TWEAK can induce apoptotic activity 
in activated cells (Chicheportiche et al., 1997). The ability of TWEAK to induce apoptosis 
alone or in combination with activating cytokines such as IFN-γ is intriguing as TWEAK 
receptor Fn14 does not possess a death domain, and so TWEAK induction of apoptosis is still 
a process which is not fully understood. There have been suggestions that TWEAK induces 
apoptosis indirectly by the activation of other ligands which have receptors possessing the 
death domain such as TNF-α. In Kym-1 cells, TWEAK activation showed enhanced apoptosis 
mediated by TNF ligand and receptor activation. Neutralising antibodies to TNF showed 
decreased subsequent apoptosis (Schneider et al., 1999). It was further shown that TWEAK 
and Fn14 can induce signalling to induce lysosomal degradation of the cellular IAP-TRAF2 
which binds Fn14. This process lead to immortalised cells sensitized to TNF-α mediated cell 
death (Vince et al., 2008). Recently it was shown that TWEAK activation can activate the 
intrinsic and extrinsic apoptotic pathways to induce cell death. TWEAK induced apoptosis 
was found to be mediated by a death signalling complex consisting of TWEAK and Fn14 
interactions with RIP-1 (receptor interacting protein – 1) and FADD, promoting TNF activated 
apoptosis via caspase 8. siRNA depletion of components of the extrinsic (Caspase 8 and 
FADD) and intrinsic (BID, BAX, BAK) apoptosis pathway showed inhibition of apoptosis after 
TWEAK activation (Ikner e Ashkenazi, 2011).  
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Nakayama et al were one of the studies to suggest an alternative receptor to TWEAK as they 
found that TWEAK could induce caspase dependent apoptosis and cathepsin B mediated 
necrosis in DR3 negative cell lines and HT-29 cells (Nakayama et al., 2002). They then further 
characterised death pathways regulated by TWEAK and found Fn14 transfected cells could 
induce cell death via multiple pathways. They found Fn14 expression on tumour cell surface 
and confirmed their previous study which showed positively regulated cell death via 
cathepsin B mediated necrosis, and ROI expression. They showed that TWEAK activated cells 
induced ROI expression induced lysosomal cathepsin B release, and in response to TWEAK 
activation, cathepsin B activation was required for subsequent reactive oxygen intermediate 
intracellular release. They showed that these positive cell death mediators were negatively 
regulated by caspase activation and TWEAK induced cell death was successfully blocked by 
Fn14 antibodies, suggesting that Fn14 mediated TWEAK induced cell death activation 
(Nakayama et al., 2003). It has been shown that TWEAK in combination with TNF-α and IFN-γ 
activation of renal tubular cells induce Fn14 dependent apoptosis. TWEAK induced apoptosis 
was shown to be in a caspase 3, 8, and 9 dependent manner which lead to cytochrome C 
release from the mitochondria in response to truncated Bid expression. They showed that 
necrosis was induced in response to caspase inactivation. When cells were activated with 
TNF-α and IFN-γ alone, no changes in cell fate responses in renal tubular cells were observed 
suggesting a TWEAK specific response (Justo et al., 2006).  
 
TWEAK has subsequently been shown to be a key regulator of multiple cell fate responses in 
numerous studies. Shimada et al 2012 showed that ROS production in a NOX2 dependent 
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mechanism was functionally implicated during ALKBH3 (a repair enzyme which promotes 
repair of DNA damage induced by methylation) induced survival and angiogenic potential in 
urothelial carcinoma cell lines. This process was dependent upon TWEAK-Fn14-VEGF 
interactions (Shimada et al., 2012). Alternatively in human dermal microvascular endothelial 
cells no changes in apoptosis, necrosis or ROS production was observed in response to 
TWEAK activation (Chen et al., 2013). In colon cancer cell lines, TWEAK activation was found 
to induce apoptosis in an ROS dependent pathway when these cells were treated with 15d-
PGJ2; a peroxisome proliferator activated receptor γ ligand (Dionne et al., 2010).  
 
TWEAK activated autophagy functions have been less characterised. Recently it was shown 
that TWEAK activation promoted skeletal muscle wasting. Skeletal muscle atrophy was 
functionally characterised by TWEAK activated pathways. They found that TWEAK activation 
induced the activation of the ATP dependent ubiquitin-proteasome pathway and induced 
autophagic responses by enhanced autophagy inducing genes, and caspase activation 
(characterised by a caspase inhibitor z VAD FMK) mediating skeletal muscle wasting. 
Inhibition of these pathways showed down-regulated muscle wasting via TWEAK activation. 
They showed that TWEAK induced skeletal muscle wasting was dependent on TWEAK 
activated NF-kB signalling pathways (Bhatnagar et al., 2012). 
 
These studies which have characterised TWEAK regulated cell fate have described TWEAK 
mediated cell fate responses to be cell and context dependent. It was highly important to 
understand TWEAK mediated cell fate responses in HIEC isolated from diseased liver tissue, 
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to help further understand the potential of TWEAK mediated inflammatory responses during 
chronic liver disease via HIEC. 
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6.1.8 Aims 
The aims of this chapter were: 
 To determine if TWEAK activated HIEC undergo cell fate responses; specifically 
autophagy, apoptosis, necrosis and ROS production. 
 To determine if these processes were regulated via Erk and NF-kB Rel A signalling 
pathways. 
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6.2 MATERIALS AND METHODS 
Materials and Methods for this chapter; please refer to sections: 2.1-2.4, 2.7 and 2.12, 
Tables: 2.1-2.4. 
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6.3 RESULTS 
To determine and analyse the effects of TWEAK activation on HIEC cell fate. HIEC were 
activated with TNF-α and TWEAK; apoptosis, necrosis, ROS production and autophagy 
responses were determined and compared (Figure 6.3.1). These were measured by markers 
for Annexin-V, 7-AAD, 2’, 7’ dichlorofluoroscin (DCF) and monodansylcadaverine (MDC), 
respectively. TNF-α was used as a positive control and unstimulated HIEC were used as a 
negative control. TWEAK activation enhanced ROS production, necrosis, apoptosis and 
autophagy in HIEC in comparison to unstimulated HIEC controls. TWEAK activated HIEC 
significantly enhanced expression of DCF, which emits fluorescence in response to oxidation; 
unstimulated HIEC showed 31.4 percentage of positive fluorescent cells in comparison to 
TWEAK activated HIEC which were 45.2 ± SEM (*p=0.02). TNF-α activated HIEC showed a 
higher expression of DCF at 51.2 percentage positive HIEC, but this was not statistically 
significant. TWEAK activated HIEC also showed a significantly high percentage of HIEC 
undergoing necrosis from 46 percent positive unstimulated HIEC to 63.5 percent TWEAK 
activated HIEC ± SEM (*p=0.04). TNF-α activated HIEC showed down-regulated necrosis at 38 
percent HIEC. TWEAK activated HIEC also showed enhanced apoptosis marker Annexin-V 
expression (46.8 percent unstimulated HIEC to 60.4 percent TWEAK activated HIEC, and 51.1 
percent TNF-α activated HIEC ± SEM). TWEAK activated HIEC also showed enhanced 
autophagic vacuole marker MDC in comparison to unstimulated HIEC (64.3 percent HIEC to 
79.9 percent TWEAK activated HIEC ± SEM). TNF-α activated HIEC down-regulated 
autophagy to 40.8 percent HIEC. TWEAK activated responses to autophagy and apoptosis 
were not statistically significant. The MFI data showed a similar pattern of expression to 
TWEAK and TNF-α activation. 
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We wanted to determine if TWEAK activated cell fate responses were mediated by signalling 
via NF-kB Rel A and Erk 1/2 pathways. To do this, the four colour reporter assay was 
repeated with inhibitors for these signalling pathways (Figure 6.3.2). TWEAK activated HIEC 
all showed enhanced expression of ROS, necrosis, apoptosis, and autophagy markers during 
percentage positive HIEC determination. In response to TWEAK activation in combination 
with Erk and NF-kB Rel A inhibition, all four cell fate determinants except the autophagy 
marker were up-regulated. The data obtained in this assay was not statistically significant, 
but a trend in observed expression patterns was seen. In TWEAK activated HIEC with Erk 
signalling inhibited, autophagy remained unchanged to the unstimulated control. When NF-
kB signalling was inhibited, autophagy decreased. Erk inhibited HIEC without TWEAK 
activation still showed up-regulated cell fate markers apart from autophagy which showed 
down-regulated responses. NF-kB inhibited HIEC showed up-regulated necrosis and 
apoptosis markers but down-regulated ROS and autophagy markers. As this data was not 
statistically significant, we can confirm that Erk 1/2 and NF-kB Rel A do not regulate HIEC cell 
fate responses. 
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Figure 6.3.1 TWEAK activation promotes necrosis and the production of ROS in HIEC: 
HIEC were stimulated with TNF-α (10ng/ml) and TWEAK (100ng/ml) for 24 hours prior to 
FACS analysis. TNF-α was used as a positive control and unstimulated HIEC were used as 
a negative control. A) Percentage positive population of HIEC expressing markers for ROS 
(2’,7’-dicholofluoroscin), necrosis (7-AAD), apoptosis (Annexin V), and autophagy 
(monodansylcadaverine), in response to TWEAK and TNF-α activation. HIEC activated 
with TWEAK significantly enhanced ROS production (*p=0.02) and necrosis (*p=0.04). B) 
Representative histograms of unstimulated HIEC and HIEC stimulated with TWEAK, 
showing ROS and necrosis marker increase on HIEC cell surface in response to TWEAK. C) 
Median fluorescence intensity from HIEC expressing markers for ROS, necrosis, 
apoptosis and autophagy in response to TWEAK and TNF-α activation. Data is shown as ± 
SEM n=6. Statistical analysis was carried out using a paired Student’s t test. 
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Figure 6.3.2 TWEAK promoted ROS and necrosis are not dependent on Erk and NF-kB 
Rel A signalling mechanisms: HIEC were stimulated with TWEAK (100ng/ml) ± Erk 
Inhibitor and ± NF-kB Inhibitor for 24 hours prior to FACS analysis. Unstimulated HIEC 
were used as a negative control. A) The percentage positive population of HIEC 
expressing markers for ROS (2’,7’-dicholofluoroscin), necrosis (7-AAD), apoptosis 
(Annexin V), and autophagy (monodansylcadaverine), in response to TWEAK activation. 
Erk and NF-kB inhibition showed patterns of enhanced apoptosis, ROS and necrosis 
markers. Erk inhibition had no effect on autophagy and NF-kB inhibition in TWEAK 
activated cells down-regulated autophagy. B) Median fluorescence Intensity from HIEC 
expressing markers for ROS, necrosis, apoptosis and autophagy in response to TWEAK 
activation. Data is shown as ± SEM n=3. This data was not statistically significant. 
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6.3.1 Summary of Results 
 TWEAK stimulated HIEC may induce ROS production and undergo necrosis over 
prolonged exposure to TWEAK. 
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6.4 DISCUSSION 
Our data showed TWEAK activated HIEC trigger cell fate responses, specifically enhanced 
ROS production and necrosis in HIEC (Figure 6.3.1). Autophagy and apoptosis responses 
were also enhanced by TWEAK activation but this data was not statistically significant. The 
percentage positive data obtained from TWEAK activated HIEC showed that the cell fate 
responses were all highly responsive to TWEAK in comparison to TNF-α. This data was in 
confirmation with all previous studies which have suggested that prolonged TWEAK 
stimulation can lead to cell fate and subsequent pathological consequences.  
 
Data obtained and discussed in this chapter showed enhanced ROS production which is a 
known mediator of inflammatory responses during pathological environments, and leads to 
damage to cells by induced cytotoxicity, enhanced production of inflammatory mediators, 
and enhancing sensitisation to inflammation (Nathan e Cunningham-Bussel, 2013). Our 
previous data showed that TWEAK may regulate chronic inflammatory liver responses via 
HIEC by the recruitment of inflammatory and angiogenic mediators, this data showed that 
these responses may be regulated via ROS production.  
 
TWEAK activated HIEC also showed significantly enhanced necrosis. Necrosis is a response 
associated to tissue damage and even fatality and is triggered when apoptosis is absent or 
deregulated. Necrotic cells can subsequently trigger an inflammatory response (Golstein e 
Kroemer, 2007). TWEAK activated HIEC may be undergoing subsequent necrosis in response 
to prolonged TWEAK activation, and using the necrotic response to further promote 
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inflammation. Necrosis results in the activation of ROS production, and ROS production leads 
to activated necrosis (Portt et al., 2011). Our data showed that the majority of cells analysed 
were expressing markers for both necrosis and ROS on the same cell (Figure 6.3.1 B), 
suggesting that these processes may be regulated by one another. Our data showed 
enhanced apoptosis but it was not statistically significant, therefore our data confirms that 
in the absence or deregulation of TWEAK activated apoptosis, HIEC may undergo necrosis to 
promote inflammatory responses. It would appear that TWEAK activated HIEC may be 
regulating inflammatory responses and as a consequence, the induction of these cell fate 
responses were observed, and a positive feedback loop of necrosis and ROS production may 
contribute to the prolonged inflammatory response via TWEAK in the liver leading to 
pathological consequences. This data is agreement with findings of Nakayama et al 2003 and 
Shimada et al 2012 who showed that ROS production and necrosis activated by TWEAK may 
lead to varying functional outcomes depending on the cell types and contexts such as, 
detrimental tumour progression and endothelial cell survival, and mediated angiogenic 
functions (Nakayama et al., 2003; Shimada et al., 2012). It is clear from this investigation that 
TWEAK activation lead cell fate responses may also be a context dependent response. 
 
The complexity of TWEAK mediated HIEC cell fate responses was highlighted when our data 
also showed that these responses could be influenced by Rel A and Erk (Figure 6.3.2). This 
data was not statistically significant, however we found that TWEAK activation enhanced all 
cell fate responses and Erk and NF-kB may suppress the HIEC cell fate responses of 
apoptosis, ROS production, and necrosis, as enhanced expression of specific markers for 
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these were observed when Erk and NF-kB signalling was inhibited. This data complimented 
our angiogenesis data where we showed that Erk and NF-kB may regulate HIEC potential to 
undergo inflammatory mediated angiogenesis, which would be advantaged by a down-
regulated response of cell death pathways and ROS production, indicating possible HIEC 
protection by these signalling pathways. Autophagy in response to Erk inhibition in TWEAK 
activated HIEC showed no change, but in NF-kB inhibited cells the autophagy response was 
inhibited. These findings were further complicated when we observed changes in cell fate 
mediation in HIEC in response to Erk and NF-kB inhibition alone without TWEAK activation, 
which showed varying responses to each marker. Furthermore our previous data had shown 
that Erk and NF-kB also regulated Fn14 cell surface HIEC expression (Chapter 5), which 
indicates the high level of regulation by Erk and NF-kB in TWEAK and Fn14 HIEC responses. 
Further experiments and statistically significant data will be necessary before drawing any 
conclusions from this preliminary data. 
 
An interesting question which has arisen from this study is, if TWEAK activation is activating 
a necrotic response in HIEC, how were angiogenic responses mediated by TWEAK induction 
which require cell survival processes such as proliferation and migration. Data from this 
investigation showed that TWEAK activated HIEC were still viable (Appendix 2) and could 
contribute to angiogenic responses such as proliferation, migration, and tubule formation 
specifically under inflammatory conditions. Under the same conditions however, TWEAK can 
activate necrosis to a significant number of HIEC. One explanation would be that both 
responses of angiogenesis and necrosis are mediated by or mediate the inflammatory 
267 
 
response via NF-kB. Therefore all the subsequent responses that we observe in response to 
TWEAK activation may all be a product of a specific inflammatory response in the liver. From 
our data it would appear that TWEAK activated responses of HIEC may be time course 
dependent, where over shorter time periods TWEAK may promote angiogenesis to support 
liver regeneration and repair, however over longer periods of time TWEAK activation leads 
to detrimental cell fate responses. This finding would be in agreement with the large number 
of studies which often cite that TWEAK can regulate often conflicting functions, and is 
dependent upon environment, conditions, and signalling pathways.  
 
To conclude this chapter, we have found that TWEAK activated HIEC may regulate cell fate 
responses during inflammatory liver disease in particular necrosis and ROS production. It 
would be of importance to further determine which specific pathways and mechanisms 
mediate the necrosis response in HIEC, and if ROS and necrosis are dependent on the 
activation of one another in response to TWEAK activated HIEC. It would also be highly 
important to determine if these TWEAK mediated cell fate responses were dependent on 
Fn14, and if they can be further regulated via inflammatory induction by additional 
cytokines. 
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CHAPTER 7 
Final Summary and Further Work 
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7.1 SUMMARY  
TWEAK and Fn14 are recently identified TNFSF members which have been characterised in 
several functions. There are limited studies observing the role of TWEAK and Fn14 in the 
liver, however studies to date have shown that TWEAK and Fn14 may regulate hepatic 
proliferative and regenerative responses, and mediate hepatic pathogenesis via 
inflammatory regulation. This has been determined by several in vitro and in vivo assays, 
specifically PHx and liver injury models where elevated TWEAK and Fn14 expression has 
been observed in comparison to normal controls, and TWEAK and Fn14 have been shown to 
support inflammatory cell and factor mediation and recruitment, and hepatic and progenitor 
cell proliferation (Jakubowski, Ambrose, Parr, Lincecum, Wang, Zheng, Browning, 
Michaelson, Baetscher, Baestcher, et al., 2005; Tirnitz-Parker et al., 2010; Kuramitsu et al., 
2013; Karaca et al., 2014; Tirnitz-Parker, Olynyk e Ramm, 2014). Furthermore, TWEAK and 
Fn14 have been shown to critically mediate angiogenesis directly in several in vitro and in 
vivo assays, and have also been shown to indirectly mediate angiogenesis by enhancing 
other angiogenesis regulators (Lynch et al., 1999; Wiley et al., 2001). TWEAK and Fn14 have 
also been shown to specifically mediate tumourigenesis which requires inflammatory, 
angiogenic, and proliferative responses (Feng et al., 2000; Ho et al., 2004). 
 
This investigation set out to further understand TWEAK and Fn14 regulation of hepatic 
inflammatory and regenerative responses. It can be suggested from the literature that under 
normal conditions Fn14 and TWEAK may regulate normal liver homeostasis, and under 
chronic insult and injury conditions these processes may be deregulated by sustained 
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TWEAK and Fn14 expression, leading to pathological remodelling and loss of liver function, 
which has also been shown in several studies of inflammatory diseases (Desplat-Jégo et al., 
2005; Kamata et al., 2006; Michaelson et al., 2012). More specifically we wanted to 
determine if TWEAK and Fn14 can regulate specific inflammatory and angiogenic functions 
via HIEC. HIEC function in hepatic pathogen detection and clearance, regulation and 
exchange of fluids, solutes, and molecules between the sinusoidal lumen and parenchyma, 
therefore they can regulate hepatic immune and inflammatory responses which is further 
facilitated by a host of immune receptors on their cell surface (Jenne e Kubes, 2013). Notably 
they can facilitate hepatic regeneration by remodelling of vascular structures by 
angiogenesis post liver insult, facilitated by expression of growth and angiogenic factors 
(Sato et al., 2001). The incidence of chronic liver disease is an increasing problem as patients 
requiring liver transplants are exceeding the supply of available livers. Therefore, 
understanding TWEAK and Fn14 regulated HIEC responses will be essential to developing 
target specific therapeutics in future, aimed at facilitating liver regenerative responses to 
ease the demand on liver transplants. 
 
Data obtained from this investigation has contributed towards the limited knowledge we 
currently have of TWEAK and Fn14 mediated functional responses during inflammatory liver 
conditions. Using IHC techniques we showed TWEAK expression in liver diseased tissue was 
predominantly found in areas of mono-nuclear cell infiltration in close proximity to portal 
vessels. Fn14 expression was found in hepatocytes, and high Fn14 expression was observed 
surrounding portal vessels, neovessels, ductular reactive cells, and areas surrounding 
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granuloma formation. This data indicated that TWEAK and Fn14 may regulate inflammatory 
responses, angiogenesis, and the subsequent formation of PALT. We confirmed previous 
findings of several studies where TWEAK and Fn14 up-regulated expression during 
pathogenesis has been seen, as our IHC data revealed that normal donor tissue showed 
milder Fn14 expression. This was further supported by TWEAK and Fn14 mRNA expression 
detected using quantitative PCR, which was significantly up-regulated in diseased liver tissue 
in comparison to normal liver tissue. Fn14 expression was highly up-regulated in comparison 
to TWEAK expression, indicating that TWEAK and Fn14 may play specific roles during 
inflammatory liver disease progression, perpetuation, and pathogenesis; with Fn14 possibly 
playing a more local role during normal liver physiology and TWEAK responding to Fn14 via 
inflammatory cells in settings of acute to chronic inflammation. 
  
Our investigation made novel observations and highlighted the importance of TWEAK and 
Fn14 regulated HIEC expression and functional responses. Fn14 expression was highly 
induced by cytokines and growth factors on HIEC. We found Fn14 protein expression up-
regulated on HIEC cell surface using flow cytometry and IF techniques in response to IL-1β, 
TNF-α, and FGF. We observed Fn14 present as a punctate stain in the cytoplasm indicating 
compartmentalised storage of Fn14 within HIEC, and further found that Fn14 protein may be 
shuttled from the Golgi to endoplasmic reticulum in the cytoplasm, and to the cell surface. It 
appeared that Fn14 stored in the Golgi was subsequently released into the cytoplasm upon 
cytokine stimulation, and may be transported to the cell membrane for protein-protein 
interactions. TGF-β, TWEAK, and IL-17A cytokine activation on the other hand, significantly 
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down-regulated Fn14 cell surface protein expression on HIEC, indicating possible 
contribution to the promotion of Fn14 degradation on HIEC cell surface. This data was in 
confirmation with a recent study observing Fn14 transport within the Golgi apparatus and 
lysosomal mediated degradation of Fn14, accelerated in response to TWEAK (Gurunathan et 
al., 2014). Our data indicated the possibility of TGF-β and IL-17A enhancing TWEAK 
responses to HIEC, facilitating this process.  
 
No TWEAK protein expression was observed on HIEC, however our IHC data revealed TWEAK 
presence in inflammatory infiltrates, therefore we wanted to determine TWEAK expression 
from total PBMC. We observed TWEAK mRNA expression present in total PBMC, which was 
highly inducible by IFN-γ. Monocytes have been found to highly express TWEAK, and specific 
monocyte subsets have been found to contribute to chronic inflammation in the liver 
(Liaskou et al., 2013). We therefore examined TWEAK mRNA expression and responses to 
inflammatory cytokine IFN-γ which highly induces TWEAK expression. We observed TWEAK 
expression present in different monocyte subsets which were differentially regulated by IFN-
γ activation. In CD14+ and dual positive monocyte subsets IFN-γ activation up-regulated 
TWEAK mRNA expression. In CD16+ monocytes, IFN-γ activation down-regulated TWEAK 
mRNA expression.  
 
We further wanted to determine TWEAK and HIEC regulated leukocyte recruitment 
functions to understand the presence of TWEAK in inflammatory infiltrates. We found that 
TWEAK activated HIEC marginally but significantly contributed to leukocyte adhesion with a 
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higher affinity for monocyte recruitment, and leukocyte recruitment via TWEAK activated 
HIEC was found to be highly dependent on the interactions of TWEAK with other cytokines 
such as TNF-α, suggesting that TWEAK plays a more supportive role during leukocyte 
recruitment and adhesion rather than an integral role. This data indicated that specific 
TWEAK mediated inflammatory responses via leukocyte interactions is a highly regulated 
process and may contribute to inflammatory liver disease pathogenesis, and further proved 
that TWEAK and Fn14 functions may be regulated via paracrine mechanisms; where Fn14 
present on HIEC may interact with TWEAK present on leukocytes which infiltrate liver tissue 
from circulation during liver insult.  
 
TWEAK regulated angiogenesis has been characterised in many studies, but has not been 
characterised extensively in the liver and specifically in HIEC. Our data showed that TWEAK 
may regulate angiogenesis via HIEC, which complimented our IHC data which revealed Fn14 
presence in areas of neovascularisation. We found that TWEAK activation significantly 
enhanced HIEC tube formation which was mediated by Fn14. We then found that these 
processes were highly regulated via NF-kB and Erk transcription factors. Our data further 
suggested that TWEAK activation of HIEC may induce angiogenic cytokine induction 
responses specific to liver tissue, depending on the tissue histology; with diseased liver 
tissue showing a higher response to TWEAK mediated angiogenic cytokine expression, in 
comparison to normal tissue which showed a milder angiogenic cytokine response. We 
further showed that TWEAK may functionally regulate angiogenesis in inflammatory liver 
disease isolated HIEC via a specific set of angiogenesis mediators; Angiopoietin-1, CXCL16, IL-
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8, MCP-1, and VEGF. In tissue where granulomas were not present the cytokine induction in 
response to TWEAK was of a wider range and not specific. We further showed using IHC that 
Fn14 expression was highly up-regulated in diseased liver in portal vessels surrounding 
granulomas. There were limitations to the angiogenic cytokine array which would influence 
any conclusions we could draw. We would need a larger number of samples to analyse from 
normal donor patients and patients with CILD, we would need more statistically significant 
data and follow up studies of the influences of the significant cytokines regulating HIEC 
angiogenesis via TWEAK.  
 
We further found that TWEAK and Fn14 functions were regulated by NF-kB Rel A and Erk 
signalling; from expression of this ligand and receptor on HIEC and angiogenesis inducing 
functions. Our data found that TWEAK activated HIEC induce pro-inflammatory NF-kB Rel A 
activation early on, and then subsequently activated Erk as a later response which may 
contribute to inflammatory angiogenesis regulation. We found that exposure to TWEAK over 
time induced ROS production and necrosis in HIEC, this may contribute to potential 
pathogenesis in the liver via TWEAK activated responses. Our signalling data revealed that 
NF-kB and Erk regulated HIEC responses were complex and as other studies have confirmed, 
these responses are dependent on the cellular environment and conditions, as often 
conflicting functions in response to TWEAK activation in HIEC could be observed. Our data 
has shown that TWEAK and Fn14 are indeed a highly complex, highly regulated, 
multifunctional system which can potentially be manipulated in the development of future 
novel therapeutics to aid inflammatory liver disease regulation. 
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Current data reviewed in this thesis suggests that excessive TWEAK and Fn14 expression 
leads to detrimental consequences, in our study these consequences suggest inflammatory 
liver disease progression. Future TWEAK and Fn14 based therapeutics would ideally target 
enhanced TWEAK and Fn14 expression, and the potential to regulate this. It has been found 
using in vivo mouse models that TWEAK and Fn14 do not interfere with normal growth and 
development (Maecker et al., 2005), however several studies have confirmed that they 
significantly contribute to disease maintenance and progression rather than disease 
initiation. Therefore it is hoped that TWEAK and Fn14 inhibition would have limited adverse 
effects in patients. TWEAK and Fn14 suppression can be employed by using RNAi technology, 
or interfering with TWEAK and Fn14 protein-protein interactions preventing ligand and 
receptor multimerisation, TRAF association with Fn14, and TWEAK-Fn14 interactions, which 
all lead to signal transduction. Current TWEAK and Fn14 based clinical trials have used 
TWEAK mAb’s to inhibit TWEAK activity. In RA patients the use of BIIB023; a TWEAK blocking 
mAb in a clinical phase I trial has shown the ability to safely down-regulate soluble TWEAK 
serum expression, which is usually associated with chronic inflammation and tissue 
destruction during RA. Up to 20mg/kg dosage had the ability to suppress TWEAK expression 
for up to 28 days, and also was found to down-regulate other inflammatory inducing 
proteins including MCP-1, MIP-1β and TIMP-1. This antibody was found to have minimal 
adverse effects and no infections were reported, suggesting that BIIB023 does not interfere 
with the adaptive immune response (Wisniacki et al., 2013). A phase II trial is scheduled to 
observe BIIB023 efficacy in the renal response during LN (Michaelson et al., 2012). Another 
phase I trial has tested the ability of RG7212 anti TWEAK mAb in Fn14 positive tumours. 
They found tumour shrinkage accompanied by enhanced host immune responses and no 
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toxicity (Yin et al., 2013). Anti-TWEAK mAb technology has its own limitations as it may not 
be able to fully inhibit Fn14 responses which have been occasionally shown to be 
independent of TWEAK. Therefore continued development and research leading to potential 
TWEAK and Fn14 based therapies is essential. 
 
This investigation set out to determine the potential functions that TWEAK and Fn14 may 
have during inflammatory liver disease, and how these functions may be regulated via HIEC 
interactions with this ligand and receptor. This thesis has successfully started to develop a 
better understanding of TWEAK and Fn14 regulated responses in liver disease via HIEC, and 
indicates that they may contribute to inflammatory, angiogenic, and the regulation of 
potential pathogenic functions. It is essential to continue to further understand TWEAK and 
Fn14 regulation in the liver, furthermore in individual hepatic cells, their crosstalk and 
communication, and how this may translate into human studies as an aim for developing 
novel liver regeneration promoting therapies.   
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Figure 7.1 TWEAK and Fn14 regulated HIEC functional responses during inflammation: 
Fn14 was expressed on HIEC cell surface and interacts with TWEAK expressed on circulating 
leukocytes via paracrine interactions. Fn14 expression on HIEC was highly regulated by 
TNF-α, IL-1β and FGF, promoting Fn14 synthesis and Golgi transport to the cell surface for 
protein-protein interactions. Fn14 protein in HIEC may subsequently be degraded by 
TWEAK activation possibly promoted by IL-17A and TGF-β activation. TWEAK and Fn14 
function via Erk 1/2 and NF-kB Rel A signalling. TWEAK activated HIEC promote angiogenic 
responses and leukocyte adhesion during inflammation. Sustained TWEAK activation 
promotes HIEC ROS production and necrosis.  
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7.2 FURTHER WORK 
In future there is a lot to still learn about the functional regulation of inflammatory liver 
disease by TWEAK and Fn14 via HIEC. Data in this thesis has suggested that TWEAK and Fn14 
may regulate hepatic inflammatory and regenerative responses via HIEC, which may 
subsequently contribute to portal associated lymphoid tissue formation. Following this there 
still remain important questions, the answers of which will support our current data and 
enhance our understanding. 
 
 It would be of importance to further characterise normal liver and liver disease 
specific TWEAK and Fn14 expression using IHC and mRNA analysis, to draw significant 
conclusions of any differences found between tissue types.  
 We showed different responses of TWEAK mRNA expression in monocyte subsets to 
IFN-γ, more experiments will be required to further characterise these differences 
and to obtain statistically significant results. It will then be important to determine 
the potential effects of TWEAK on trans-endothelial migration of monocyte subsets 
to HIEC, using transwell assays to determine the phenotypic traits of the receptive 
monocytes when they are regulated by TWEAK. We determined that TWEAK 
activated HIEC may facilitate leukocyte recruitment, it will be important to further 
characterise the TWEAK inflammatory response by further experiments and using 
cytokines which have shown Fn14 expression regulation. It will also be essential to 
further characterise monocyte subset responses to TWEAK activated HIEC using flow 
based adhesion assays. This will help to further understand and determine 
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mechanistic details and regulation of HIEC recruitment of leukocytes. It will also be 
important to further characterise any differences of TWEAK activated HIEC under 
flow between normal and diseased liver isolated HIEC. 
 We characterised the Erk and p38 MAPK signalling pathways by TWEAK activated 
HIEC, it will also be important to determine if TWEAK activated HIEC signal through 
the Jnk Pathway. Our data showed that Erk and NF-kB potentially regulate Fn14 
expression via cytokine and growth factor activation, however further experiments 
will be required to determine this. TWEAK and Fn14 responses are highly regulated 
by TRAF association, therefore profiling TWEAK and Fn14 HIEC response activated 
TRAFs will be ideal. 
 We determined that TWEAK activated HIEC induce ROS production and are 
susceptible to necrosis, it will be important to determine if these cell fate responses 
of TWEAK activation are mediated by Fn14, and to further characterise if TWEAK 
responses are further regulated by inflammatory cytokines which have been 
previously implicated in TWEAK and Fn14 functional responses. It will then be 
essential to characterise signalling during TWEAK activated necrosis and ROS 
production by the use of cathepsin inhibitors and calcium probes.  
 We determined that TWEAK activated HIEC may contribute to angiogenesis, it will be 
important to further characterise if TWEAK activated angiogenesis via HIEC is 
mediated by VEGF and FGF dependent pathways. It is highly important to further 
characterise the angiogenic cytokine profiles, more assays will be required and 
inhibitors to the specific angiogenic proteins which showed a significant result will be 
ideal for proof of concept experiments. It will also be beneficial to determine if 
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TWEAK and Fn14 knock-out mice liver tissue after inflammatory liver injury, also 
show down-regulated angiogenesis protein responses using IHC, to further confirm 
the regulated inflammatory angiogenesis responses via TWEAK. It will then be highly 
important to carry out in vivo angiogenesis experiments using TWEAK, and determine 
HIEC responses, to further confirm findings from our in vitro pro-angiogenesis data.  
 Data suggested TWEAK and Fn14 regulate PALT formation in the liver. Proof of 
concept experiments will be essential to determine TWEAK and Fn14 involvement in 
PALT formation in inflammatory liver disease, using TWEAK and Fn14 knock out 
mouse models with induced liver injury by propioni bacterium acnes.  
 It will be beneficial to determine TWEAK and Fn14 expression patterns in TWEAK and 
Fn14 knock out mouse liver tissue with induced liver injury models, to further 
characterise TWEAK and Fn14 specific inflammatory disease regulation. 
 Translational studies will be essential to develop future therapeutics targeting the 
TWEAK and Fn14 pathway during CLD. A start will be to determine soluble TWEAK 
levels in patient serum with chronic inflammatory liver disease, to analyse if TWEAK 
can be a potential marker of CLD. 
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Appendix 1 
Angiogenesis Protein Function 
Activin A Activin A is a multifunctional protein involved in processes such as follicle stimulating hormone biosynthesis and secretion, 
regulation of the menstrual cycle, cell fate, homeostasis, and wound repair (Chen et al., 2006). 
ADAMTS-1 ADAMTS-1 interacts with VEGF and may have functions during normal growth, function and development of organs (Vázquez et 
al., 1999). 
Angiogenin Angiogenin is a stimulator of new vessel formation (Gao e Xu, 2008). 
Angiopoietin-1 Angiopoetins are proteins involved in angiogenesis specifically during blood vessel maturation and stability (Thurston, 2003; 
Barton, Tzvetkova e Nikolov, 2005).  Angiopoietin-2 
Angiostatin/Plasminog
en 
Angiostatin is an endogenous inhibitor of angiogenesis (Cao et al., 1996). 
Amphiregulin Amphiregulin may promote the growth of epithelial cells and may also act as a tumour suppressor gene (Zaiss et al., 2013). 
Artemin Artemin is part of the GDNF family of ligands and has been shown to promote angiogenesis (Banerjee et al., 2012). 
C5a Complement c5a has been shown to regulate inflammation and angiogenesis during pathogenesis (Conroy et al., 2009). 
Coagulation Factor III CFIII can regulate angiogenesis directly by clotting independent mechanisms, and indirectly via clotting dependent mechanisms,  
or by regulating growth regulatory molecules (Bluff et al., 2008). 
CXCL16 CXCL16 is a chemokine produced by dendritic cells and has been found to be an angiogenesis factor in HUVEC (Zhuge et al., 
2005). 
DPPIV Dipeptidyle peptidase 4 has been found to regulate immune regulation, apoptosis and signal transduction. Recently it has been 
associated with the development of cancers and tumours (Kitlinska et al., 2003). 
EGF Epidermal growth factor regulates cell survival, proliferation, and differentiation (Herbst, 2004). 
EG-VEGF Endocrine gland derived VEGF has been shown to regulate endocrine specific angiogenesis (Brouillet et al., 2010). 
Endoglin Endoglin in part of the TGF beta 1 receptor complex and has been found to be involved in cardiac development and vascular  
remodelling (ten Dijke, Goumans e Pardali, 2008). 
Endostatin/ Collagen 
XVIII 
Endostatin is an endothelial cell proliferation, angiogenesis, and tumourigenesis inhibitor (Folkman, 2006). 
Endothelin-1 Endothelin is primarily produced by endothelial cells and is involved in vascular homeostasis and has been found to stimulate  
angiogenesis (Boron e Boulpaep, 2009). 
FGF acidic Fibroblast growth factor; involved in wound healing, embryonic development and angiogenesis, they also regulate cell survival, 
proliferation, differentiation, and in vivo development (Dorey e Amaya, 2010). FGF basic 
FGF-4 
FGF-7 
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GDNF Glial cell line derived neutrophic factor; is a neutrotrophic factor which has been shown to regulate cell survival, differentiation,  
migration and neurite outgrowth (Shang et al., 2011). 
GM-CSF Granulocyte macrophage colony stimulating factor is secreted by immune cells, endothelial cells and fibroblasts. It is a white 
blood cell growth factor . 
GroA GroA is a chemoattractant regulating leukocyte trafficking and an angiogenesis regulator (Paleolog, 1996). 
HB-EGF Heparin binding like EGF growth factor; has various functions which are dependent on its interactions with other proteins.  
One of its critical functions have been in promoting wound healing and angiogenesis (Mehta e Besner, 2007). 
HGF Hepatocyte growth factor functions to regulate cell growth, motility and morphogenesis and subsequently has a significant role 
during angiogenesis, tumourigenesis, and tissue regeneration (Rosen et al., 1997)(Rosen et al., 1997)(Rosen et al., 1997). 
IGFBP-1 There are suggestions of IGFBP-1 (insulin like growth factor binding protein) having anti angiogenic properties (Shay et al., 
2011). 
IGFBP-2 IGFBP-2 showed enhanced VEGF gene promoter activity and subsequent angiogenesis promotion (Azar et al., 2011). 
IGFPB-3 IGFBP-3 showed enhanced angiogenesis through IGF-1 signaling and SphK1 activation (Granata et al., 2007). 
IL-1β IL-1β has been shown to regulate tumour invasiveness and angiogenesis (Voronov, Carmi e Apte, 2007). 
IL-8 IL-8 has been shown to promote angiogenesis, tumour growth and metastasis (Heidemann et al., 2003). 
IP-10  Plasma interferon gamma inducible protein 10 has been shown to inhibit VEGF functions (Bodnar, Yates e Wells, 2006) 
LAP(TGF-B1) Latency associated peptide (TGF b1); stimulate cell growth, differentiation, proliferation and apoptosis (Pepper, 1997). 
Leptin Leptin has been shown to regulate endothelial cell proliferation and increase the expression of MMP's and subsequently  
regulate angiogenesis (Anagnostoulis et al., 2008)(Anagnostoulis et al., 2008)(Anagnostoulis et al., 2008)(Anagnostoulis et al., 
2008)(Anagnostoulis et al., 2008)(Anagnostoulis et al., 2008)(Anagnostoulis et al., 2008)(Anagnostoulis et al., 
2008)(Anagnostoulis et al., 2008)(Anagnostoulis et al., 2008)(Anagnostoulis et al., 2008)(Anagnostoulis et al., 2008). 
MCP-1 (CCL2) MCP-1 has been shown to regulate the angiogenic potential of TGF-b by the recruitment of vascular smooth muscle cells and  
mesenchymal cells towards endothelial cells (Niu et al., 2008). 
MIF Macrophage migratory inhibitory factor has important inflammatory, immune and cell growth responses. Specifically anti-tumour 
and anti-angiogenesis functions (Nishihira, 2000). 
MIP-1a Macrophage inflammatory protein 1 alpha; has been shown to decrease angiogenesis and subsequent wound healing by a  
reduction of macrophages at the wound site (Yoshida et al., 2003). 
MMP-8 Matrix metalloproteinase family function during the breakdown of the extracellular matrix (Rundhaug, 2005). 
MMP-9 
NRG1-β Neuregulin 1 beta is known to stimulate the up-regulation of VEGF A and therefore can promote in vivo and in vitro angiogenesis 
(Hedhli et al., 2012). 
Pentraxin 3 (PTX3) PTX 3 is released in response to inflammatory signals and has been known to inhibit angiogenesis (Leali et al., 2011). 
PD-ECGF Platelet derived endothelial cell growth factor is known to stimulate angiogenesis and promote the growth of endothelial cells 
(Fujimoto et al., 1999). 
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PDGF-AA Platelet derived growth factor. Regulate cell growth and division and have significant roles during angiogenesis (Sato et al., 
1993).  PDGF-AB/BB 
Persephin Persephin is part of the GDNF family of ligands which have been found to regulate a number of processes such as cell survival,  
growth, differentiation and migration (Milbrandt et al., 1998). 
Platelet factor 4 PF4 is released from activated platelets and promotes blood coagulation and may have roles during wound repair and 
inflammation.  
It has also been found to inhibit cell proliferation, migration and angiogenesis (Bikfalvi, 2004). 
PIGF Placental growth factor is an inflammation and angiogenesis regulator (Luttun, Tjwa e Carmeliet, 2002)  
Prolactin Prolactin has been found to stimulate and inhibit angiogenesis in different settings (Corbacho, Martínez De La Escalera e Clapp, 
2002). 
Rantes Rantes has shown pro-angiogenic functions specifically endothelial cell migration, spreading and neovessel formation (Suffee et 
al., 2012). 
sICAM-1 Soluble Intracellular adhesion molecule 1 can regulate in vitro and in vivo angiogenesis (Deng et al., 2007). 
Serpin B5 Also known as Maspin which functions as an angiogenesis inhibitor and a tumour suppressor (Richardson et al., 2007). 
Serpin E1 Plasminogen activator inhibitor-1; mainly produced by endothelium and inhibits serine proteases and the activity or matrix  
metalloproteinases. 
Serpin-F1 Also known as pigment epithelium derived factor which may function as an anti tumourigenic, anti angiogenic and neutrophic 
protein (Richardson et al., 2007). 
TIMP-1 Metalloproteinase inhibitor; functions to promote cell proliferation, may be involved in platelet aggregation and recruitment in  
endometrial tissue remodelling, and may have anti apoptotic function (Reed et al., 2003) .  TIMP-4 
Thrombospondin-1 Thrombospondins may inhibit angiogenesis and tumourigenesis. These may regulate cell adhesion, migration and growth 
(Lawler, 2000). Thrombospondin-2 
uPA Urokinase-type plasminogen activator may function during thrombolysis and extracellular matrix degradation (Ribatti et al., 
1999). 
Vasohibin Vasohibin is an inhibitor of angiogenesis (Shimizu et al., 2005). 
VEGF Vascular endothelial growth factor; a signalling protein expressed by cells during vasculogenesis and angiogenesis.  
VEGF-C functions during lymphangiogenesis (Ferrara, 2002). VEGF-C 
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Appendix 2 
Activated HIEC do not alter HIEC viability 
To determine if any of the stimulations used in all of the experiments in this study altered HIEC 
viability, an MTT assay was performed on HIEC. Stimulations with TWEAK, TNF-α, IFN-γ, FGF, 
IL-1β, TGF-β, IL-17A, Erk Inhibitor and NF-kB Inhibitor were compared to an unstimulated HIEC 
control. No negative change in HIEC viability was observed when the cells were stimulated in 
comparison to un-stimulated HIEC (n=3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HIEC are viable after stimulation with TWEAK and TNF-α: An MTT assay was used to 
determine if the HIEC used in the angiogenesis assay were viable after stimulation with 
TNF-a (10ng/ml) and TWEAK (100ng/ml) for 8 hours. TNF-α and TWEAK stimulated HIEC 
showed at least 100% viablilty after 8 hours, mean ± SE. 
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